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Obesity, diabetes, and associated co-morbidities are part of a major health epidemic in the 
United States, and they are becoming more rampant globally as well. Much still remains to be 
understood regarding the intricate mechanisms controlling whole-body energy balance and how 
dysregulation leads to disease. Regular exercise benefits systemic health, and it is hypothesized 
that myokines secreted from contracting skeletal muscle can mediate these effects. To identify 
novel exercise-regulated myokines, we measured the levels of 66 cytokines in serum and in 
glycolytic and oxidative muscles from wildtype mice subjected to either a sprint, endurance run, 
or one week of voluntary wheel running. Overall, many significant changes were observed in both 
serum and muscle in response to exercise, and our study identified 22 novel exercise-regulated 
myokines. Additionally, this is the first report comparing the cytokine profiles between muscle 
fiber types in response to different exercise regimes, and we demonstrated that there were more 
differences than commonalities between oxidative and glycolytic muscle. Lastly, a subset of the 
cytokine changes observed in circulation did not reflect changes in the skeletal muscle but rather 
correlated with gene expression changes in adipose tissue or liver. In another study, we focused 
on elucidating the role of a specific myokine, myonectin, in regulating systemic energy metabolism 
using a genetic knockout mouse model. Loss of myonectin had minimal or negligible effects on 
glucose metabolism, lipid metabolism, and exercise capacity in male and female mice fed a 
control, low-fat diet. However, when challenged with a high-fat diet to induce obesity, myonectin 
deficiency altered lipid handling and storage in males. Specifically, knockout mice exhibited a 
striking impairment in clearing serum lipids following a meal or oral lipid gavage compared to 
their wildtype littermates. Additionally, myonectin deficiency resulted in a dramatic reduction of 
high-fat diet-induced hepatic steatosis and, in parallel, a significant increase in adipose tissue mass 
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with concomitant adipocyte hypertrophy. The increased adiposity in knockout mice was promoted, 
in part, through increased adipose tissue lipoprotein lipase activity. In sum, our studies highlight 
novel and important functions of myokines in exercise and lipid metabolism, linking skeletal 
muscle to systemic energy homeostasis. 
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Obesity, diabetes, and associated co-morbidities 
The recent dramatic increase in the prevalence of obesity is alarming, with recent estimates 
categorizing nearly 40% of adults and more than 18% of children in the United States as clinically 
obese (1). Approximately 13% of the world’s population is obese, a figure which has nearly tripled 
in the last four decades (2). It is widely accepted that obesity is causally related to the development 
of comorbidities such as type 2 diabetes and cardiovascular disease, both of which are among the 
leading causes of death in the United States (3–6). Not only do these metabolic health issues have 
a negative impact on the well-being of affected individuals, but also they pose an enormous 
economic burden on society (5–7). There is a dire need to understand the basic biology underlying 
metabolic dysregulation associated with excess caloric intake and a sedentary lifestyle, novel 
findings of which may lead to innovative treatments or preventative measures. 
 
Systemic control of energy homeostasis 
Controlling energy homeostasis is a complex, systems-level task for an organism. 
Fundamentally, this requires balancing food intake and energy expenditure to promote survival in 
times of fluctuating energy supply and demand. To do so, the body has to adapt its metabolism to 
its current metabolic state. For example, feeding stimulates anabolic processes to promote nutrient 
storage whereas fasting is dominated by catabolic processes to break down stored nutrients for 
energy utilization (8, 9). Exercise presents a unique metabolic challenge to an animal whereby 
high energy substrates are directed to the working skeletal muscle for ATP production, and fuel 
selection is dependent on exercise intensity (8). Proper control of nutrient intake, storage, and 
utilization specific to the metabolic state is dependent on the ability of different organs and organ 
systems to communicate their status and needs to other parts of the body. This inter-organ crosstalk 
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is mediated by nutrient flow, neuronal signals, and the endocrine system. Integration of these 
signals results in activation or suppression of specific metabolic pathways in a tissue-specific 
manner to maintain whole-body metabolic homeostasis. (8, 9). Secreted proteins represent a major 
part of the endocrine system, and greater than 10 percent of all protein-coding genes in the human 
genome are predicted to be secreted proteins based on the presence of a signal peptide (10). Most 
major metabolic organs are capable of both receiving endocrine signals as well as producing 
secreted proteins for inter-organ communication, including the gut, liver, adipose, and skeletal 
muscle (9). When energy balance is perturbed by overconsumption of calories and a sedentary 
lifestyle, the resulting disruption of signaling pathways regulated by these circulating hormones 
not only exacerbates the metabolic phenotype but also can lead to the development of 
comorbidities (11). Thus, studying the function of secreted proteins in normal physiology and 
metabolic disease may facilitate the discovery of novel therapeutic targets or strategies. 
 
Myokines 
Proteins secreted from the skeletal muscle are called myokines, and they can act in an 
autocrine, paracrine, and/or endocrine manner (12). Myostatin was the first characterized myokine, 
and it was discovered in the process of identifying new transforming growth factor beta (TGF-) 
superfamily members. It is most well-known for its autocrine and paracrine roles as a negative 
regulator of muscle growth (13). Since then, numerous other myokines have been identified and 
characterized, spanning diverse roles in physiology. These include interleukin (IL)-7, IL-8, 
leukemia inhibitory factor (LIF), IL-15, brain-derived neurotrophic factor (BDNF), irisin, 
fibroblast growth factor 21 (FGF21), decorin, and secreted protein acidic and rich in cysteine 
(SPARC), among others (14, 15). Many proteomic studies have been carried out to characterize 
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the entire skeletal muscle secretome. Depending on the experimental design and method used, 
most of these studies have estimated that there are hundreds of myokines actively produced and 
secreted by skeletal muscle (16–20); hence, many remain to be characterized.  
 
Myokines and exercise 
Well before the discovery of myostatin, the existence of myokines was postulated, 
specifically in the context of exercise; it was hypothesized that exercising skeletal muscle must 
secrete some “exercise factor” into circulation in order to explain the observations that exercise is 
sufficient to reduce blood glucose by promoting glucose uptake and utilization in both exercising 
and non-exercising skeletal muscle, and that these effects are independent of the nervous system 
(21). Regular exercise is protective against many diseases, including cardio-metabolic disorders, 
whereas physical inactivity is a major risk factor for disease and premature mortality (15). 
However, the underlying mechanisms linking the inverse relationship between exercise and 
disease are not fully understood. Thus, there have been major efforts to identify “exercise factors” 
or “exerkines” which may mediate the beneficial health effects of exercise. Interleukin-6 (IL-6), 
the most extensively studied myokine, was the first protein shown to be secreted from contracting 
skeletal muscle. In the context of exercise, it functions in an endocrine manner to mobilize energy 
substrates and then in an autocrine fashion to promote substrate uptake and utilization in the 
skeletal muscle (15). However, in the context of injury or infection, IL-6 functions as a pro-
inflammatory molecule and plays a role in activating the adaptive immune response (22). In 
addition to acute inflammation, elevated baseline IL-6 levels are partly responsible for chronic 
low-grade inflammation that is characteristic of obesity and type 2 diabetes (23). With regular 
exercise, resting levels of IL-6 are actually decreased while expression of the receptor IL-6Ra is 
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upregulated, thereby increasing IL-6 sensitivity and preventing IL-6-mediated chronic 
inflammation (15). Thus, IL-6 is a prime example of a myokine with acute functions in exercise 
that mechanistically links chronic exercise with improved health.  
 
Finding novel exercise-induced myokines  
Various approaches have been taken to identify novel exercise-induced myokines that 
could mediate the beneficial effects of exercise, similarly to IL-6. One method is in vitro studies 
using differentiated myotubes in culture that are stimulated to contract with electrical pulses. The 
conditioned media is then examined with proteomics methods to identify secreted proteins (24). 
The major advantage to this approach is the ability to detect bona-fide myokines; whatever was 
detected in the media came directly from the muscle cells. However, cell culture is an imperfect 
mimic of skeletal muscle in vivo: the organ is comprised of other cell types in addition to myotubes, 
electrical pulse stimulation does not fully reproduce the physiological changes exhibited in 
contracting skeletal muscle, and not all local and systemic factors that interact with the muscle are 
represented in vitro (24, 25). There have also been many human studies. Most often, blood and 
muscle biopsies are taken before and after exercise and subjected to transcriptomics or proteomics 
to identify changes induced by exercise (24). One drawback to human studies is that muscle 
biopsies are most often taken from a large leg muscle like the vastus lateralis, which contains a 
mix of muscle fiber types, so it is not feasible to determine the contribution of individual muscle 
fiber types (24). Additionally, it is not practical in humans to take tissue samples from other 
metabolic organs to assess if changes seen in the serum are due to protein expression and secretion 
in non-muscle tissues as a secondary response to myokine signaling from the exercising skeletal 
muscle. In general, a major limitation to the traditional proteomics approach using mass 
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spectrometry is that it is not sensitive enough to detect factors that are at very low abundance (25). 
Many circulating factors in the serum are known to be in the ng/mL or even pg/mL range and thus 
would not even be detected by these methods even though small changes in concentration of some 
circulating proteins are known to exert significant biological effects (25). Lastly, many in vitro 
and in vivo studies rely on mRNA expression data only and infer that those changes reflect protein 
levels, which may produce misleading conclusions (25). Chapter 2 describes a study that 
overcomes many of these limitations and provides novel insights regarding exercise-regulated 
changes in secreted proteins.  
 
Adiponectin and C1q/TNF Related Proteins (CTRPs) 
 While the focus of the study detailed in Chapter 2 is on finding novel myokines, Chapter 3 
describes a study characterizing the physiological role of a particular myokine called complement 
component 1q (C1q)/tumor necrosis factor (TNF)-related protein 15 (CTRP15). CTRP15 is part 
of the CTRP family of secreted proteins. CTRPs were first discovered in 2004 from a database of 
expressed sequence tags based on homology to adiponectin (26). Adiponectin is an extensively 
studied adipokine (hormone secreted from the adipose tissue) having pleiotropic roles in 
metabolism. The hormone sensitizes the body to insulin by stimulating AMP-activated protein 
kinase (AMPK) signaling in liver and skeletal muscle to enhance fat oxidation and glucose uptake 
and reduce hepatic gluconeogenesis (27). Despite being almost exclusively expressed in and 
secreted from adipose tissue, circulating adiponectin levels are paradoxically reduced in obese 
humans and mice (28, 29). The same holds true for diabetic patients (30). In fact, studies suggest 
that adiponectin can be a causative link between obesity and metabolic co-morbidities: a 
combination of genetic factors (e.g. single-nucleotide polymorphisms (SNPs) in the adiponectin 
 7 
gene) and environmental factors that lead to obesity (e.g. high-fat diet) result in lower adiponectin 
levels, and adiponectin action is further decreased due to lower expression of its receptors in the 
obese state. This reduction in adiponectin action has been causatively linked to the development 
of insulin resistance, type 2 diabetes, metabolic syndrome, and atherosclerosis (27). Given the 
significant role adiponectin plays in metabolism and the etiology of metabolic diseases, the 




 CTRPs share the same domain structure as adiponectin: an N-terminal signal peptide to 
promote secretion, a short variable domain with one or more conserved cysteine residues, a 
collagen-like domain, and a C-terminal globular c1q domain (Fig. 1) (11). The c1q domain is 
homologous to the complement protein of the same name and is structurally similar to TNF, 
inspiring the name of the protein family (C1q/TNF related protein) (26). All CTRPs form trimers 
and many form higher order oligomeric structures, the formation of which is mediated by disulfide 
bond formation between conserved cysteine residues in the variable N-terminal domain (11). 
Different oligomeric forms of adiponectin have been shown to have different functions in vivo 
(31). Whether the same holds true for CTRPs remains largely unexplored. The exception is 
CTRP12 in which different isoforms form different oligomeric complexes and preferentially 
activate different signaling pathways: the full-length isoform forms trimers and larger complexes 
and activates protein kinase B (AKT) signaling whereas the cleaved, globular isoform forms 
dimers and activates mitogen-activated protein kinase (MAPK) signaling (32). Interestingly, many 
CTRPs have been shown to form hetero-oligomeric complexes with other CTRPs or with  
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Figure 1. Schematic of CTRPs. With the exception of CTRP4, every CTRP consists of four domains: a 
signal peptide for secretion (dark grey), an N-terminal domain with one or more conserved Cys residues 
(white), a collagen domain with varying numbers of Gly-X-Y repeats (light gray), and a C-terminal globular 
domain homologous to the immune complement C1q (blue). The numbers on the right refer to the percent 
amino acid identity between human and mouse orthologs when comparing the full-length protein (first 
column) or the C-terminal globular domain (second column). CTRP4 and CTRP8 are omitted – the former 
consists of only two tandem C1q domains, while the latter is absent in the mouse genome. (figure and 
figure legend copied with permission from reference 11) 
 
adiponectin (33–38); the physiological significance is currently unknown but it is possible that 
hetero-oligomers function in a manner different from the homo-oligomers, which would 
functionally increase the CTRP gene-to-ligand ratio (33). Many CTRPs are also glycosylated, 
which is likely to be important for protein folding in the endoplasmic reticulum, stability, and 
secretion (39). However, the functional significance of post-translational modifications of CTRPs 
has not been explored, with the exception of CTRP12. Cleavage of CTRP12 to generate the 
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globular isoform is regulated, in part, by N-linked glycosylation on a conserved asparagine residue 
in close proximity to the cleavage site (40).  
 
CTRP function 
All CTRPs are highly conserved throughout vertebrate evolution, implicating that each has 
a significant role in biology (11). Like adiponectin, many CTRPs are expressed in and secreted 
from white adipose tissue, but in general their tissue expression profiles in mice and humans are 
broader than that of adiponectin (11). For most CTRPs, expression and/or circulating levels are 
altered by acute or chronic metabolic state in mice ([reviewed in 11], 41–45). The functional roles 
of CTRPs have begun to be elucidated using overexpression and knockout mouse models. As 
expected based on homology to adiponectin, many of these mouse models have significant 
metabolic phenotypes, including differences in body weight (42, 46, 47), glucose homeostasis (44, 
45), lipid homeostasis, or both glucose and lipid metabolism (41, 43, 46–48) (metabolic 
phenotypes also reviewed in 11). The relevance to human physiology has been confirmed with 
studies that have correlated serum or tissue CTRP levels with metabolic state or metabolic 
pathology including obesity, type 2 diabetes, and/or non-alcoholic fatty liver disease ([reviewed 
in 11], 43–45, 49–58). With an increasing focus on investigating CTRP function using rodent 
models, many CTRPs have been found to have physiological roles outside of nutrient metabolism, 
including inflammation (44, 45, 59), cardiac function (60–64), blood pressure (65), kidney 
function (data in press), bone function (66), atherogenesis (67–69), tissue fibrosis (45, 62), 
vascular remodeling (70), neuroinflammation/brain function (71), autophagy (72), and iron 
metabolism (73–75) (non-metabolic phenotypes also reviewed in 11). In humans, tissue or serum 
levels of CTRPs have been associated (positively or negatively) with the following disease states 
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in addition to nutrient metabolism: congestive heart failure (76), coronary artery disease (67, 77), 
late onset retinal degeneration, pulmonary arterial hypertension (78), polycystic ovarian syndrome 
(79), and anemia (80–82) (non-metabolic disease states correlated with CTRPs also reviewed in 
11). One major limitation to the study of CTRP function is that there is limited research regarding 
their receptors. CTRP8 was shown to bind to and activate the G-protein-coupled receptor (GPCR) 
relaxin receptor 1 (RXFP1) in human glioblastoma cells, inducing cell migration and production 
of cathepsin B, a lysosomal protease correlated with tumor invasion (83). This interaction outside 
of the context of glioblastoma has not been investigated. CTRP9 can activate adiponectin receptor 
1 (AdipoR1) to promote vasorelaxation in mouse aorta, which may have implications in 
endothelial dysfunction in cardiovascular disease (84). Lastly, CTRPs 10, 11, 13, and 14 were 
shown to bind to brain-specific angiogenesis inhibitor 3 (BAI3), a cell-adhesion GPCR, and the 
c1q globular domains were sufficient to decrease the excitatory synapse density in cultured 
neurons (85). However, the in vivo physiological relevance has not yet been determined. Given the 
diverse roles of the CTRP family of proteins and their relevance to so many disease states, further 
study of CTRP function and elucidation of relevant receptors will not only provide insight into 
normal physiology but also may provide a basis for therapeutic strategies aimed at developing 
receptor agonists or antagonists. 
 
CTRP15/myonectin/erythroferrone 
CTRP15 is unique among the CTRP family in that it is almost exclusively expressed in 
skeletal muscle in both humans and mice in normal conditions (38) whereas other members display 
a broader expression profile (11). For this reason, CTRP15 is also referred to as “myonectin.” 
Interestingly, the expression of most known myokines is not restricted to the skeletal muscle but 
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rather they are more widely expressed, so it seems myonectin is unique among myokines in its 
very limited expression profile under basal conditions (38). Myonectin expression in the skeletal 
muscle is upregulated after exercise (38, 64), and mouse studies have linked this exercise-induced 
increase in myonectin with improved outcomes after myocardial ischemia-reperfusion injury (64). 
However, during stress erythropoiesis in mice stimulated by blood loss or erythropoietin (EPO) 
administration, myonectin is highly induced in erythroblasts in the bone marrow and spleen (75). 
Under these circumstances, myonectin signals to the liver to suppress hepcidin expression, a 
negative regulator of iron mobilization, thereby increasing iron availability for new red blood cells 
(75). Based on this discovery, myonectin is also referred to as “erythroferrone” (75). The relevance 
to iron metabolism in humans has also been demonstrated. In patients with anemia due to chronic 
kidney disease, serum levels of myonectin rise in response to EPO or erythropoiesis-stimulating 
agents (86, 87). Similarly, blood loss or EPO administration to healthy individuals is sufficient to 
increase circulating levels of myonectin (81). Basal levels of myonectin are higher in patients with 
iron deficiency anemia (80) and beta thalassemia (81), and lower in patients with anemia of 
inflammation (82), implying myonectin’s involvement in pathogenesis or response to anemia 
diseases.  
The first piece of evidence for myonectin’s role in nutrient metabolism is its unique 
expression pattern in mice based on metabolic state: mRNA and circulating levels are at low, basal 
levels during fasting but are dramatically upregulated upon re-feeding following an overnight fast 
(38). Interestingly, it seems that any nutrient flux through the muscle is sufficient to stimulate the 
expression and release of myonectin – both lipid and glucose administration are independently 
sufficient to show the same effect both in vivo and in cultured myotubes (38). In line with its 
postprandial expression pattern, myonectin stimulates nutrient uptake into peripheral tissues: 
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injection of recombinant myonectin into wildtype mice is sufficient to lower serum free fatty acid 
levels, and myonectin acts directly on adipocytes and hepatocytes in culture to stimulate fatty acid 
uptake from the media (38). Additionally, myonectin serves as a postprandial cue to stimulate the 
mammalian target of rapamycin (mTOR) pathway in the liver to inhibit autophagy, an intracellular 
recycling process that is activated during fasting (72). In humans, serum levels of myonectin have 
been correlated with metabolic pathologies: myonectin is higher in patients with metabolic 
syndrome than controls (57), and people with newly diagnosed type 2 diabetes have more 
myonectin than those with impaired glucose tolerance who, in turn, have higher myonectin than 
control patients (58). So far, these myonectin studies with respect to metabolism have been limited 
to recombinant protein infusion into mice, in vitro experiments using immortalized cell lines, and 
human correlational studies. Chapter 3 describes a study that investigates the in vivo physiological 
function of myonectin in regulating metabolic homeostasis in normal physiological conditions or 
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CHAPTER 2:  
Multiplex quantification identifies novel exercise-regulated 
myokines/cytokines in plasma and in glycolytic and oxidative skeletal muscle* 
 
*Text and figures in this chapter were published in Molecular and Cellular Proteomics in 2018: 
Little, H. C., Tan, S. Y., Cali, F., Rodriguez, S., Lei, X., Wolfe, A., Hug, C., and Wong, G. W. (2018) 
Multiplex Quantification Identifies Novel Exercise-regulated Myokines/Cytokines in Plasma and in 









Exercise is known to confer major health benefits, but the underlying mechanisms are not 
well understood. The systemic effects of exercise on multi-organ systems are thought to be partly 
due to myokines/cytokines secreted by skeletal muscle. The extent to which exercise alters 
cytokine expression and secretion in different muscle fiber types has not been systematically 
examined.  Here, we assessed changes in 66 mouse cytokines in serum, and in glycolytic (plantaris) 
and oxidative (soleus) muscles, in response to sprint, endurance, or chronic wheel running. Both 
acute and short-term exercise significantly altered a large fraction of cytokines in both serum and 
muscle, twenty-two of which are considered novel exercise-regulated myokines. Most of the 
secreted cytokine receptors profiled were also altered by physical activity, suggesting an exercise-
regulated mechanism that modulates the generation of soluble receptors found in circulation. A 
greater overlap in cytokine profile was seen between endurance and chronic wheel running. 
Between fiber types, both acute and chronic exercise induced significantly more cytokine changes 
in oxidative compared to glycolytic muscle. Further, changes in a subset of circulating cytokines 
were not matched by their changes in muscle, but instead reflected altered expression in liver and 
adipose tissues. Lastly, exercise-induced changes in cytokine mRNA and protein were only 
minimally correlated in soleus and plantaris. In sum, our results indicate that exercise regulates a 
large number of cytokines whose pleiotropic actions may be linked to positive health outcomes. 
These data provide a framework to further understand potential crosstalk between skeletal muscle 






Physical inactivity is a major risk factor contributing to cardio-metabolic disorders in 
modern society (1, 2). Conversely, regular exercise confers systemic health benefits (3-6). The 
underlying mechanisms responsible for the positive physiological effects of exercise, however, are 
not well understood (7, 8). The systemic effects of exercise on multi-organ systems has long 
thought to be, at least in part, due to myokines and cytokines secreted by skeletal muscle in 
response to exercise (9-11). These exercise-induced myokines are believed to mediate crosstalk 
between skeletal muscle and other organ compartments. Depending on the method used and 
biological contexts, proteomics-based analyses of the muscle “secretome” have identified 
hundreds of proteins secreted by muscle cells (12-19). The functions for most of these muscle-
derived secretory proteins are poorly defined, and it is unclear whether their expression and 
secretion are regulated by muscle contraction in vivo. Importantly, biologically potent molecules, 
such as cytokines, that normally exist at low levels (typically in the ng/mL and pg/mL range) are 
generally not detected by current proteomics methods.  
The cytokine interleukin (IL)-6 is one of the first myokines shown to be actively secreted 
by contracting skeletal muscle in human (20, 21). Since its discovery, other cytokines such as IL-
7 (22), IL-15 (23), leukemia inhibitory factor (LIF) (24), and vascular endothelial growth factor 
(VEGF) (25) have also been shown to be functionally relevant exercise-induced myokines, either 
acting in an autocrine/paracrine manner within muscle, or acting via an endocrine fashion to affect 
biological processes in non-muscle tissues. Recent in vitro studies using electrical pulse 
stimulation of primary human myotubes and antibody-based detection approaches also identified 
significant numbers of contraction-induced myokines/cytokines (26, 27). While these in vitro 
studies allow the unequivocal identification of bona fide muscle cell-derived myokines, limitations 
 23 
to these cell models have also been noted. Although differentiated primary myotubes in culture 
serve as a reasonable proxy for mature muscle cells, they do not capture the three-dimensional 
muscle fibers in the context of other potentially important accessory cell types (e.g., vascular 
endothelial cells, satellite cells, immune cells, and sympathetic nerve cells), nor do the cultured 
myotubes fully resemble the metabolically distinct glycolytic and oxidative fiber types.  Further, 
electrical pulse stimulation of myotubes does not fully recapitulate both the stimulatory and 
inhibitory pathways induced by exercising skeletal muscle (28). As such, in vivo studies in humans 
or animal models will complement and extend the in vitro studies, enabling a more complete 
understanding of skeletal muscle’s response to exercise.   
Cytokines, chemokines, and secreted cytokine receptors constitute a large family of 
secretory proteins with pleiotropic immune and non-immune functions (29-33). As such, changes 
in local and systemic levels of these molecules in response to exercise could potentially account, 
at least in part, for the positive effects of physical activities. The present study aimed to address 
three related questions. First, while a handful of cytokines has thus far been shown to be secreted 
by exercising muscle in vivo, the extent to which different types of physical activity (sprint, 
endurance, voluntary wheel running) regulates cytokine expression and secretion in glycolytic 
versus oxidative muscle fibers has not been systematically examined. Most human exercise studies 
examined transcriptional and protein changes in vastus lateralis, a quadriceps muscle with mixed 
fiber types. The metabolism of in vitro differentiated primary human myotubes also tended to be 
glycolytic rather than oxidative. Thus, the use of mouse exercise models allows us to address 
questions that are difficult to study in humans and primary cell culture system. Secondly, it is 
generally assumed that changes in serum cytokine in response to exercise are directly related to 
changes in their expression and secretion in skeletal muscle. It remains unknown to what extent 
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the changes in plasma cytokine levels are due to secondary adaptive changes in their expression 
and secretion in non-muscle tissues in response to exercise. This could potentially occur if the 
primary exercise-induced cytokines in turn stimulate the expression and secretion of secondary 
cytokines in other non-muscle tissues. Thirdly, several transcriptomics studies have been carried 
out to look at changes in human muscle gene expression in response to exercise (34-37). Whether 
changes in mRNA level translate into changes in protein level in human skeletal muscle are often 
not examined, in large part limited by the availability of protein-specific antibodies and the cost of 
validating a large number of candidate proteins.  
With the use of the conventional ELISA method, it is not feasible to simultaneously 
measure the levels of large numbers of cytokines in a mouse due to limited blood volume that 
could be sampled. Technological advancement in recent years has made it feasible now to 
simultaneously quantify a large number of cytokines in serum and tissues using only small volume 
of blood or quantity of tissue. Using a bead-based multiplex profiling method, we seek to measure 
cytokine levels in mice in response to an acute sprint or endurance run, or a short-term access to a 
running wheel for one week (representing chronic exercise). Here, we examined a total of 66 
known cytokines (including secreted cytokine receptors and acute phase proteins) that represent a 
well-studied set of molecules with diverse functions and activities. These cytokines act on diverse 
cell types to modulate a variety of biological processes that include inflammation, chemotaxis, 
apoptosis, metabolism, angiogenesis, and cell proliferation (38). Given the pleiotropic systemic 
effects of exercise, we hypothesized that acute and chronic exercise would dynamically alter 
cytokine levels in circulation and in different muscle fiber types (e.g., oxidative and glycolytic). 
Indeed, our results show that exercise modulates the expression of a large number of cytokines in 
different muscle fiber types depending on the type of physical activity (sprint, endurance, or 
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chronic wheel running). Many of these cytokines are considered novel exercise-regulated 
myokines. Concordance between mRNA and protein level was observed for only a small subset 
of cytokines. Further, we showed that a subset of circulating cytokines is likely induced and 
secreted in non-muscle tissues in response to exercise, highlighting the primary skeletal muscle 




Eight-week-old C57BL/6J male mice were purchased from The Jackson Labs. All mice 
were housed in polycarbonate cages under a 12:12-h light-dark photocycle (6 AM – 6 PM)  and 
had access to food and water ad libitum throughout the study period. Mice were allowed to 
acclimate for one week before experimentation. All animal experiments were approved by the 
Animal Care and Use Committee of The Johns Hopkins University School of Medicine.  
Mice were randomly divided into 4 groups of 10 mice for the following control or exercise 
paradigms: sedentary, sprint exercise, endurance exercise, and voluntary exercise. At 9 weeks of 
age, blood was collected from the tail vein for pre-exercise measurements from all mice, including 
the sedentary group. While serum samples from the sedentary group were not used for analysis, 
blood was still collected from this group to normalize treatment and handling among all groups. 
Samples were collected at the same time of day for all mice (10:30 AM). Serum was separated 
using Microvette® CB 300 LH (The SARSTEDT Group, Numbrecht, Germany), and separated 
serum was stored at -80C until analysis.  
For sprint and endurance exercise conditions, mice were acclimatized to the treadmill (Exer 
3/6 treadmill; Columbus Instruments) for 3 days before the exercise test as follows: day 1: mice 
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were placed on the stationary treadmill for 10 min (with the shock grid on); day 2: mice were run 
on the treadmill at a speed of 5 m/min for 10 min at a 10 incline; day 3: mice were run on the 
treadmill at 10 m/min for 10 min at a 10 incline. A shock grid at the back of the treadmill 
encouraged mice to continue running by administering a mild shock each time they stepped off 
the belt. The acute exercise tests were performed on the fourth day when the mice were 10 weeks 
of age. 
Sprint exercise: Baseline blood glucose and lactate levels were measured with glucose and 
lactate meters (Nova Biomedical) from a drop of blood obtained through the tail vein. Mice were 
run on the treadmill set to a fixed incline of 15 until exhaustion using the following speed 
protocol: 5 m/min for 1 min, 10 m/min for 2 min, then 2 min intervals of the following speeds 
(m/min): 10, 14, 18, 22, 26, 28, 30, 32, 34, 36, 38, 40. Mice were run in multiple groups beginning 
at 9:30 AM. A mouse was considered exhausted when it remained on the shock grid for 5 
continuous seconds and, after being blown by one puff of air at 5 sec, still didn’t move back to 
treadmill within 2 sec of the air puff. Immediately after finishing the run, blood glucose and lactate 
levels were measured (Table 1). Within 5 min of finishing the run, mice were anesthetized with 
isoflurane, euthanized with cervical dislocation, and the following tissues were collected: blood 
from the retro-orbital sinus via heparin-coated capillary tubes (Fisher 22-362-566), soleus, 
plantaris, and gastrocnemius muscles, visceral (epididymal) and subcutaneous (inguinal) white 
adipose tissue, and liver. Separated serum and tissues were flash frozen in liquid nitrogen, and all 
samples were stored at -80C until analysis. 
Endurance exercise: Baseline blood glucose and lactate levels were measured and then 
mice were run on the treadmill at a fixed incline of 10 until exhaustion using the following speed 
protocol: 10 m/min for 30 min, then an increase of 2 m/min every 15 min thereafter. Mice were 
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run in multiple groups beginning at 9:30 AM. Mice were considered exhausted using the same 
criteria as detailed above. After measuring post-run glucose and lactate values (Table 1), mice 
were euthanized within 5 min of finishing the run and tissues were collected in the same manner 



























Sprint 25.7 ± 0.6 186 ± 6 2.0 ± 0.3 11 ± 1 156 ± 20 199 ± 9 11.0 ± 0.6 
Endurance run 26.6 ± 0.6 176 ± 5 3.0 ± 0.4 72 ± 5 912 ± 85 210 ± 6 5.5 ± 0.3 
Voluntary wheel running 25.7 ± 0.5 183 ± 5 --         
Sedentary 25.3 ± 0.4 193 ± 6 2.3 ± 0.2         
 
Table 1. Body weight, total run time and distance, and pre- and post-exercise blood glucose and 
lactate levels. All values shown as average + S.E. N=10 mice per group. 
 
Voluntary exercise: At 10 weeks of age, mice were separated into individual cages and a 
running wheel (Columbus Instrument) was placed in each cage such that mice had free access to 
it. This represents a form of chronic exercise. After one week, mice were sacrificed and tissues 
were collected as described above. Running wheels were left in the cages until the time of sacrifice 
(10:30 AM). 
Sedentary control: At 10 weeks of age, mice that were normally housed in the cage (with 
no running wheel) were sacrificed and tissues were collected as described above. Mice were 
sacrificed at 10:00 AM. 
Throughout the study, all mice were treated in the exact same manner, with the exception 




Muscle lysate preparation 
One plantaris and one soleus muscle from each mouse was used.  Muscles were lysed in 
500 L PBS supplemented with protease inhibitor cocktail (Sigma). First, muscles were 
homogenized with a 1 mL glass dounce homogenizer (Wheaton), using the loose pestle followed 
by the tight pestle. Subsequently, the suspension was subjected to sonication to complete the tissue 
lysis (Branson Sonifier 150; 5-10 s at the lowest setting). Homogenates were centrifuged at 12,000 
x g for 20 min at 4C and the supernatant was transferred to a new tube. Total protein content in 
the supernatant was quantified with a Bradford protein assay (Sigma), and the cleared lysate was 
stored at -80C until analysis. 
 
Multiplex assays for measuring cytokine protein level 
Multiplex assays for 66 mouse cytokines (covering the majority of the well-studied 
cytokines) were performed using a Luminex bead-based multiplex system according to 
manufacturer’s protocol (EMD Millipore, Billerica, MA). This method is sensitive and 
reproducible (39, 40) and has been validated in multiple studies (27, 41). The following 4 assay 
kits (covering 66 analytes according to their dynamic range) from Millipore were used to measure 
the concentrations of cytokines in mouse serum, soleus homogenate, and plantaris homogenate: 
MCYTOMAG-70K, MECY2MAG-73K, MSCRMAG-42K, and MTH17MAG-47K. IFN-γ 
protein levels in soleus and plantaris were measured with the kit MCYTOMAG-70K. However, 
IFN-γ levels in serum were measured using a more sensitive assay kit MECY2MAG-73K. Many 
cytokine receptors are known to be proteolytic cleaved and the soluble ligand-binding ectodomain 
circulates in plasma (42). Thus, secreted sCD30, sIL-1RI, sIL-1RII, sIL-2Ra, sIL-4R, sIL-6R, 
sTNFRI, sTNFRII, sVEGFR1, sVEGFR2, sVEGFR3, sgp130, and sRAGE were also measured as 
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part of the 66 cytokines profiled. The experiments were set up according to the manufacturer’s 
protocol and the assays were performed as we have previously described (43). In brief, standards 
were provided for each mouse cytokine, from which standard curves were generated. Serum was 
diluted according to the manufacturer’s protocol and cleared muscle lysates were assayed 
undiluted. For soleus lysates, an average of 18.05  6.79 pg protein was added per well, and for 
plantaris lysates, an average of 38.84  10.43 pg protein was added per well. All samples (n=10 
mice per group) and standards were analyzed using a Luminex 200 instrument (Luminex, Austin, 
TX) and XPonent 3.1 Software (Millipore, Billerica, MA). Concentrations were determined for 
each of the 66 mouse cytokines relative to an appropriate 6-point regression standard curve in 
which the mean fluorescence for each cytokine standard was transformed into known 
concentrations (pg/mL or ng/mL). For muscle lysates, cytokine concentrations were normalized to 
total protein before further analysis. The multiplex assays were carried out on three separate 
occasions, each time with different samples: 1) pre- and post- exercise serum from sprint and 
endurance mice, 2) pre- and post- exercise serum from voluntary running mice, and 3) all muscle 
lysates from all 4 exercise regimes. All samples that were used for direct comparison or 
normalization were run on the same plate.  
 
QuantiGene Plex assay (QGP) for measuring cytokine mRNA level  
QuantiGene Plex assays enable simultaneous quantification of up to 80 genes of interest in 
a single well of a 96-well plate. This method is hybridization-based and incorporates branched 
DNA (bDNA) technology (44, 45). Because it relies on signal amplification rather than target 
amplification for direct measurement of RNA transcripts, no RNA isolation and reverse 
transcription is needed. QuantiGene assay has comparable or better linear range and relative 
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accuracy when compared to standard real-time PCR method (46). All Gene-specific QuantiGene 
probes were validated and provided by Thermo Fisher Scientific. Soleus and plantaris muscle 
fibers harvested from mice were weighed, and placed on dry ice until ready to process. 5-15 mg 
of tissue was used in sample preparation. Tissues were lysed in 300 μL of homogenizing solution 
(QGP Assay Kit, Thermo Fisher Scientific, Waltham, MA) per 10 mg tissue, using an MP24 
fastprep (MP Biomedicals, Santa Ana, CA) with MP lysing matrix A tubes (Cat #6910-100, MP 
Biomedicals). Tissue homogenates were heated at 65°C for 1 h, with vortexing every 10 min. 
Heated samples were centrifuged at room temperature for 15 min at 16,000 x g to sediment the 
matrix, and the supernatant was transferred to clean microcentrifuge tubes. The supernatant was 
clarified by repeating the above centrifugation step, and the resultant supernatant transferred to 
another clean microcentrifuge tube. Supernatants were added directly to the QGP hybridization 
plate following the addition of master mix prepared according to manufacturer’s instructions. The 
hybridization plate was incubated overnight at 57°C with shaking at 600 rpm. The next day, the 
plate was processed according to manufacturer’s instructions, and read on a Luminex 200 
instrument (Luminex, Austin, TX). Data was analyzed and fold change calculated according to 
manufacturer’s instructions, using Hprt and Actb as reference genes. Statistical analyses were 
performed using a one-way ANOVA with Dunnett’s post-test with the sedentary group as the 
control.  
 
Quantitative real-time PCR analysis 
Total RNA was isolated from liver, visceral (epididymal) and subcutaneous (inguinal) 
white adipose tissues using Trizol® (Life Technologies). Random primers and GoScript reverse 
transcriptase (Promega) were used to generate cDNA. Quantitative real-time PCR analyses were 
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performed on CFX Connect Real-Time system (Bio-Rad) using iTaq Universal SYBR Green 
Supermix (Bio-Rad). The data were normalized to 36B4 (also known as acidic ribosomal 
phosphoprotein P0 (RPLP0)) to generate a Ct value, and then a Ct was obtained by 
normalizing the data to the mean Ct of the control group (47). 36B4 gene was selected for 
normalization because it had the least variation across tissue samples. All primers used for real-
time PCR analyses are listed in Table 2.  
 
Gene Forward primer Reverse primer 
CXCL1 (KC) CTGGGATTCACCTCAAGAACATC CAGGGTCAAGGCAAGCCTC 
EPO ACTCTCCTTGCTACTGATTCCT ATCGTGACATTTTCTGCCTCC 
IL-20 TCTTGCCTTTGGACTGTTCTCC GTTTGCAGTAATCACACAGCTTC 
IL-17a TTTAACTCCCTTGGCGCAAAA CTTTCCCTCCGCATTGACAC 
IL-17f TGCTACTGTTGATGTTGGGAC AATGCCCTGGTTTTGGTTGAA 
sgp130 (IL-6ST) CCGTGTGGTTACATCTACCCT CGTGGTTCTGTTGATGACAGTG 
IL-16 AAGAGCCGGAAATCCACGAAA GTCTCAAAAGGGTCAGGGTACT 
CCL17 (TARC) GACGACAGAAGGGTACGGC GCATCTGAAGTGACCTCATGGTA 
IFN-γ ATGAACGCTACACACTGCATC CCATCCTTTTGCCAGTTCCTC 
CX3CL1 (Fractalkine) ACGAAATGCGAAATCATGTGC CTGTGTCGTCTCCAGGACAA 
TIMP-1 GCAACTCGGACCTGGTCATAA CGGCCCGTGATGAGAAACT 
IL-4R TCTGCATCCCGTTGTTTTGC GCACCTGTGCATCCTGAATG 
TNF-RII ACACCCTACAAACCGGAACC AGCCTTCCTGTCATAGTATTCCT 
CXCL10 (IP10) CCAAGTGCTGCCGTCATTTTC GGCTCGCAGGGATGATTTCAA 
TNF-RI CCGGGAGAAGAGGGATAGCTT TCGGACAGTCACTCACCAAGT 
G-CSF ATGGCTCAACTTTCTGCCCAG CTGACAGTGACCAGGGGAAC 
CCL12 (MCP-5) ATTTCCACACTTCTATGCCTCCT ATCCAGTATGGTCCTGAAGATCA 
CCL20 (MIP-3a) GCCTCTCGTACATACAGACGC CCAGTTCTGCTTTGGATCAGC 
36B4 AGATTCGGGATATGCTGTTGGC TCGGGTCCTAGACCAGTGTTC 
 
Table 2. Quantitative real-time PCR primers used in the study 
 
Confirmatory experiment with a second cohort of mice 
A second independent cohort of endurance and sedentary mice was used to confirm some 
of the findings obtained from the multiplex assays. As before, 8 week-old C57BL/6J mice were 
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purchased from Jackson Labs for the experiments with N=10 per group. However, data for the 
endurance group reflects N=6 because 2 mice refused to run despite being adequately acclimated 
to the treadmill and 2 mice were running when the treadmill experienced technical issues so had 
to be taken out of the study. The experiments were conducted exactly as described previously with 
the exception of timing of the pre-exercise blood draws. Given that a large volume of serum was 
needed to satisfy the volume requirements for multiple ELISAs, blood was drawn on two separate 
occasions before the exercise experiment: once 3 weeks before the endurance run and once 2 weeks 
before the run. Serum from both blood draws was combined before it was assayed. Mice were 
allowed to recover for two full weeks after the last pre-exercise blood draw as opposed to the one 
week of recovery with the first cohort. Thus, the mice in this second cohort were approximately 2 
weeks older and a few grams heavier than their counterparts in the first cohort on the day of the 
experiment. Otherwise, all data including time to exhaustion, blood glucose, and blood lactate 
levels matched very well between the two cohorts. Soleus and plantaris lysates were prepared as 
described except both muscles were used and the volume of buffer was reduced to 350 L. These 
changes were implemented to increase the signal in the ELISAs. 
The following cytokines were measured via ELISA in the pre- and post- exercise serum 
from the endurance group and soleus and plantaris lysates from all endurance and sedentary mice: 
MCP-5, KC, MIP-2, MIP-3, IFN, and sTNFRI. ELISAs for all targets were purchased from R&D 
Systems with the exception of sTNFRI, which was purchased from Thermo Scientific. Assays 
were carried out according to the manufacturer’s protocol. Muscle lysates were assayed undiluted, 





For a given analyte, not all samples were successfully detected in the multiplex analysis. 
Data for a given analyte was analyzed when analyte levels were detected in at least 3 out of the 10 
samples. To enable paired t-test analysis (where N ≥ 3), serum analyte levels must be detected in 
both pre- and post-exercise samples from the same mouse. It should be noted that the vast majority 
(~90%) of statistically significant data were obtained from sample size N=9-10. For statistical 
analysis, a paired t-test was used to analyze pre-exercise versus post-exercise serum data. The 
nonparametric Wilcoxon matched pairs test was used to analyze data in which the differences (post 
minus pre) were not Gaussian. Lysate data were analyzed by 1-way-ANOVA. The means from 
each exercise condition were compared to that from the sedentary condition using Dunnett’s post-
test. P < 0.05 was considered significant. All data is reported as mean  SEM. Data was analyzed 
using Graph Pad Prism 7 software. For each data set, false discovery rate analysis was also 
performed with GraphPad Prism 7 using the recommended two-stage step-up method of 
Benjamini, Krieger and Yekutieli. The false discovery rate (Q) was set to 5%. 
 
RESULTS 
Using multiplex technology to measure cytokine levels 
Three exercise paradigms—sprint, endurance exercise, and voluntary wheel running—
representing an acute and chronic forms of physical activity, were used in the present study to 
assess changes in circulating serum cytokines, as well as their protein levels in glycolytic 
(plantaris) and oxidative (soleus) muscles. A bead-based multiplex profiling method was used to 
quantify 66 cytokines in both serum and muscle lysates. We could reliably detect and measure up  
to 52 cytokines from among the 66 cytokines profiled (Tables 3 and 4). This is not surprising 
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Table 3  
Serum cytokine        
 
























G-CSF 290 ± 26 341 ± 73 343 ± 69 250 ± 33 3244 ± 457 787 ± 149 *** 
Eotaxin-1/CCL11 1265 ± 171 1526 ± 233 1417 ± 261 1654 ± 216 1344 ± 378 1475 ± 342 
GM-CSF 77 ± 32 52 ± 10 -- 30 ± 9 48 ± 11 69 ± 30 
IFN-β1 -- -- -- -- -- -- 
IFN-γ 491 ± 50 337 ± 49 ** 472 ± 37 285 ± 36 *** 367 ± 54 113 ± 10 ** 
IL-1α 111 ± 15 125 ± 12 125 ± 25 122 ± 22 148 ± 27 247 ± 84 
IL-1β 37 ± 15 20 ± 7 21 ± 5 37 ± 14 -- 23 ± 6 
IL-2 -- -- -- -- 8 ± 1 6 ± 3 
IL-3 -- -- -- -- -- -- 
IL-4 -- -- -- -- -- -- 
IL-5 13 ± 2 9 ± 1   15 ± 3 11 ± 1 11 ± 2 
IL-6 15 ± 4 30 ± 11 11 ± 2 9 ± 0 56 ± 10 15 ± 3 * 




5 ± 1 6 ± 1 
IL-9 377 ± 131 443 ± 308 669 ± 549 501 ± 155 229 ± 45 272 ± 40 
IL-10 13 ± 3 10 ± 2 -- -- 4 ± 1 9 ± 4 
IL-11 304 ± 49 274 ± 21 416 ± 40 476 ± 115 -- -- 
IL-12 (p40) 15 ± 3 17 ± 2 10 ± 1 14 ± 3 15 ± 5 15 ± 4 
IL-12 (p70)   20 ± 5   26 ± 9 12 ± 5 17 ± 6 
IL-13 36 ± 4 42 ± 1 32 ± 0 40 ± 4 11 ± 2 10 ± 2 
IL-15 33 ± 17 42 ± 17 64 ± 51 78 ± 26 63 ± 27 100 ± 36 
IL-16 3525 ± 311 2590 ± 431 * 4062 ± 338 2321 ± 186 *** 4761 ± 747 1509 ± 147 ** 
IL-17A -- -- -- -- -- -- 
IL-17A/F 1922 ± 77 1567 ± 73 * 1919 ± 126 1828 ± 295 286 ± 39 203 ± 15 
IL-17F -- -- -- 
 
10 ± 5 14 ± 8 
IL-20 1431 ± 187 2183 ± 343 * 1568 ± 220 2427 ± 446 434 ± 91 359 ± 76 
IL-21 -- -- -- -- -- -- 
IL-22 7 ± 3 53 ± 49 9 ± 2 10 ± 2 15 ± 5 9 ± 2 
IL-23 388 ± 66 884 ± 212 410 ± 53 762 ± 106 735 ± 91 352 ± 61 
IL-27 1212 ± 186 1311 ± 137 920 ± 120 1110 ± 72 1307 ± 307 1201 ± 102 
IL-28B -- 17104 ± 9808 -- -- -- 119 ± 22 
IL-33 -- 2062 ± 2016 -- 98 ± 31 -- -- 
IP-10/CXCL10 159 ± 9 154 ± 19 172 ± 13 109 ± 19 * 246 ± 19 229 ± 7 
KC/CXCL1 125 ± 25 309 ± 78 * 143 ± 27 284 ± 30 ** 619 ± 110 392 ± 52 * 
LIF -- -- -- -- -- -- 
LIX/CXCL5 5100 ± 1955 4250 ± 1027 3935 ± 1499 4771 ± 1302 717 ± 224 2998 ± 1013 
MCP-1/CCL2 102 ± 25 102 ± 13 61 ± 8 77 ± 7 27 ± 6 49 ± 9 
M-CSF 21 ± 7 35 ± 10   23 ± 9 14 ± 3 14 ± 4 
MIG/CXCL9 171 ± 13 208 ± 17 188 ± 22 172 ± 17 136 ± 14 151 ± 20 
MIP-1α/CCL3 74 ± 11 90 ± 7 68 ± 5 85 ± 16 40 ± 11 51 ± 14 
MIP-1β/CCL4 41 ± 6 38 ± 4 35 ± 0 36 ± 13 46 ± 5 37 ± 4 
MIP-2/CXCL2 199 ± 32 215 ± 21 124 ± 13 169 ± 15 * 206 ± 56 270 ± 28 
RANTES/CCL5 24 ± 4 26 ± 3 17 ± 2 19 ± 2 16 ± 2 16 ± 3 
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Table 3 - continued  
Serum cytokine        
 
























TNF-α 9 ± 0 11 ± 2 9 ± 1 14 ± 3 15 ± 4 15 ± 4 
VEGF -- -- -- -- -- -- 
Exodus-2/CCL21 10433 ± 392 10817 ± 635 11022 ± 379 11095 ± 433 20853 ± 1796 20777 ± 1125 
Fractalkine/CX3CL1 2431 ± 92 2607 ± 116 2427 ± 57 2770 ± 119 * 609 ± 47 730 ± 47 
MDC/CCL22 394 ± 46 492 ± 53 496 ± 48 455 ± 40 161 ± 34 136 ± 20 
MCP-5/CCL12 416 ± 36 392 ± 33 368 ± 37 293 ± 31 * 252 ± 36 160 ± 23 ** 
MIP-3α/CCL20 269 ± 11 237 ± 9 272 ± 11 215 ± 10 * 102 ± 6 74 ± 4 ** 
MIP-3β/CCL19 687 ± 52 676 ± 71 745 ± 70 776 ± 122 143 ± 29 77 ± 12 
TARC/CCL17 327 ± 13 227 ± 12 *** 359 ± 61 176 ± 9 ** 73 ± 10 56 ± 6 
TIMP-1 4641 ± 198 4515 ± 678 4842 ± 222 2905 ± 52 *** 5184 ± 372 3313 ± 179 *** 
sCD30 -- -- -- -- -- 67 ± 0 
sgp130 658 ± 69 430 ± 53 * 527 ± 32 459 ± 43 616 ± 56 649 ± 54 
sIL-1RI 1760 ± 298 1679 ± 198 2189 ± 263 1705 ± 210 2914 ± 362 1966 ± 378 
sIL-1RII 6343 ± 149 6348 ± 117 6445 ± 153 6685 ± 134 11780 ± 446 11412 ± 281 
sIL-2Ra 366 ± 25 376 ± 20 367 ± 14 392 ± 32 467 ± 21 448 ± 26 
sIL-4R 2434 ± 477 1851 ± 257 2481 ± 311 1601 ± 153 ** 2859 ± 204 2302 ± 163 
sIL-6R 11627 ± 508 10710 ± 437 11691 ± 226 11713 ± 487 19337 ± 639 17804 ± 754 
sRAGE 252 ± 63 332 ± 140 347 ± 154 -- -- -- 
sTNFRI 2786 ± 205 2823 ± 196 3032 ± 252 2101 ± 139 *** 8200 ± 597 6461 ± 372 * 
sTNFRII 5833 ± 559 5028 ± 292 5851 ± 663 5156 ± 589 ** 9591 ± 572 7926 ± 288 * 
sVEGFR1 997 ± 349 618 ± 100 507 ± 70 507 ± 74 368 ± 79 707 ± 240 
sVEGFR2 33031 ± 1833 28423 ± 2901 29170 ± 1504 36032 ± 1903 -- -- 
sVEGFR3 26831 ± 1438 28009 ± 711 29247 ± 448 29785 ± 888 61281 ± 2402 62438 ± 2043 







# of cytokine 
detected 
48 45 49 
# of cytokine 
changed 
8 13 10 
% of cytokine 
changed 
17% 29% 20% 
 
Table 3. Summary of cytokine protein levels in serum in response to sprint, endurance run, or 
voluntary wheel running for 1 week. All values shown as average + S.E. Those cytokines that are below 







  Soleus  (protein) Plantaris  (protein) 
  
      














Analyte (Fold change) (Fold change) (Fold change) (Fold change) (Fold change) (Fold change) 
  
   
  
  
G-CSF -- -- -- -- -- -- 
Eotaxin-1/CCL11 1.09 ± 0.08 0.82 ± 0.03 *** 0.57 ± 0.01 1.10 ± 0.07 0.96 ± 0.10 ** 0.64 ± 0.05 
GM-CSF 1.57 ± 0.34 1.35 ± 0.21 -- 0.36 ± 0.08 0.43 ± 0.13 0.17 ± 0.03 
IFN-β1 -- -- -- -- -- -- 
IFN-γ * 1.47 ± 0.12 * 1.55 ± 0.22 *** 0.10 ± 0.01 0.67 ± 0.10 0.97 ± 0.21 ** 0.15 ± 0.02 
IL-1α * 1.23 ± 0.10 *** 1.40 ± 0.08 *** 0.20 ± 0.01 0.83 ± 0.07 1.05 ± 0.18 ** 0.31 ± 0.02 
IL-1β * 1.57 ± 0.17 *** 1.86 ± 0.18 1.13 ± 0.03 1.17 ± 0.08 * 1.36 ± 0.10 0.78 ± 0.05 
IL-2 1.21 ± 0.08 * 1.28 ± 0.09 *** 0.18 ± 0.01 0.80 ± 0.08 1.02 ± 0.17 ** 0.32 ± 0.02 
IL-3 -- -- -- -- -- -- 
IL-4 1.07 ± 0.13 0.81 ± 0.13 -- 0.76 ± 0.09 0.97 ± 0.18 ** 0.32 ± 0.02 
IL-5 2.16 ± 0.46 1.14 ± 0.20 0.36 ± 0.06 0.63 ± 0.21 0.49 ± 0.18 0.20 ± 0.10 
IL-6 * 1.29 ± 0.10 ** 1.42 ± 0.12 *** 0.17 ± 0.01 0.81 ± 0.08 1.06 ± 0.18 *** 0.22 ± 0.01 
IL-7 -- -- -- 0.74 ± 0.15 1.48 ± 0.54 -- 
IL-9 1.13 ± 0.06 *** 1.35 ± 0.07 *** 0.22 ± 0.02 0.86 ± 0.08 1.08 ± 0.14 *** 0.19 ± 0.02 
IL-10 * 2.22 ± 0.51 1.33 ± 0.17 1.08 ± 0.26 0.79 ± 0.14 0.94 ± 0.20 1.24 ± 0.16 
IL-11 -- -- -- -- -- -- 
IL-12 (p40) ** 1.73 ± 0.18 *** 2.10 ± 0.15 *** 0.16 ± 0.01 0.75 ± 0.13 0.86 ± 0.13 *** 0.10 ± 0.01 
IL-12 (p70) -- -- -- -- -- -- 
IL-13 -- -- -- 0.48 ± 0.11 0.75 ± 0.19 0.21 ± 0.03 
IL-15 1.65 ± 0.22 ** 2.06 ± 0.21 * 0.14 ± 0.02 * 0.56 ± 0.10 0.76 ± 0.11 *** 0.05 ± 0.01 
IL-16 0.89 ± 0.08 0.71 ± 0.03 *** 1.88 ± 0.18 1.14 ± 0.08 0.98 ± 0.09 0.90 ± 0.11 
IL-17A -- -- -- 0.63 ± 0.10 0.90 ± 0.18 -- 
IL-17A/F -- -- -- -- -- -- 
IL-17F -- -- -- -- -- -- 
IL-20 1.23 ± 0.08 1.56 ± 0.13 * 1.70 ± 0.19 0.71 ± 0.13 1.62 ± 0.54 0.97 ± 0.23 
IL-21 -- -- -- -- -- -- 
IL-22 * 1.51 ± 0.18 1.35 ± 0.17 ** 0.28 ± 0.01 0.83 ± 0.11 0.71 ± 0.11 *** 0.23 ± 0.01 
IL-23 1.28 ± 0.13 1.22 ± 0.26 -- 0.47 ± 0.06 0.53 ± 0.08 -- 
IL-27 -- -- -- 0.77 ± 0.08 0.91 ± 0.17 -- 
IL-28B -- -- -- 0.65 ± 0.07 0.71 ± 0.11 -- 
IL-33 1.04 ± 0.11 * 0.61 ± 0.07 * 0.64 ± 0.06 1.27 ± 0.17 0.86 ± 0.12 0.62 ± 0.07 
IP-10/CXCL10 * 1.58 ± 0.14 * 1.61 ± 0.19 1.01 ± 0.13 0.81 ± 0.05 0.96 ± 0.10 *** 0.25 ± 0.05 
KC/CXCL1 1.52 ± 0.11 ** 1.72 ± 0.26 * 0.45 ± 0.02 0.61 ± 0.0769 1.01 ± 0.17 *** 0.12 ± 0.01 
LIF -- -- -- -- -- -- 
LIX/CXCL5 -- -- -- 0.49 ± 0.09 0.85 ± 0.21 -- 
MCP-1/CCL2 1.22 ± 0.16 1.46 ± 0.31 0.96 ± 0.18 1.21 ± 0.19 1.15 ± 0.14 0.91 ± 0.20 
M-CSF 1.68 ± 0.32 0.90 ± 0.21 0.34 ± 0.03 0.75 ± 0.07 0.89 ± 0.16 *** 0.24 ± 0.01 
MIG/CXCL9 1.51 ± 0.09 1.56 ± 0.21 1.35 ± 0.27 1.06 ± 0.06 1.01 ± 0.08 *** 0.39 ± 0.07 
MIP-1α/CCL3 1.45 ± 0.16 1.54 ± 0.14 1.18 ± 0.06 1.22 ± 0.09 *** 1.51 ± 0.10 ** 0.60 ± 0.07 
MIP-1β/CCL4 -- -- -- -- -- -- 
MIP-2/CXCL2 1.58 ± 0.29 *** 2.89 ± 0.39 1.30 ± 0.18 0.45 ± 0.12 0.82 ± 0.26 0.18 ± 0.05 
RANTES/CCL5 * 1.46 ± 0.15 * 1.49 ± 0.18 *** 0.21 ± 0.01 0.76 ± 0.10 0.73 ± 0.13 *** 0.19 ± 0.02 
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Table 4 - continued 
  Soleus  (protein) Plantaris  (protein) 
  
      














Analyte (Fold change) (Fold change) (Fold change) (Fold change) (Fold change) (Fold change) 
  
   
  
  
TNF-α -- -- -- -- -- -- 
VEGF ** 0.64 ± 0.09 *** 0.63 ± 0.05 *** 0.38 ± 0.03 *** 0.62 ± 0.05 ** 0.70 ± 0.05 * 0.76 ± 0.07 
Exodus-2/CCL21 0.70 ± 0.12 * 0.54 ± 0.11 0.69 ± 0.06 1.08 ± 0.07 0.80 ± 0.05 * 0.66 ± 0.11 
Fractalkine/CX3CL1 -- -- ** 0.62 ± 0.05 -- 1.09 ± 0.34 -- 
MDC/CCL22 1.12 ± 0.10 1.16 ± 0.10 0.80 ± 0.06 0.87 ± 0.07 1.04 ± 0.17 0.63 ± 0.11 
MCP-5/CCL12 0.61 ± 0.08 * 0.42 ± 0.06 * 1.51 ± 0.18 0.73 ± 0.08 0.73 ± 0.15 0.92 ± 0.24 
MIP-3α/CCL20 1.11 ± 0.06 * 1.20 ± 0.05 *** 0.33 ± 0.01 0.84 ± 0.06 0.90 ± 0.14 *** 0.29 ± 0.03 
MIP-3β/CCL19 1.20 ± 0.16 1.00 ± 0.11 ** 1.65 ± 0.14 0.96 ± 0.09 1.15 ± 0.08 0.86 ± 0.11 
TARC/CCL17 -- -- -- -- -- -- 
TIMP-1 0.76 ± 0.09 0.55 ± 0.06 *** 4.16 ± 0.67 0.87 ± 0.11 0.78 ± 0.13 * 3.01 ± 1.01 
sCD30 0.95 ± 0.05 0.82 ± 0.07 
 
0.77 ± 0.03 0.88 ± 0.13 0.83 ± 0.26 
sgp130 1.09 ± 0.11 1.34 ± 0.11 * 0.60 ± 0.09 1.39 ± 0.11 1.64 ± 0.25 2.02 ± 1.12 
sIL-1RI 1.10 ± 0.09 1.14 ± 0.04 *** 0.57 ± 0.03 0.86 ± 0.06 1.03 ± 0.07 ** 0.66 ± 0.06 
sIL-1RII 1.04 ± 0.10 0.78 ± 0.05 0.78 ± 0.06 * 1.65 ± 0.33 1.19 ± 0.08 0.82 ± 0.11 
sIL-2Ra -- -- -- -- -- -- 
sIL-4R -- -- -- -- -- -- 
sIL-6R 1.08 ± 0.17 0.80 ± 0.10 0.94 ± 0.07 ** 2.10 ± 0.41 1.48 ± 0.14 0.69 ± 0.07 
sRAGE 1.19 ± 0.10 1.28 ± 0.14 *** 0.17 ± 0.01 0.73 ± 0.06 0.82 ± 0.13 *** 0.16 ± 0.06 
sTNFRI 0.87 ± 0.06 ** 0.73 ± 0.06 0.82 ± 0.05 1.10 ± 0.07 1.07 ± 0.05 0.82 ± 0.14 
sTNFRII 0.89 ± 0.06 0.70 ± 0.05 *** 1.66 ± 0.13 1.11 ± 0.07 1.08 ± 0.06 1.05 ± 0.14 
sVEGFR1 1.05 ± 0.06 * 0.79 ± 0.03 *** 0.64 ± 0.03 1.23 ± 0.12 1.32 ± 0.09 0.71 ± 0.07 
sVEGFR2 * 0.84 ± 0.04 *** 0.61 ± 0.03 * 0.83 ± 0.04 0.91 ± 0.05 0.79 ± 0.06 0.88 ± 0.10 
sVEGFR3 0.89 ± 0.11 0.90 ± 0.07 0.88 ± 0.04 1.52 ± 0.10 1.49 ± 0.15 1.46 ± 0.37 
EPO 1.24 ± 0.10 * 1.40 ± 0.09 -- 0.63 ± 0.08 0.90 ± 0.17 -- 
  
   
  
  
# of cytokines 
detected 
45 45 42 51 52 44 
# of cytokines 
changed 
11 21 26 4 3 22 
% of cytokines 
changed 
24% 47% 62% 8% 6% 50% 
 
Table 4. Summary of cytokine protein levels in soleus and plantaris muscles in response to sprint, 
endurance run, or voluntary wheel running for 1 week. All values are normalized to the control 
sedentary group and shown as fold change + S.E. Those cytokines that are below the detection limit of the 
assay are indicated by “--”. N=10 mice per group. *p< 0.05; **p<0.01; ***p<0.001. 
 
given that some cytokines are expressed at very low levels and are only upregulated in the context 
of immune activation in response to infection. Remarkably, a large fraction of the cytokines 
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detected were significantly altered by acute and chronic exercise (Tables 3 and 4). When adjusted 
for false discovery, most of the significant changes still remain (Tables 5-7). Using a second 
independent cohort of mice subjected to an endurance run, we confirmed the validity of the 
multiplex assay using the standard, conventional ELISA method. Of the six chosen targets 
analysed, three (MCP-5/CCL12, KC/CXCL1, and MIP-2/CXCL2) were significantly different 
between pre- and post-exercise serum, and the direction of change matched that of the multiplex 
data (Fig. 1). Similarly, three targets were significantly different between sedentary and exercised 
soleus, and the direction of change matched that of the multiplex data (MCP-5/CCL12, IFN-γ, and 
sTNFRI). In agreement with the multiplex data, none of the targets (except sTNFRI) were 
significantly different between sedentary and exercised plantaris as measured by ELISA (Fig. 1). 
 
Changes in serum cytokine levels in response to different exercise regimes 
In serum, we observed significant changes in eight (17%), thirteen (29%), and ten (20%) 
circulating cytokines in response to a single bout of sprint, endurance run, and 1-week voluntary 
wheel running, respectively (Table 3). A much greater overlap was seen between a single bout of 
endurance run and voluntary wheel running (Fig. 2). With the exception of CXCL1, the direction 
of change in serum levels was consistent among all the overlapping cytokines in three of the 
exercise paradigms. While there was overlap, a single bout of sprint and endurance run also altered 
different sets of cytokines (Fig. 2). Of the serum cytokines altered by acute or chronic exercise, 4 





Table 5  
Serum cytokine        
 
























G-CSF 0.5550 0.9079 0.2812 0.4488 0.0007 *** 0.0162 * 












IFN-γ 0.0022 ** 0.0543 0.0002 *** 0.0027** 0.0039 ** 0.0360 * 
IL-1α 0.5432 0.9079 0.9188 0.8866 0.3478 0.5951 



















IL-5 0.5000 0.9079 
 

















  0.5000 0.7202 
IL-11 0.6136 0.9154 0.9531 0.8866 
  





  0.3750 0.6188 
IL-13 0.5000 0.9079 
 
  0.8707 0.9401 
IL-15 0.8750 0.9387 0.6250 0.7793 0.9999 0.9428 












  0.5000 0.7202 







IL-22 0.8750 0.9387 0.9999 0.8866 0.1471 0.3524 
IL-23 0.2500 0.7711 0.0625 0.1663 0.0625 0.1966 













IP-10/CXCL10 0.8331 0.9387 0.0469 * 0.1439 0.4331 0.6670 







LIX/CXCL5 0.9102 0.9557 0.6684 0.8068 0.0568 0.1966 
MCP-1/CCL2 0.8438 0.9387 0.1875 0.3859 0.1400 0.3524 
M-CSF 0.3750 0.8813 
 
  0.9870 0.9428 
MIG/CXCL9 0.1866 0.7084 0.3499 0.5171 0.6316 0.7944 
MIP-1α/CCL3 0.3350 0.8701 0.2513 0.4178 
  
MIP-1β/CCL4 0.3750 0.8813 0.9999 0.8866 0.2158 0.4483 
MIP-2/CXCL2 0.6134 0.9154 0.0463 * 0.1439 0.9999 0.9428 
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Table 5 - continued  
Serum cytokine        
 
























RANTES/CCL5 0.6875 0.9387 0.6875 0.8068 0.8566 0.9401 








Exodus-2/CCL21 0.5497 0.9079 0.8754 0.8866 0.9731 0.9428 
Fractalkine/CX3CL1 0.1825 0.7084 0.0192 * 0.0766 0.0681 0.1966 
MDC/CCL22 0.1100 0.4935 0.3008 0.4616 0.7695 0.9116 
MCP-5/CCL12 0.4405 0.9079 0.0391 * 0.1418 0.0098 ** 0.0755 
MIP-3α/CCL20 0.0924 0.4935 0.0109 * 0.0483 * 0.0032 ** 0.0360 * 
MIP-3β/CCL19 0.8609 0.9387 0.7689 0.8522 0.0625 0.1966 
TARC/CCL17 0.0001 *** 0.0049 ** 0.0039 ** 0.0222 * 0.2324 0.4483 







sgp130 0.0426 * 0.2949 0.2009 0.3859 0.6362 0.7944 
sIL-1RI 0.7973 0.9387 0.0930 0.2183 0.1579 0.3524 
sIL-1RII 0.9755 1.0000 0.5566 0.7403 0.3439 0.5951 
sIL-2Ra 0.7318 0.9387 0.4104 0.5848 0.5144 0.7202 
sIL-4R 0.3061 0.8701 0.0098 ** 0.0483 * 0.0656 0.1966 







sTNFRI 0.8547 0.9387 0.0005 *** 0.0050 ** 0.0119 * 0.0785 
sTNFRII 0.1012 0.4935 0.0039 ** 0.0222 * 0.0237 * 0.1369 
sVEGFR1 0.3286 0.8701 0.9988 0.8866 0.3125 0.5775 
sVEGFR2 0.2428 0.7711 0.0781 0.1948 
  
sVEGFR3 0.4512 0.9079 0.5798 0.7463 0.5757 0.7823 
EPO 0.0335 * 0.2755 0.2157 0.3912 0.1602 0.3524 
 








Table 6  
Soleus  (protein)        
  Sprint/ Sedentary Endurance/ Sedentary Voluntary wheel running/ 
Sedentary 























Eotaxin-1/CCL11 0.5651 0.8798 0.1151 0.1165 0.0001 *** 0.0002 *** 








IFN-γ 0.0408 * 0.1962 0.0134 * 0.0238 * 0.0001 *** 0.0002 *** 
IL-1α 0.0478 * 0.1962 0.0005 *** 0.0028 ** 0.0001 *** 0.0002 *** 
IL-1β 0.0297 * 0.1962 0.0007 *** 0.0033 ** 0.8656 0.5159 







IL-4 0.9554 0.9833 0.7401 0.5118 
  
IL-5 0.0574 0.1994 0.9874 0.6299 0.4007 0.2761 







IL-9 0.1663 0.3775 0.0001 *** 0.0009 *** 0.0001 *** 0.0002 *** 




















IL-15 0.0703 0.2116 0.0023 ** 0.0072 ** 0.0270 * 0.0271 * 


























IL-22 0.0414 * 0.1962 0.2239 0.2048 0.0027 ** 0.0035 ** 














IL-33 0.9867 0.9900 0.0339 * 0.0481 * 0.0451 * 0.0382 * 
IP-10/CXCL10 0.0171 * 0.1962 0.0117 * 0.0238 * 0.9997 0.5376 













MCP-1/CCL2 0.7783 0.9761 0.3025 0.2599 0.9976 0.5376 
M-CSF 0.1756 0.3775 0.9884 0.6299 0.1950 0.1433 
MIG/CXCL9 0.1754 0.3775 0.1195 0.1168 0.4415 0.2950 







MIP-2/CXCL2 0.4107 0.6868 0.0003 *** 0.0021 ** 0.8335 0.5105 
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Table 6 – continued 
 Soleus  (protein) 
       
  
Sprint/ Sedentary Endurance/ Sedentary Voluntary wheel running/ 
Sedentary 











          
RANTES/CCL5 0.0454 * 0.1962 0.0325 * 0.0481 * 0.0004 *** 0.0006 *** 
TNF-α         
VEGF 0.0012 ** 0.0384 * 0.0009 *** 0.0036 ** 0.0001 *** 0.0002 *** 
Exodus-2/CCL21 0.1696 0.3775 0.0178 * 0.028 * 0.1478 0.1124 
Fractalkine/CX3CL1       0.0043 ** 0.0053 ** 
MDC/CCL22 0.6107 0.9001 0.4004 0.3339 0.2480 0.1764 
MCP-5/CCL12 0.1270 0.3373 0.0143 * 0.0238 * 0.0370 * 0.0348 * 
MIP-3α/CCL20 0.2723 0.5345 0.0126 * 0.0238 * 0.0001 *** 0.0002 *** 
MIP-3β/CCL19 0.6213 0.9001 0.9999 0.6299 0.0051 ** 0.0059 ** 
TARC/CCL17         
TIMP-1 0.9289 0.9833 0.6882 0.5003 0.0001 *** 0.0002 *** 
sCD30 0.8683 0.9833 0.2715 0.2405   
sgp130 0.9033 0.9833 0.1075 0.1129 0.0386 * 0.0348 * 
sIL-1RI 0.6579 0.9001 0.4672 0.3784 0.0008 *** 0.0011 ** 
sIL-1RII 0.9583 0.9833 0.0957 0.1129 0.1016 0.0800 
sIL-2Ra         
sIL-4R         
sIL-6R 0.9339 0.9833 0.5849 0.4482 0.9665 0.5376 
sRAGE 0.3387 0.5882 0.1041 0.1129 0.0001 *** 0.0002 *** 
sTNFRI 0.3044 0.5577 0.0066 ** 0.017 * 0.0828 0.0676 
sTNFRII 0.7341 0.9470 0.0564 0.0695 0.0001 *** 0.0002 *** 
sVEGFR1 0.8220 0.9767 0.0139 * 0.0238 * 0.0001 *** 0.0002 *** 
sVEGFR2 0.0188 * 0.1962 0.0001 *** 0.0009 *** 0.0106 * 0.0117 * 
sVEGFR3 0.6402 0.9001 0.7103 0.5034 0.5825 0.3778 
EPO 0.2547 0.5227 0.0446 * 0.0602   
 









Table 7  
Plantaris  (protein)        
  Sprint/ Sedentary Endurance/ Sedentary Voluntary wheel running/ 
Sedentary 























Eotaxin-1/CCL11 0.6784 0.8957 0.9650 1.0000 0.0050 ** 0.0066 ** 







IFN-γ 0.2919 0.7955 0.9988 1.0000 0.0012 ** 0.0023 ** 
IL-1α 0.6456 0.8957 0.9869 1.0000 0.0017 ** 0.0029 ** 
IL-1β 0.3687 0.7955 0.0181 * 0.3231 0.1910 0.1656 







IL-4 0.3977 0.7955 0.9947 1.0000 0.0019 ** 0.0030 ** 
IL-5 0.4091 0.7955 0.2137 1.0000 0.0608 0.0638 
IL-6 0.5963 0.8957 0.9777 1.0000 0.0006 *** 0.0014 ** 
IL-7 0.8920 0.9784 0.6170 1.0000 
  
IL-9 0.6094 0.8957 0.8781 1.0000 0.0001 *** 0.0004 *** 














IL-13 0.3068 0.7955 0.7279 1.0000 0.1020 0.1028 
IL-15 0.0374 * 0.6143 0.3561 1.0000 0.0002 *** 0.0006 *** 
IL-16 0.6156 0.8957 0.9985 1.0000 0.7976 0.5273 





















IL-22 0.5315 0.8740 0.1887 1.0000 0.0001 *** 0.0004 *** 
IL-23 0.1043 0.7955 0.1811 1.0000 
  
IL-27 0.3590 0.7955 0.8409 1.0000 
  
IL-28B 0.0782 0.7955 0.2264 1.0000 
  
IL-33 0.4253 0.7974 0.8678 1.0000 0.1971 0.1656 
IP-10/CXCL10 0.2034 0.7955 0.9713 1.0000 0.0001 *** 0.0004 *** 







LIX/CXCL5 0.2763 0.7955 0.8310 1.0000 
  
MCP-1/CCL2 0.6894 0.8957 0.8797 1.0000 0.9694 0.5683 
M-CSF 0.3396 0.7955 0.8444 1.0000 0.0003 *** 0.0008 *** 
MIG/CXCL9 0.8945 0.9784 0.9999 1.0000 0.0001 *** 0.0004 *** 







MIP-2/CXCL2 0.2469 0.7955 0.9120 1.0000 0.0575 0.0630 
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Table 7 – continued  
Plantaris  (protein)        
  Sprint/ Sedentary Endurance/ Sedentary Voluntary wheel running/ 
Sedentary 












      







VEGF 0.0005 *** 0.0263 * 0.0057 ** 0.1526 0.0358 * 0.0410 * 
Exodus-2/CCL21 0.8292 0.9464 0.2388 1.0000 0.0158 * 0.0199 * 
Fractalkine/CX3CL1 
 
  0.9999 1.0000 
  
MDC/CCL22 0.7866 0.9177 0.9897 1.0000 0.1522 0.1370 
MCP-5/CCL12 0.4725 0.8554 0.4658 1.0000 0.9679 0.5683 
MIP-3α/CCL20 0.5248 0.8740 0.7869 1.0000 0.0001 *** 0.0004 *** 







TIMP-1 0.9955 1.0000 0.9809 1.0000 0.0243 * 0.0292 * 
sCD30 0.6660 0.8957 0.8600 1.0000 0.8342 0.5273 
sgp130 0.6167 0.8957 0.2059 1.0000 0.1325 0.1284 
sIL-1RI 0.3228 0.7955 0.9762 1.0000 0.0032 ** 0.0045 ** 













sIL-6R 0.0048 ** 0.1260 0.2630 1.0000 0.6915 0.4710 
sRAGE 0.2022 0.7955 0.5269 1.0000 0.0001 *** 0.0004 *** 
sTNFRI 0.7507 0.8957 0.8913 1.0000 0.3584 0.2737 
sTNFRII 0.7392 0.8957 0.8782 1.0000 0.9698 0.5683 
sVEGFR1 0.2953 0.7955 0.1043 1.0000 0.1412 0.1318 
sVEGFR2 0.7196 0.8957 0.1527 1.0000 0.5676 0.4207 
sVEGFR3 0.2636 0.7955 0.3285 1.0000 0.3393 0.2672 
EPO 0.1810 0.7955 0.8614 1.0000 
  
 






























Figure 1. Measurements of six cytokines in a second independent cohort of mice subjected to an 
endurance run using conventional ELISA method. (A) ELISA quantification of MCP-5/CCL12, MIP-
3/CCL20, KC/CXCL1, MIP-2/CXCL2, IFN-, and sTNFRI in pre- and post-exercise serum. (B) ELISA 
quantification of MCP-5/CCL12, MIP-3/CCL20, KC/CXCL1, MIP-2/CXCL2, IFN-, and sTNFRI in 

































































































































































































































































































































































Figure 2. Venn diagram of cytokines altered by sprint, endurance run, or voluntary wheel running 
in serum.  Upregulated cytokines are highlighted in red. Downregulated cytokines are highlighted in green. 
Cytokines that are upregulated in one exercise paradigm but downregulated in another are highlighted in 
purple. 
 
Changes in cytokine levels in soleus and plantaris in response to different exercise regimes 
In oxidative soleus muscle, an even greater proportion of the detected cytokines was altered 
by acute and chronic exercise relative to the sedentary control group (Table 4). The protein levels 
of eleven (24%), twenty-one (47%), and twenty-six (62%) cytokines were significantly changed 
in response to a single bout of sprint, endurance run, and 1-week voluntary wheel running, 
respectively.  Again, we observed a much greater overlap between a single bout of endurance run 
and 1-week voluntary wheel running (Fig. 3A). However, the direction of change (up or 
downregulated) among the overlapping cytokines was different depending on the types of physical  
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Figure 3. Venn diagram of cytokines altered by sprint, endurance run, or voluntary wheel running 
in soleus and plantaris muscles.  Upregulated cytokines are highlighted in red. Downregulated cytokines 
are highlighted in green. Cytokines that are upregulated in one exercise paradigm but downregulated in 
another are highlighted in purple.  
 
activity (Table 4 and Fig. 3A). Despite significant overlap, different types of physical activity 
clearly altered different sets of cytokines in soleus muscle (Fig. 3A). Of the 34 cytokines whose 
levels changed in soleus muscle by acute or chronic exercise, 11 were upregulated, 11 were 
downregulated, and 12 were either up or downregulated depending on the types of physical 
activity.    
A very different cytokine profile was seen for the glycolytic (plantaris) muscle when 
compared to the oxidative (soleus) muscle. Relative to the sedentary control group, the protein 
levels of four (8%), three (6%), and twenty-two (50%) cytokines were significantly changed in 
plantaris muscle in response to a single bout of sprint, endurance run, and 1-week voluntary wheel 
running, respectively (Table 4).  In striking contrast to the soleus muscle, only 3-4 cytokines were 





























































Soleus (protein) Plantaris (protein)A B
IL-10
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of the cytokine changes in plantaris were seen in mice subjected to 1-week of voluntary wheel 
running. Minimal (1-2 cytokines) overlap was observed in plantaris for the three different types of 
exercise. Of the 25 cytokines altered in plantaris muscle by acute or chronic exercise, 4 were 
upregulated, 20 were downregulated, and 1 was either up or downregulated depending on the types 
of physical activity. 
 
Overlap of cytokine changes in serum, soleus, and plantaris in response to each type of 
exercise 
Next, we asked how many of the systemic changes in circulating serum cytokines 
paralleled the local protein changes in soleus and plantaris. This would help address which among 
the systemic cytokine changes in blood is directly due to the expression and secretion from skeletal 
muscle. Surprisingly, for a single bout of sprint, no overlap in cytokine profiles was seen between 
serum, soleus, and plantaris muscles (Fig. 4A). Different sets of cytokines were apparently altered 
in oxidative (soleus) and glycolytic (plantaris) muscles, with the majority of changes seen in soleus 
muscle fibers. Combined, a total of 21 cytokines were altered by sprint, with 13 upregulated, 7 
downregulated, and 1 with opposite changes between serum and soleus muscle.  
For a single bout of endurance run, the majority of the cytokine changes were seen in serum 
and soleus muscle (Fig. 4B). However, no overlap (common to all three) was seen between serum, 
soleus, and plantaris. Although seven cytokine changes showed overlap between serum and soleus 
muscle, the direction of change (up or downregulated) was different for three of the cytokines (Fig. 
4B).  Combined, a total of 28 cytokines were altered by a single bout of endurance run, with 13 
upregulated, 12 downregulated, and 3 with opposite changes between serum and soleus muscle. 
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Figure 4. Venn diagram of cytokines altered by sprint, endurance run, or voluntary wheel running 
in serum and in soleus and plantaris muscles.  Upregulated cytokines are highlighted in red. 
Downregulated cytokines are highlighted in green. Cytokines that are upregulated in one tissue exercise 





























































































Of the three different types of exercise, the greatest number of cytokines changes were seen 
in the 1-week voluntary wheel running group relative to the sedentary control group (Fig. 4C). 
Large numbers of cytokine changes showed overlap between serum and soleus or plantaris, as well 
as between oxidative (soleus) and glycolytic (plantaris) fibers. Interestingly, most of the cytokine 
changes induced by voluntary wheel running were in the “downregulated” direction (Fig. 4C; 
highlighted in green); in contrast, a large fraction of the cytokine changes seen in sprint and 
endurance run were in the “upregulated” direction (Fig. 4A and B; highlighted in red).  Combined, 
a total of 34 cytokines were altered by 1-week voluntary wheel running, with 2 upregulated, 28 
downregulated, 4 with opposite changes between different tissues. 
 
Changes in cytokine mRNA levels in plantaris and soleus in response to different exercise 
regimes 
We next examined changes in cytokine mRNA levels in oxidative (soleus) and glycolytic 
(plantaris) muscles in response to the three different types of exercise. We used the QuantiGene 
Plex assays to simultaneously measure the mRNA levels of 63 cytokines (Tables 8 and 9). With 
the exception of CXCL9 transcript, we were able to detect the mRNA of 62 cytokines.  Relative 
to the sedentary control group, the mRNA levels of six (10%), eight (13%), and fourteen (22%) 
cytokines were significantly changed in soleus in response to sprint, endurance run, and voluntary 
wheel running, respectively. In plantaris muscle, however, the mRNA levels of five (8%), thirteen 
(21%), and five (8%) cytokines were significantly changed in response to sprint, endurance, and 
voluntary wheel running, respectively. Surprisingly, most of the mRNA changes in soleus and 
plantaris show relatively little overlap between the three types of physical activity (Fig. 5A and 
B). In soleus muscle, 10 cytokine mRNA were upregulated, 7 downregulated, and 3 changed in  
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Table 8 
   Soleus Muscle (mRNA) 
   Sprint/Sedentary Endurance/sedentary 
Voluntary wheel 
running/sedentary 
Accesion # Gene (Fold change) (Fold change) (Fold change) 
      
NM_009971 G-CSF/Csf-3 0.71 ± 0.13 0.45 ± 0.14 0.87 ± 0.18 
NM_009969 GM-CSF/Csf-2 1.40 ± 0.18 1.10 ± 0.16 0.92 ± 0.21 
NM_010510 IFN-β1 1.50 ± 0.23 1.27 ± 0.19 1.06 ± 0.26 
NM_008337 IFN-γ 1.33 ± 0.21 1.25 ± 0.23 0.92 ± 0.20 
NM_010554 IL-1α 1.42 ± 0.37 2.18 ± 0.54 0.98 ± 0.15 
NM_008361 IL-1β 1.28 ± 0.12 1.02 ± 0.17 1.37 ± 0.13 
NM_008366 IL-2 1.40 ± 0.45 2.33 ± 1.3 0.59 ± 0.11 
NM_010556 IL-3 1.60 ± 0.19 1.25 ± 0.19 0.98 ± 0.19 
NM_021283 IL-4 1.35 ± 0.20 1.05 ± 0.21 0.80 ± 0.19 
NM_010558 IL-5 1.34 ± 0.21 1.20 ± 0.20 0.95 ± 0.23 
NM_031168 IL-6 1.53 ± 0.25 1.38 ± 0.20 1.28 ± 0.28 
NM_008371 IL-7 1.50 ± 0.23 1.29 ± 0.14 0.93 ± 0.20 
NM_008373 IL-9 1.22 ± 0.10 1.13 ± 0.13 0.79 ± 0.17 
NM_010548 IL-10 1.34 ± 0.19 1.35 ± 0.33 0.95 ± 0.09 
NM_008350 IL-11 1.22 ± 0.18 1.03 ± 0.12 0.95 ± 0.16 
NM_008352 IL-12 (p40)/ IL-12B 1.47 ± 0.16 1.19 ± 0.18 * 1.54 ± 0.15 
NM_008351 IL-12 (p70) 1.17 ± 0.16 1.09 ± 0.20 0.96 ± 0.19 
NM_008355 IL-13 1.39 ± 0.20 1.35 ± 0.38 0.87 ± 0.18 
NM_008357 IL-15 1.07 ± 0.06 0.90 ± 0.07 *** 0.59 ± 0.04 
NM_010551 IL-16 1.05 ± 0.06 ** 0.67 ± 0.04 0.86 ± 0.06 
NM_010552 IL-17A/CTLA8 1.47 ± 0.20 1.26 ± 0.18 1.06 ± 0.24 
NM_021380 IL-20 0.99 ± 0.11 * 0.57 ± 0.13 ** 0.53 ± 0.10 
NM_021782 IL-21 1.29 ± 0.18 1.06 ± 0.13 0.96 ± 0.22 
NM_016971 IL-22 1.52 ± 0.27 1.20 ± 0.19 1.07 ± 0.30 
NM_031252 IL-23 1.52 ± 0.27 1.33 ± 0.19 1.03 ± 0.25 
NM_145636 IL-27 1.25 ± 0.10 1.07 ± 0.14 0.90 ± 0.11 
NM_177396 IL-28B/IFNl3 1.29 ± 0.16 0.94 ± 0.11 0.78 ± 0.17 
NM_029594 IL-31 1.45 ± 0.26 1.15 ± 0.15 1.02 ± 0.23 
NM_133775 IL-33 1.16 ± 0.08 * 1.31 ± 0.11 0.94 ± 0.06 
NM_021274 IP-10/CXCL10 1.10 ± 0.17 1.53 ± 0.22 * 2.57 ± 0.72 
NM_008176 KC/CXCL1 *** 1.74 ± 0.11 1.36 ± 0.15 0.94 ± 0.10 
NM_008501 LIF 1.26  ± 0.18 0.95  ± 0.10 1.00  ± 0.16 
NM_009141 LIX/CXCL5 1.68  ± 0.35 1.46  ± 0.21 1.63  ± 0.36 
NM_011333 MCP-1/CCL2 1.24  ± 0.11 1.21  ± 0.09  * 2.59  ± 0.81 
NM_007778 M-CSF/Csf-1 0.97 ± 0.05 **0.67 ± 0.03 0.81 ± 0.09 
NM_008599 MIG/CXCL9 -- -- -- 
NM_011337 MIP-1α/CCL3 1.45 ± 0.20 1.06 ± 0.17 1.02 ± 0.21 
NM_013652 MIP-1β/CCL4 1.25 ± 0.13 1.00 ± 0.17 1.02 ± 0.13 
NM_009140 MIP-2/CXCL2 1.56 ± 0.25 1.31 ± 0.21 1.16 ± 0.30 
NM_013653 RANTES/CCL5 0.91 ± 0.07 0.71 ± 0.18 *** 2.22 ± 0.30 
NM_013693 TNF-α 1.16 ± 0.21 0.91 ± 0.14 1.09 ± 0.18 
NM_001287056 VEGF-A 0.97 ± 0.11 0.85 ± 0.03 ***0.41 ± 0.03 
NM_002989 Exodus-2/CCL21 1.09 ± 0.16 1.20 ± 0.07 0.78 ± 0.10 
NM_009142 Fractalkine/CX3CL1 1.03 ± 0.12 0.83 ± 0.08 1.25 ± 0.11 
NM_009137 MDC/CCL22 1.34 ± 0.20 1.25 ± 0.31 1.41 ± 0.27 
NM_011331 MCP-5/CCL12 1.32 ± 0.21 1.00 ± 0.11 * 1.64 ± 0.19 
NM_016960 MIP-3α/CCL20 1.36 ± 0.20 1.07 ± 0.12 1.01 ± 0.21 
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Table 8 – continued 
   Soleus Muscle (mRNA) 
   Sprint/Sedentary Endurance/sedentary 
Voluntary wheel 
running/sedentary 
Accesion # Gene (Fold change) (Fold change) (Fold change) 
      
NM_011888 MIP-3β/CCL19 1.23 ± 0.09 1.00 ± 0.15 0.77 ± 0.11 
NM_011332 TARC/CCL17 1.38 ± 0.16 1.05 ± 0.13 1.17 ± 0.22 
NM_011593 TIMP-1 0.84 ± 0.12 0.75 ± 0.05 ***8.37 ± 2.16 
NM_009401 CD30/ Tnfrsf8 1.36 ± 0.26 1.39 ± 0.25 1.14 ± 0.28 
NM_010560 gp130/ IL-6ST ** 1.13 ± 0.03 * 0.88 ± 0.03 *** 0.64 ± 0.03 
NM_008362 IL-1RI 1.08 ± 0.06 1.12 ± 0.03 *** 0.71 ± 0.02 
NM_010555 IL-1RII 1.40 ± 0.14 1.27 ± 0.11 0.92 ± 0.13 
NM_008367 IL-2Ra * 1.53 ± 0.14 1.22 ± 0.13 0.68 ± 0.13 
NM_001008700 IL-4R * 1.39 ± 0.14 ** 1.48 ± 0.08 1.18 ± 0.12 
NM_010559 IL-6R *1.30 ± 0.10 *1.31 ± 0.07 **0.62 ± 0.06 
NM_007425 RAGE / Ager 1.12 ± 0.11 1.13 ± 0.12 1.15 ± 0.13 
NM_011609 TNF-RI / Tnfrsf1a 1.16 ± 0.07 0.93 ± 0.03 0.88 ± 0.04 
NM_011610 TNF-RII / Tnfrsf1b 1.27 ± 0.12 1.21 ± 0.08 1.26 ± 0.09 
NM_010228 VEGFR1 / Flt1 * 1.27 ± 0.09  1.10 ± 0.04 ***0.52 ± 0.06 
NM_010612 VEGFR2 / Kdr 0.87 ± 0.06 ***0.55 ± 0.03 ***0.50 ± 0.04 
NM_008029 VEGFR3 / Flt4 1.10 ± 0.10 1.13 ± 0.06 0.81 ± 0.07 
      
 # of cytokine changed 6 8 14 
 % of cytokine changed 10% 13% 22% 
 
Table 8. Summary of cytokine mRNA levels in soleus muscle in response to sprint, endurance run, 
or voluntary wheel running for 1 week. All values are normalized to the control sedentary group and 
shown as fold change + S.E. Those cytokines whose mRNA that are not detected are indicated by “--”. 












Table 9  





Accesion # Gene (Fold change) (Fold change) (Fold change)  
  
   
NM_009971 G-CSF/Csf-3 1.10 ± 0.29 -- 0.91 ± 0.22 
NM_009969 GM-CSF/Csf-2 1.13 ± 0.12 0.72 ± 0.05 0.80 ± 0.08 
NM_010510 IFN-β1 1.09 ± 0.16 0.82 ± 0.07 0.87 ± 0.08 
NM_008337 IFN-γ 0.93 ± 0.10 0.73 ± 0.06 0.81 ± 0.10 
NM_010554 IL-1α 1.37 ± 0.18 0.58 ± 0.05 0.94 ± 0.17 
NM_008361 IL-1β 1.14 ± 0.15 0.73 ± 0.07 0.89 ± 0.11 
NM_008366 IL-2 1.24 ± 0.30 0.74 ± 0.13 1.24 ± 0.37 
NM_010556 IL-3 1.14 ± 0.13 0.97 ± 0.08 0.91 ± 0.21 
NM_021283 IL-4 **2.31 ± 0.42 1.37 ± 0.22 1.55 ± 0.24 
NM_010558 IL-5 1.00 ± 0.16 0.71 ± 0.07 0.77 ± 0.08 
NM_031168 IL-6 0.91 ± 0.10 0.73 ± 0.06 0.81 ± 0.11 
NM_008371 IL-7 1.05 ± 0.12 0.94 ± 0.13 0.85 ± 0.10 
NM_008373 IL-9 1.32 ± 0.15 0.71 ± 0.07 0.84 ± 0.13 
NM_010548 IL-10 1.08 ± 0.08 0.73 ± 0.06 0.82 ± 0.19 
NM_008350 IL-11 1.14 ± 0.11 0.89 ± 0.06 0.89 ± 0.08 
NM_008352 IL-12 (p40)/ IL-12B 1.24 ± 0.17 0.82 ± 0.06 1.02 ± 0.17 
NM_008351 IL-12 (p70) 1.04 ± 0.10 * 0.71 ± 0.06 0.75 ± 0.07 
NM_008355 IL-13 1.01 ± 0.13 0.79 ± 0.11 0.87 ± 0.23 
NM_008357 IL-15 1.09 ± 0.07 1.04 ± 0.04 1.16 ± 0.05 
NM_010551 IL-16 1.10 ± 0.08 0.83 ± 0.15 0.95 ± 0.07 
NM_010552 IL-17A/CTLA8 1.00 ± 0.14 0.87 ± 0.06 0.78 ± 0.09 
NM_021380 IL-20 0.97 ± 0.07 ***0.55 ± 0.06 * 0.75 ± 0.06 
NM_021782 IL-21 1.26 ± 0.19 0.81 ± 0.08 0.90 ± 0.12 
NM_016971 IL-22 1.12 ± 0.14 0.69 ± 0.07 0.78 ± 0.11 
NM_031252 IL-23 0.96 ± 0.12 0.80 ± 0.07 0.82 ± 0.08 
NM_145636 IL-27 1.30 ± 0.07 * 0.90 ± 0.08 1.08 ± 0.17 
NM_177396 IL-28B/IFNl3 1.08 ± 0.12 0.67 ± 0.05 0.76 ± 0.12 
NM_029594 IL-31 0.96 ± 0.14 0.71 ± 0.05 0.73 ± 0.07 
NM_133775 IL-33 1.27 ± 0.10 1.29 ± 0.10 0.91 ± 0.08 
NM_021274 IP-10/CXCL10 0.72 ± 0.08 0.64 ± 0.15 0.76 ± 0.11 
NM_008176 KC/CXCL1 ***2.65 ± 0.45 1.45 ± 0.18 0.99 ± 0.12 
NM_008501 LIF 0.95 ± 0.07 **0.64 ± 0.04 0.81 ± 0.06 
NM_009141 LIX/CXCL5 1.35 ± 0.16 1.02 ± 0.06 1.09 ± 0.13 
NM_011333 MCP-1/CCL2 1.21 ± 0.27 1.12 ± 0.18 1.37 ± 0.23 
NM_007778 M-CSF/Csf-1 0.96 ± 0.04 ***0.58 ± 0.03  0.94 ± 0.06 
NM_008599 MIG/CXCL9 -- -- -- 
NM_011337 MIP-1α/CCL3 0.95 ± 0.12 0.74 ± 0.07 0.78 ± 0.08 
NM_013652 MIP-1β/CCL4 1.12 ± 0.15 * 0.62 ± 0.10 0.90 ± 0.06 
NM_009140 MIP-2/CXCL2 1.11 ± 0.16 0.90 ± 0.09 0.93 ± 0.10 
NM_013653 RANTES/CCL5 0.88 ± 0.14 0.55 ± 0.09 1.18 ± 0.21 
NM_013693 TNF-α 1.11 ± 0.16 0.81 ± 0.04 ** 1.63 ± 0.17 
NM_001287056 VEGF-A * 0.85 ± 0.06 * 0.87 ± 0.02 ***0.76 ± 0.02 
NM_002989 Exodus-2/CCL21 1.03 ± 0.06 0.79 ± 0.10 * 0.73 ± 0.07 
NM_009142 Fractalkine/CX3CL1 0.93 ± 0.07 ** 0.70 ± 0.03 1.01 ± 0.08 
NM_009137 MDC/CCL22 1.17 ± 0.15 0.91 ± 0.08 1.31 ± 0.22 
NM_011331 MCP-5/CCL12 1.05 ± 0.12 0.74 ± 0.05 0.92 ± 0.09 
NM_016960 MIP-3α/CCL20 1.05 ± 0.12 0.76 ± 0.08 0.87 ± 0.09 
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Accesion # Gene (Fold change) (Fold change) (Fold change)  
  
   
NM_011888 MIP-3β/CCL19 1.10 ± 0.10 0.79 ± 0.04 0.77 ± 0.07 
NM_011332 TARC/CCL17 1.16 ± 0.14 0.60 ± 0.06 0.83 ± 0.09 
NM_011593 TIMP-1 0.88 ± 0.14 * 0.46 ± 0.05 ***2.3 ± 0.23 
NM_009401 CD30/ Tnfrsf8 1.04 ± 0.13 0.67 ± 0.04 0.91 ± 0.10 
NM_010560 gp130/ IL-6ST 1.05 ± 0.03 ** 0.87 ± 0.02 0.91 ± 0.03 
NM_008362 IL-1RI 1.03 ± 0.05 0.95 ± 0.05 0.95 ± 0.06 
NM_010555 IL-1RII 1.05 ± 0.05 0.90 ± 0.07 0.88 ± 0.08 
NM_008367 IL-2Ra * 1.30 ± 0.11 1.01 ± 0.05 0.78 ± 0.07 
NM_001008700 IL-4R 1.08 ± 0.07 1.14 ± 0.05 0.94 ± 0.05 
NM_010559 IL-6R 1.16 ± 0.11 ** 1.37 ± 0.05 0.87 ± 0.05  
NM_007425 RAGE / Ager 1.25 ± 0.10 0.91 ± 0.07 0.96 ± 0.10 
NM_011609 TNF-RI / Tnfrsf1a 1.06 ± 0.04 ** 0.86 ± 0.03 1.04 ± 0.02 
NM_011610 TNF-RII / Tnfrsf1b 1.16 ± 0.05 0.95 ± 0.04 1.01 ± 0.04 
NM_010228 VEGFR1 / Flt1 1.14 ± 0.08 0.99 ± 0.03 0.84 ± 0.03 
NM_010612 VEGFR2 / Kdr ** 0.77 ± 0.05 ***0.43 ± 0.02 0.95 ± 0.04 
NM_008029 VEGFR3 / Flt4 1.03 ± 0.05 0.96 ± 0.05 0.98 ± 0.04  
  
   
 
# of cytokine changed 5 13 5  
% of cytokine changed 8% 21% 8% 
 
Table 9. Summary of cytokine mRNA levels in plantaris muscle in response to sprint, endurance run, 
or voluntary wheel running for 1 week. All values are normalized to the control sedentary group and 
shown as fold change + S.E. Those cytokines whose mRNA that are not detected are indicated by “--”. 




Figure 5. Venn diagram of cytokine mRNA altered by sprint, endurance run, or voluntary wheel 
running in soleus and plantaris muscles.  Upregulated cytokines are highlighted in red. Downregulated 
cytokines are highlighted in green. Cytokines that are upregulated in one exercise paradigm but 
downregulated in another are highlighted in purple.  
 
the opposing directions depending on the types of exercise. In plantaris muscle, 5 cytokine mRNA 
were upregulated, 12 downregulated, and 1 changed in the opposite direction between endurance 
and chronic wheel running.  
 
Concordance between changes in cytokine mRNA and protein levels in muscle in response 
to exercise 
Next, we addressed the issue of concordance between changes in cytokine mRNA and 
protein expression in soleus and plantaris muscles. In oxidative (soleus) muscle, parallel reductions 
in transcript and protein were observed for IL-15, VEGF, sIL1RI, sVEGFR1, sVEGFR2, and 
sgp130, whereas parallel increases were only observed for CCL12 and TIMP-1. In glycolytic 
(plantaris) muscle, parallel reductions in transcript and protein were observed for VEGF and 







































CCL21, whereas a parallel increase was only observed for TIMP-1. Essentially, the majority of 
the cytokine changes reported here showed discordance between transcript and protein levels 
(comparing Tables 4, 8, and 9).    
 
Expression of cytokines in adipose and liver in response to exercise whose changes in serum 
were not matched by changes in muscle  
Given that the changes in a subset of serum cytokines were not matched by the 
corresponding changes in their protein levels in muscle, we addressed whether this could be due 
to secondary adaptive changes in their expression in non-muscle tissues. Acute and chronic 
exercise can alter systemic metabolism in response to energetic demands, and we have previously 
shown that different metabolic states alters circulating cytokine levels (43). Thus, we determined 
the expression of cytokine transcripts in liver and two major fat depots (visceral and subcutaneous 
white adipose tissues), major metabolic organs known to produce and secrete a wide array of 
cytokines and chemokines in response to different physiological stimuli. We focused our analyses 
only on those cytokines whose altered serum levels were not accounted for by changes in protein  
levels in skeletal muscle in response to exercise. As shown in Fig. 6, depending on the types of 
exercise, expression of cytokine transcripts could be either up- or down-regulated in the liver 
and/or adipose tissues. With a couple exceptions, most of these changes in mRNA paralleled the  
 
Figure 6. Quantitative real-time PCR analysis of select cytokine transcripts in liver and adipose 
tissues in response to acute and chronic exercise.  Relative mRNA expression of different cytokines in 
liver, visceral (epididymal) and subcutaneous (inguinal) fat depots. We only focus our analysis on those 
cytokines whose altered circulating levels were not matched by the corresponding changes in protein levels 
in skeletal muscle. All mRNA expression values were normalized to 36B4. These values were then 
normalized to the sedentary condition and the data are shown as average + S.E. All p-values were calculated 
using an unpaired t-test with Welch's correction (comparing the exercise condition to the sedentary 






















































































































































































cytokine changes seen in circulation. For example, for a single bout of sprint, increased serum 
EPO and IL-20 levels were paralleled by increased mRNA expression in visceral white adipose 
tissue, whereas reduced serum IL-17F, sgp130, and INF-γ levels were paralleled by reduction in 
mRNA expression in either visceral or subcutaneous adipose tissue. For a single bout of endurance 
run, reduced serum sIL-4R, sTNF-RII, TIMP-1, IL-16, INF-γ, and CCL20 levels were paralleled 
by reduced mRNA expression in liver and/or adipose tissue. For voluntary wheel running, 
reduction in serum sTNF-RII, TIMP-1, and CCL12 levels were paralleled by reduced mRNA 
expression in subcutaneous adipose tissue. These results suggest that changes in a subset of 
circulating cytokines could, at least in part, be accounted for by the corresponding changes in 
transcript levels in liver and/or adipose tissues. 
 
DISCUSSION 
Here, we undertook an antibody-based profiling approach to determine the extent by which 
exercise modulates local cytokine levels in glycolytic and oxidative muscle fibers, as well as their 
systemic circulating levels, in response to three different types of physical activity—an acute sprint 
and endurance run, or chronic exercise in the form of voluntary wheel running. We chose to focus 
on cytokine family members as potential myokines given their well-known pleiotropic functions 
that could potentially link exercise to myriad physiological effects that include immunity (48), 
inflammation (6), metabolism (43), food intake (32, 49), and autophagy (50).  
All the significant changes in cytokine mRNA and protein levels are summarized in Table 
10. From our antibody-based profiling studies of exercise-regulated cytokines, several notable 
observations are highlighted. a) Chronic exercise in the form of wheel running consistently 
induced more cytokine changes than an acute single bout of sprint or endurance run. This is  
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Table 10 
  Serum Soleus Soleus Plantaris Plantaris 
  Protein Protein mRNA Protein mRNA 
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Table 10 - continued 
  Serum Soleus Soleus Plantaris Plantaris 
  Protein Protein mRNA Protein mRNA 
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Table 10. Summary of all the statistically significant changes in cytokine mRNA and protein levels 
in response to sprint (S), endurance run (E), and voluntary wheel running (VWR).  
 
perhaps not surprising as repeated bouts of exercise lead to skeletal muscle adaptation (51). b) 
Acute and chronic exercise appear to alter distinct sets of cytokines in serum and skeletal muscle, 
with varying degrees of overlap depending on the type of physical activity. This presumably 
reflects differences in skeletal muscle adaptation to repeated voluntary wheel running versus a 
stress-like response to an acute bout of exercise. c) There is more overlap in cytokine profile 
between a single bout of endurance exercise and chronic wheel running, particularly in serum and 
oxidative soleus muscle. This suggests that exercise intensity affects the nature of the cytokine 
response, as endurance and chronic wheel running represent low-intensity exercise whereas an 
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exhaustive sprint reflects high-intensity exercise. d) We observed more exercise-regulated 
cytokine changes in skeletal muscle than in serum. This could reflect a higher local concentration 
of cytokines and hence our greater ability to reliably detect their differences. The circulating 
plasma levels of most cytokines are in the nanogram and picogram per milliliter range. Due to the 
dilution effect of plasma, only relatively large changes in cytokine secretion into circulation by 
skeletal muscle in response to exercise would be detected. Alternatively, some exercise-regulated 
cytokines act locally within skeletal muscle and are not secreted into circulation. e) Interestingly, 
between muscle fiber types, we observed significantly more cytokine changes in oxidative soleus 
compared to glycolytic plantaris muscles irrespective of the types of exercise (sprint, endurance, 
wheel running). With some exceptions (52), in most human exercise studies, gene and protein 
expression analyses were performed on quadriceps muscle biopsies consisting of mixed fiber 
types. As such, cytokine response to exercise in different muscle fiber types in humans is largely 
unknown. Our study thus highlighted the utility of animal models in addressing questions difficult 
to answer in human-based exercise studies. f) In oxidative soleus muscle, we observed significant 
overlaps in cytokine profiles in response to sprint, endurance run, and chronic wheel running. In 
striking contrast, only minimal overlaps in cytokine profiles were observed in glycolytic plantaris 
muscle. Thus, not only are more cytokines changed in soleus compared to plantaris, but also those 
changes seen in soleus show greater overlap between different types of physical activity. These 
types of unexpected insights relevant to skeletal muscle physiology illustrate the advantage of 
assessing gene and protein expression in different muscle fiber types. g) In a single bout of 
exhaustive sprint and endurance run, we observed significantly more cytokines being upregulated 
than downregulated in serum and in muscle. This may reflect normal physiological stress 
responses associated with acute exercise.  In marked contrast, chronic voluntary wheel running 
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predominantly resulted in cytokine downregulation in serum and muscle. These differences likely 
reflect skeletal muscle adaptation to chronic exercise and may be linked to general improvements 
in inflammatory profiles associated with regular exercise.  
IL-6 is the first and most widely studied exercise-regulated cytokine (53). As expected 
based on previous studies in humans, we observed a significant increase in IL-6 protein level in 
mouse skeletal muscle in response to a single bout of sprint or endurance exercise (Table 4). 
Interestingly, only oxidative (soleus), but not glycolytic (plantaris), muscle fibers show increased 
IL-6 protein level in response to sprint or endurance run. One week of voluntary wheel running, 
however, resulted in reduced IL-6 in both soleus and plantaris, as well as in serum. This reduction 
presumably reflects skeletal muscle adaptation to repeated bouts of exercise. In healthy humans 
subjected to 10 weeks of endurance training, contraction-induced IL-6 expression was reduced 
(54). Intriguingly, neither sprint nor endurance run acutely raised the circulating level of IL-6 in 
serum (Table 3). This could be due to exercise intensity, or insufficient quantities of IL-6 being 
secreted into systemic circulation to acutely raise its serum level. While most human studies 
reported increase plasma IL-6 levels after high intensity exercise, some studies did not observe a 
similar increase in plasma IL-6 after a lower intensity exercise (37). It has been noted that 
circulating levels of cytokines can vary widely between individuals subjected to different types of 
exercise (28).   
Intriguingly, most of the secreted cytokine receptors (10 out of 13) profiled are altered by 
exercise. These include sgp130, sRAGE, sIL-1RI, sIL-1RII, sIL-4R, sIL-6R, sTNF-RI, sTNF-RII, 
sVEGFR1, and sVEGFR2. The soluble form of cytokine receptors in plasma can be generated by 
multiple mechanisms that include ectodomain shedding by zinc metalloproteinases (e.g., 
TACE/ADAM17 and ADAM19), as well as by alternative mRNA splicing (42).  Protease-
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mediated release of receptor ectodomain has been demonstrated for TNF-RI, TNF-RII, IL-1RII, 
IL-4R, and IL-6R, whereas the soluble forms of gp130, RAGE, VEGFR1, and VEGFR2 are 
generated by alternative mRNA splicing (42, 55). While previous studies have looked at soluble 
IL-6R levels in response to exercise in humans (56, 57), our current study represents the first 
attempt to quantify changes in multiple secreted cytokine receptors in response to exercise. Our 
results suggest that soluble cytokine receptors could be generated by potentially novel exercise-
regulated proteolytic and alternative mRNA splicing mechanisms. In principle, these soluble 
receptors could influence cytokine signaling by functioning as receptor agonists or antagonists. 
Interestingly, there is a subset of 17 circulating cytokines whose changes in serum were 
not matched by their corresponding changes in muscle. Presumably, these cytokines (EPO, IL-20, 
IL-17A/F, sgp130, sIL-4R, CCL17, G-CSF, CX3CL1, CXCL1, IL-16, TIMP-1, sTNF-RII, sTNF-
RI, IFN-, CXCL10, CCL20, and CCL12) are produced and secreted by non-muscle tissues. These 
changes could be attributed to several potential mechanisms that are dependent or independent of 
contracting skeletal muscle. Primary cytokines, and other potential myokines, that are secreted into 
circulation by contracting skeletal muscle could convey a signal to other non-muscle tissues to 
alter the expression and secretion of secondary cytokines. Liver and adipose tissues are also known 
to produce and secrete a variety of different cytokines. Given the energetics demands of 
contracting skeletal muscle, indirect metabolic changes in liver and adipose tissue induced by 
exercise could potentially also alter the expression and secretion of secondary cytokines. In 
support, we indeed observed parallel changes in cytokine expression in liver and/or adipose tissue 
in response to exercise that could, at least in part, account for their changes in circulation but not 
in skeletal muscle. Thus, our data highlighted the primary cytokine response of skeletal muscle 
 64 
and the secondary cytokine response in non-muscle tissues resulting from potential exercise-
mediated tissue crosstalk.  
When skeletal muscles isolated from the same mice were subjected to quantitative mRNA 
analysis, we found only minimal concordance between cytokine mRNA and protein levels, 
irrespective of exercise regimen. These observations suggest the importance of posttranscriptional 
regulation of cytokine expression and secretion in contracting skeletal muscle in vivo. Some of 
these posttranscriptional mechanisms could involve exercise-regulated stabilization of cytokine 
mRNA transcripts and/or microRNA (miRNA) mediated regulation of mRNA translation (28). 
Given that posttranscriptional control of cytokine/myokine expression in response to exercise is 
largely unexplored, our data provided a basis and impetus to further explore these 
underappreciated mechanisms in the context of physical activity.  
 Of the 66 cytokines profiled, a surprisingly large fraction is altered by acute and/or short-
term exercise. Most of these altered cytokines are shown for the first time to be regulated by 
exercise in vivo. In recent studies, Scheler et al. profiled 23 different cytokines in cultured human 
myotubes using similar bead-based multiplex approach and showed that 11 cytokines are regulated 
by electrical pulse stimulation (27); these include IL-8, CXCL1, IL-6, LIF, IL-4, IL-13, IL17A, 
IL-1β, G-CSF, TNF, and CCL2. Raschke et al. used an antibody array to profile 179 peptides 
(covering different classes of secretory proteins in addition to cytokines), and identified 23 novel 
exercise regulated cytokines in electrical pulse stimulated human myotubes (26); these include IL-
1α, IL-3, IL-10, IL-16, IL-22, IL-28A, IL-29, IL-31, IFN-γ, TPO, RAGE, CCL1, CCL4, CCL15, 
CCL17, CCL18, CCL21, CCL23, CCL24, CCL26, CXCL6, CXCL9, and CXCL13. Of the known 
exercise-regulated cytokines reported in cultured human myotubes (26, 27), we were able to 
confirm the majority of them in vivo, in particular those cytokines that were included in our 
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multiplex assay. This suggests that many of the cytokine responses we observed are most likely 
due to changes in the expression and secretion of cytokines from skeletal myotubes. Our results 
validate the use of rodent exercise models to study cytokine/myokine response in humans. 
Excluding these recently described exercise-regulated cytokines in cultured human myotubes, our 
in vivo mouse studies—involving three different exercise regimens and two different muscle fiber 
types—identified an additional 22 novel exercise-regulated cytokines/myokines not previously 
reported. These include IL-9, IL-12 (p40), IL-20, IL-33, M-CSF, CXCL10, CXCL2, CCL5, CCL3, 
CCL12, CCL19, CCL20, EPO, TIMP-1, sgp130, sIL-1RI, sIL-1RII, sIL-6R, sTNF-RI, sTNF-RII, 
sVEGFR1, and sVEGFR2. Of these novel exercise-regulated myokines, a subset (IL-20, CXCL2, 
CXCL10, CCL12, CCL20, sTNF-RI, sTNF-RII, and TIMP) can be considered “exercise factors” 
based on the definition that they are produced by skeletal muscle in response to exercise and are 
secreted into the circulation (11).   
Most of the exercise-regulated cytokines we uncovered play myriad roles in the immune 
and non-immune systems. Many cytokine functions are physiological context-dependent and their 
effects are cell-type specific (38); their excessive production or suppression are often causally 
linked to disease. In the context of exercise, the levels of a surprisingly large number of cytokines 
are changed either locally within skeletal muscle or systemically. It appears that both the pro- and 
anti-inflammatory cytokines are altered by acute and chronic exercise in rodents (Table 10) and 
in humans (58). It has been suggested that the beneficial local and systemic effects of chronic 
exercise are due to exercise-induced hormesis, whereby a low level of stress upregulates existing 
cellular and molecular pathways that improve whole-body physiology (e.g., metabolism and 
immunity) (58, 59). Thus, it may be a specific combination of cytokines (with diverse and opposing 
functions) whose direction, magnitude, and duration of change underlie exercise-induced 
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hormesis. In this context, it is worth noting that chronic exercise with running wheel induced more 
cytokine changes than either an acute low-intensity (endurance) or high-intensity (sprint) exercise. 
While this is beyond the scope of the present study, future investigations using genetic gain- or 
loss-of-function mouse models of select cytokines are clearly needed to further pinpoint the 
biological effects of muscle-derived cytokines/myokines in muscle and non-muscle tissues.  
Several limitations and caveats are noted in the present studies. First, we did not analyze 
all the known cytokines discovered to date. This is limited by cost and the availability of cytokine-
specific multiplex reagents. Second, we did not use an in vitro exercise model (e.g., EPS-
stimulated myotubes) to directly show that the cytokine changes we see in soleus and plantaris 
muscle fibers are indeed derived from skeletal myotubes and not from other potential cell types 
such as satellite cells, endothelial cells, fibroblastic cells, and resident immune cells. It is known 
that eccentric or resistance exercise, or prolonged running (e.g., marathon), in humans result in 
muscle damage, leading to the influx of inflammatory leukocytes that can be the source of 
cytokines upregulated in muscle [extensively reviewed in (60)]. While we cannot rule out this 
possibility, the type and duration of exercise the mice were subjected to in our study generally do 
not cause significant muscle damage. Indeed, when obese mice were subjected to endurance 
interval training, significantly less inflammation and macrophage infiltration were observed in 
skeletal muscle (61). Since our in vivo study confirmed a majority of the exercise-regulated 
cytokines in cultured human myotubes (26, 27), we presume the novel exercise-regulated 
cytokines found in the present study are likely to be derived from myotubes. Third, we only 
measured transcript, and not protein, levels of a select set of cytokines in liver and adipose tissues.  
Thus, whether changes in mRNA translate into changes in protein levels remain to be determined. 
Fourth, we did not directly demonstrate the release of cytokines from exercised muscle into 
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circulation.  While this may be technically challenging to perform in mice, in situ cytokine flux 
analysis will provide further insights into how different muscle fiber types modulate the production 
and secretion of cytokines in response to different exercise.  Fifth, although mice run only during 
the dark cycle (62), one potential caveat of the voluntary exercise group was that the mice had 
access to the running wheel until the morning before they were sacrificed. However, when we 
examined the cytokine profiles, the number and type of cytokine changes were significantly 
different between acute (sprint and endurance run) and chronic (wheel running) exercise groups 
despite some overlaps (Fig. 2 and 3), suggesting that we could discriminate between the two 
exercise effects. Sixth, the pre-exercise values of some cytokines in the voluntary wheel running 
group were significantly higher than the pre-exercise values for the sprint and endurance groups. 
The reason for this is unknown. While all mice were handled identically, the serum samples from 
the wheel running group were not analyzed at the same time as the sprint and endurance groups. 
However, samples that were directly compared to one another or used for normalization were 
always analyzed on the same plate; specifically, serum samples from the pre- and post- sprint and 
endurance groups were run together while the samples from the pre- and post- wheel running were 
run together. Our analyses focused on the changes in cytokine levels in each pre- and post-exercise 
condition. We do not directly compare serum data between exercise regimens. Thus, the 
differences in absolute values between exercise conditions should not affect the interpretation of 
our data. Despite these limitations, our current studies reveal important insights concerning 
exercise regulation of local and systemic cytokine levels.  
In summary, our current cytokine profiling study in mice, along with other published 
studies on exercise-regulated myokines in humans and animal models, indicate that physical 
activity can significantly alter the skeletal muscle secretome. Many myokines/cytokines have 
 68 
pleiotropic functions, and some may have opposite effects depending on biological and 
physiological contexts. Given this complexity, we speculate that a right combination, magnitude, 
and direction of myokine changes induced by regular exercise, rather than one or two dominant 
secretory proteins, are likely responsible for the multi-organ effects and health benefits of exercise. 
The inherent systems-level response to physical activity may pose a major challenge to produce 
an “exercise pill” that can mimic and recapitulate all the local and systemic physiological and 
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We recently described myonectin (also known as CTRP15 and erythroferrone) as a novel 
skeletal muscle-derived myokine with metabolic functions. Here, we use a genetic mouse model 
to determine myonectin’s requirement for metabolic homeostasis. Female myonectin-deficient 
mice had larger gonadal fat pad, developed mild insulin resistance when fed a high-fat diet and 
had reduced food intake following a fast, but were otherwise indistinguishable from wild-type 
littermates. Male mice lacking myonectin, however, had reduced physical activity when fed ad-
libitum and in the postprandial state, but not during a fast. When stressed with a high-fat diet, 
myonectin knockout male mice had significantly elevated very-low-density lipoprotein (VLDL)-
triglyceride and strikingly impaired lipid clearance from circulation following an oral lipid load. 
Fat distribution between adipose and liver was also altered in myonectin-deficient male mice fed 
a high-fat diet. Greater fat storage resulted in significantly enlarged adipocytes and was associated 
with increased postprandial lipoprotein lipase activity in adipose tissue. Parallel to this was a 
striking reduction in liver steatosis due to significantly reduced triglyceride accumulation. Liver 
metabolite profiling revealed additional significant changes in bile acids and one-carbon 
metabolism pathways. Combined, our data affirm the physiological importance of myonectin in 
regulating local and systemic lipid metabolism. 
 
INTRODUCTION 
Skeletal muscle takes up the majority of circulating postprandial glucose and plays a vital 
role in maintaining whole-body energy balance (1, 2). Impaired insulin responsiveness in skeletal 
muscle is mechanistically linked to type 2 diabetes (3, 4). As a major metabolic organ, skeletal 
muscle is believed to communicate with other organs and tissues via secreted hormones to 
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influence whole-body metabolism. The discovery that skeletal muscle dynamically secretes a 
variety of myokines—proteins that stimulate muscle and non-muscle tissues to regulate various 
biological processes—has provided a novel and critical conceptual framework to understand 
skeletal muscle’s role in coordinating integrated physiology (5, 6).  
Of the hundreds of proteins secreted by skeletal muscle (7-9), only a few have been 
functionally characterized; these include myostatin (10-12), IL-6 (13), fibroblast growth factor 21 
(FGF21) (14, 15), insulin-like 6 (INSL6) (16), follistatin-like 1 (FSTL1) (17), leukemia inhibitory 
factor (LIF) (18), IL-7 (19), IL-15 (20), musclin (21, 22), and irisin (23). These myokines either 
act locally within skeletal muscle as autocrine/paracrine factors or circulate in blood as endocrine 
factors, linking skeletal muscle to the regulation of physiological processes in non-muscle tissues 
(6, 11, 13, 14, 23-27).  
We recently described myonectin/CTRP15 as a novel myokine expressed predominantly 
by skeletal muscle (28) and determined that exercise can upregulate its expression and circulating 
level (28, 29). Myonectin is a member of the C1q/TNF-related proteins (CTRPs) with a signature 
C-terminal globular C1q domain (28, 30-35). Since our initial identification and characterizations 
of myonectin (28, 36) it has also been referred to as erythroferrone, a secreted protein induced in 
erythroblasts that links stress erythropoiesis to iron mobilization in liver in response to blood loss 
(37, 38). 
Using genetic gain- or loss-of-function mouse models, we and others provided in vivo 
evidence for the important metabolic and cardiovascular functions of several CTRP family 
members (29, 33, 39-59). Unlike other family members, myonectin is the only CTRP whose basal 
expression is primarily restricted to skeletal muscle. Several lines of evidence suggest that 
myonectin is a physiologically relevant metabolic regulator (28, 36). First, overnight fasting 
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reduces and re-feeding increases myonectin mRNA and serum levels. Second, and similar to re-
feeding, a bolus of glucose or emulsified lipid administered to overnight-fasted mice increases 
circulating myonectin (28). The addition of glucose, amino acids, or free fatty acids to cultured 
myotubes also upregulates myonectin expression, suggesting that nutrient uptake and metabolism 
by muscle cells is sufficient to induce production of this protein. Third, the expression and 
circulating levels of myonectin are significantly reduced in diet-induced obese and insulin-resistant 
mice (28). Fourth, infusion of recombinant myonectin into mice reduces circulating free fatty acid 
levels by promoting free fatty acid uptake (28). Fifth, myonectin suppresses liver autophagy (36), 
an intracellular recycling pathway activated in the fasted state and inhibited in the fed state. Finally, 
circulating level of myonectin is associated with insulin resistance and type 2 diabetes in humans 
(60, 61). The caveat of our previous functional studies, however, is the reliance on recombinant 
protein infusion in mice and the use of established muscle and adipocyte cell lines (28, 36); it is 
unclear whether myonectin/erythroferrone is required for metabolic homeostasis in a physiological 
context (62). Therefore, we aimed to determine the physiological function of myonectin using a 
genetic loss-of-function mouse model. Our data provide evidence that myonectin does indeed have 
a role in regulating lipid metabolism in the context of metabolic stress induced by high-fat feeding, 
and that this effect is sex-dependent.  
 
MATERIALS AND METHODS 
Animals 
Myonectin (Erfe/Fam132b+/-) heterozygous mice were obtained from the Mutant Mouse 
Regional Resource Center (MMRRC) at UC Davis (strain B6;129S5-Fam132btm1Lex/Mmucd, ID 
MMRRC:032289-UCD). Mice were generated by Lexicon Pharmaceuticals (63). We maintained 
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the mice on the C57BL/6N genetic background for >6 generations. PCR genotyping strategy was 
provided by MMRRC. Genotyping primers for the myonectin wildtype (WT) allele were: forward, 
5’-GTCAGCCTTACCTGCCCAG-3’; and reverse, 5’-GACGTGAATCTC AGTCTGGC-3’; 
yielding a WT PCR product of 216 bp. Primers for the KO allele were: forward, 5’-GCAGCG 
CATCGCCTTCTATC-3’; and reverse, 5’-GACCGTCACTGAGGTTCCAC-3’; yielding a KO 
PCR product of 390 bp. To confirm loss of myonectin mRNA from KO mice, quantitative PCR 
was performed on muscle samples using two independent sets of myonectin-specific primers: 
Primer set # 1, forward, 5’-TGCTTGGATGCTGTT CGTCAA-3’ and reverse, 5’-
CAGATGGGATAAAGGGGCCTG-3’; primer set # 2, forward, 5’-GCGAGAGA 
GCCATCTGGAGCACTG-3’ and reverse, 5’-GGTCCCTTTCTTGGCTGCTCGGTG-3’. All 
mice were housed in polycarbonate cages with ad-libitum access to water and food in a 
temperature-controlled room with 12-hour (h) light–dark cycles. Mice were fed either a high-fat 
diet (HFD, 60% calories from fat, Research Diets, D12492) or a matched control low-fat diet 
(LFD, 10% calories from fat, Research Diets, D12450B) throughout the study beginning at 5-6 
weeks of age. Body weights of WT and myonectin-KO mice were measured weekly. At the end 
of the study, mice were euthanized 2 h after food removal in the morning or after an overnight fast 
followed by 2 h of ad-libitum re-feeding. Tissues were dissected, weighed, and snap-frozen in 
liquid nitrogen for RNA and protein extraction or prepared for histology. Additional tissues were 
stored at −80°C. All animal experiments were approved by the Animal Care and Use Committee 
of the Johns Hopkins University School of Medicine. 
 
Mouse body composition analysis 
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Body composition of myonectin-KO mice and WT littermates was determined using a 
quantitative nuclear magnetic resonance (NMR) instrument (Echo-MRI-100, Echo Medical 
Systems LLC, Waco, TX) at the Johns Hopkins University School of Medicine mouse phenotyping 
core facility. Echo-magnetic resonance imaging analyses measured total fat mass, lean mass, and 
water content.  
 
Indirect calorimetry 
Indirect calorimetry was performed as previously described (54). In brief, WT and 
myonectin-KO mice were used for simultaneous assessments of daily body weight change, food 
intake (corrected for spillage), physical activity, and whole-body metabolic profile in an open-flow 
indirect calorimeter (CLAMS, Columbus Instruments, Columbus, OH). Data were collected for 
three to four consecutive days to confirm that mice were acclimated to calorimetry chambers 
(indicated by stable body weights, food intakes, and diurnal metabolic patterns), and data from the 
following day(s) were analyzed. Rates of oxygen consumption (VO2) and carbon dioxide 
production (VCO2) in each chamber were measured throughout the studies. Respiratory exchange 
ratio (RER, VCO2/VO2) was calculated by CLAMS software (version 4.02) to estimate relative 
oxidation of carbohydrates (RER = 1.0) versus fats (RER = 0.7), not accounting for protein 
oxidation. Energy expenditure (EE) was calculated as EE = VO2 × [3.815 + (1.232 × RER)]. VO2, 
VCO2, and EE data were normalized to lean mass. Physical activity was measured by infrared 
beam breaks in the metabolic chamber. Average metabolic values were calculated per subject and 
averaged across subjects for statistical analysis. 
 
Mouse serum and blood chemistry analysis 
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Blood samples were collected by tail bleeds using capillary blood collection tubes 
(Microvette CB 300; Sarstedt, Newton, NC). Blood samples were allowed to clot on ice then 
centrifuged for 10 min at 10,000 x g to collect serum. Serum TG and cholesterol levels were 
measured using an Infinity kit (Thermo Fisher Scientific, Middletown, VA). Non-esterified free 
fatty acids were measured using a NEFA-HR (2) kit (Wako Chemicals, Richmond, VA). β-
hydroxybutyrate was measured using a LiquiColor assay (Stanbio). Assays were performed 
according to the manufacturer’s protocol.  
 
ELISA 
Insulin (Millipore), ANGPTL3 (Thermo) and ANGPTL4 (Aviva Systems Biology) levels 
were measured in serum according to the manufacturer’s protocol. 
 
Glucose and insulin tolerance tests 
For glucose tolerance tests (GTTs), mice were fasted overnight (~15 h) and subsequently 
intraperitoneally injected or orally gavaged with a glucose solution in saline at a dose of 1 g 
glucose/kg body weight. Blood was collected from the tail vein into capillary blood collection 
tubes before injection and 15 minutes (min) post-injection for assessment of insulin levels. Serum 
was isolated from blood and stored at -80°C until analysis. Tail vein blood glucose levels at the 
indicated time points were monitored with a glucometer (NovaMax Plus, Billerica, MA). For 
insulin tolerance tests (ITTs), mice were intraperitoneally injected with recombinant human insulin 
(Gibco) diluted in saline after a 2-h fast at a dose of 1-1.5 units insulin/kg body weight. Food was 
removed between 9:00 AM and 10:00 AM. Tail vein blood glucose was monitored with a 
glucometer at the indicated time points. 
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Lipid tolerance test 
After an overnight fast (~15 h), mice were orally gavaged with 20% emulsified intralipid 
(soybean oil, Sigma) at a dose of 10 μL/g body weight. Blood was collected from the tail vein into 
capillary blood collection tubes before gavage and 1, 2, 3, and 4 h post-gavage. Serum was isolated 
from blood samples and assayed for triglyceride (TG) and non-esterified fatty acids (NEFA) using 
commercially available kits according to the manufacturer’s protocol. 
 
Hepatic VLDL-TG secretion 
Mice were fasted for 4 h, beginning 2 h into the light cycle. Poloxamer 407 diluted in saline 
was intraperitoneally injected at a dose of 1 mg/g body weight to inhibit LPL activity. Blood was 
collected from the tail vein into capillary blood collection tubes before injection and at 1, 2, 4, and 
8 h post-injection. Serum was isolated from blood and assayed for TG using a colorimetric kit.  
 
Intestinal lipid absorption and secretion 
Overnight fasted mice (~15 h) were intraperitoneally injected with poloxamer 407 diluted 
in saline at a dose of 1 mg/g body weight to inhibit LPL activity. After 1 h, mice were orally 
gavaged with 20% emulsified intralipid (10 μL/g body weight). Blood was collected from the tail 
vein into capillary blood collection tubes before gavage and at 1, 2, 3, and 4 h post-gavage. Serum 
was isolated from blood samples and assayed for TG using a colorimetric kit. 
 
Blood and tissue collection 
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Mice were anesthetized with isoflurane and blood was collected from the retro-orbital 
plexus through heparin-coated capillary tubes (Fisher). Blood samples were allowed to clot on ice 
then centrifuged for 10 min at 10,000 x g. Separated serum was aliquoted and stored at -80°C. 
Organs were excised and weighed, then flash frozen in liquid nitrogen before being stored at -
80°C. 
 
Complete blood count analysis 
A complete blood count on blood samples was performed at the Pathology Phenotyping 
Core at the Johns Hopkins University School of Medicine. Blood samples were collected from the 
femoral vein using EDTA-coated blood collection tubes (Sarstedt) and analyzed using Procyte Dx 
analyzer (IDEXX laboratories). 
 
Serum lipoprotein analysis 
Lipoprotein analyses were performed at the Metabolism core at the Baylor College of 
Medicine. 300 μL of serum were pooled from 10 mice of each genotype (30 μL per mouse). Pooled 
serum samples from WT and KO mice were subjected to fractionation using fast protein liquid 
chromatography (FPLC), followed by quantification of TG and cholesterol levels in each fraction.  
 
Heparin releasable LPL activity in serum 
Mice were fasted overnight (~13 h) and given free access to food for 2 h. The experiment 
was conducted as previously described (64). Mice were briefly anesthetized with isoflurane and 
retro-orbitally injected with heparin sodium salt (Sigma) diluted in saline at a dose of 300 U/kg 
body weight. Blood was collected from the tail vein into capillary blood collection tubes before 
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injection and 5 min post-injection. Serum was isolated from blood samples. Pre-heparin serum was 
used to measure serum TG levels. Total lipase activity was measured using a commercial kit 
(BioVision) in post-heparin serum. 
 
Mouse histology                                                                                                                                    
Adipose and liver tissues from littermate-matched WT and myonectin-KO mice were fixed 
in 10% formalin at 4°C overnight. Fixed tissues were embedded in paraffin, sectioned, and stained 
with hematoxylin and eosin (H&E) at the Histology Reference Laboratory at the Johns Hopkins 
University School of Medicine.  
 
Adipocyte cell size analysis 
Adipocyte size was measured using the “MRI Adipocyte Tools” macro in the ImageJ 
software. All cells in one field of view at 100X magnification per tissue section per mouse were 
analyzed from a total of 5 WT and 5 KO littermate-matched mice for visceral (gonadal) white 
adipose tissue and 4 WT and 5 KO littermate-matched mice for subcutaneous (inguinal) white 
adipose tissue. On average, 230 cells were measured for each sample. 
 
Extraction and quantification of mouse hepatic lipid contents 
50-80 mg of frozen liver tissue was homogenized in 500 μL ultra-pure water. 200 μL lysate 
were transferred to a new tube and 1 mL of 2:1 chloroform:methanol was added. After thorough 
mixing, samples were spun at 1,700 rpm for 5 min at 4°C. The lower chloroform phase was 
transferred to a new tube and dried in a speed vacuum. Extracted lipids were resuspended in 5% 
Triton x100 in saline. Samples were assayed for TG and cholesterol using commercially available 
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colorimetric kits (Thermo Scientific). Protein content was measured in the original water lysate 
using BCA assay (Thermo), and lipid levels were normalized to total protein. 
 
Western blotting 
Frozen tissue samples were homogenized in RIPA buffer (50 mM Tris-HCl, pH 7.4; 150 
mM NaCl; 1 mM EDTA; 1% Triton X-100; 0.25% deoxycholate) supplemented with a protease 
inhibitor cocktail (Sigma) and a phosphatase inhibitor cocktail (Roche). Protein content was 
measured using BCA assay. Samples for Western blotting were diluted in SDS loading dye (final 
concentration: 50 mM Tris-HCl, pH 7.4, 2% SDS, 6% glycerol, 1% 2-mercaptoethanol, and 0.01% 
bromphenol blue) and denatured at 95C for 10 min. 10-20 g total protein were loaded into each 
lane of a 10% polyacrylamide gel (BioRad) and separated by electrophoresis. The BioRad Trans-
Blot Turbo semi-dry system was used to transfer protein onto PVDF membranes. Blots were 
blocked in 5% non-fat milk in PBST then exposed to primary antibodies overnight at 4C. After 
washing, blots were exposed to secondary antibodies conjugated to HRP for 1 h then developed in 
ECL (Amersham ECL select). Bands were visualized with MultiImage III FluorChem Q (Alpha 
Innotech) and quantified using Alphaview Software (Alpha Innotech). All primary antibodies were 
diluted 1:1000 in PBST + 0.02% sodium azide and all secondary antibodies were diluted 1:5,000 
in 5% non-fat milk in PBST. Antibodies used: LPL (GeneTex, GTX101125), Hsc70 (Santa Cruz, 
sc-7298), perilipin 2 (Thermo, PA1-16972), mouse IgG-HRP (Cell Signaling, 7076), and rabbit 
IgG-HRP (Cell Signaling, 7074). 
 
Liver metabolomics analysis 
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Metabolite quantifications of WT (n=10) and myonectin-KO (n=10) liver samples were 
performed by Metabolon (Morrisville, NC) using their metabolomics platform. Sample 
processing, compound identification by tandem mass spectrometry, metabolite quantification and 
data normalization, data extraction, and curation were all performed according to the standard 
protocol of Metabolon.  
 
Stimulated adipose tissue lipolysis 
Mice were fasted for 5 h beginning at 9:30 AM. The β3-adrenergic receptor agonist, CL 
316-243 (Santa Cruz), was diluted in saline and intraperitoneally injected at a dose of 1 mg/kg 
body weight. Blood was collected from the tail vein into capillary blood collection tubes before 
injection and at 15 min post-injection. Blood glucose was monitored with a glucometer before and 
at 15 min after CL 316-243 injection. Serum was separated from blood and assayed for NEFA and 
glycerol using calorimetric kits (Wako and Sigma, respectively). 
 
Tissue LPL activity 
Tissue LPL activity was measured as previously described (65). Briefly, frozen tissue 
samples were pulverized in liquid nitrogen using a mortar and pestle. Approximately 50 mg 
pulverized tissue were incubated in Krebs-Ringer solution containing BSA and heparin. After 
clarifying, the supernatant was used to measure LPL activity using a commercial kit (Roar 
Biomedical). Activity was normalized to tissue weight. 
 
Quantitative real-time PCR analysis 
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RNA was isolated from tissues using TRIzol reagent (Invitrogen) according to the 
manufacturer’s protocol and treated with DNAse I (New England Biolabs) to remove genomic 
DNA. For each sample, 1-2 μg total RNA were reverse transcribed using random primers and the 
GoScript reverse transcription system from Promega. Quantitative real-time PCR was performed 
on a CFX connect system using iTaq Universal SYBR Green PCR master mix (BioRad). Gene 
expression was first normalized to 36b4 [also known as acidic ribosomal phosphoprotein P0 
(Rplp0)] to generate a ΔCt value, and then ΔΔCt was obtained by normalizing data to mean ΔCt of 
the control group (66). Primers used are listed in Table 1.  
 
Maximal exercise capacity 
Maximal sprint and endurance exercise tests were performed as we described previously 
(67). Briefly, 12-week-old mice fed a standard chow diet were first subjected to the endurance 
exercise test. Mice were acclimated to the treadmill for three days before the experiment and the 
exercise test was carried out on the fourth day. Blood glucose and lactate values were measured 
before and after exercise using glucose and lactate meters (Nova Biomedical). Blood was collected 
from the tail vein into capillary blood collection tubes before and after exercise, and silver nitrate 
sticks were used to cauterize the wound. Mice were run in multiple groups beginning at 9:30 AM 
until exhaustion. After 2.5 weeks of recovery, mice were subjected to the sprint exercise test. A 
day before the experiment, mice were re-acclimated to the treadmill using the same protocol as the 
original day-3 acclimation. For the sprint exercise experiment, mice were run in multiple groups 
beginning at 8:30 AM until exhaustion. As with the endurance test, blood, glucose, and lactate 
were collected before and after exercise. The experimenter was blinded with respect to genotype 
during all exercise tests. 
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Table 1 
Gene Alias Forward primer (5' to 3') Reverse primer (5' to 3') 
Rplp0 36B4 AGATTCGGGATATGCTGTTGGC TCGGGTCCTAGACCAGTGTTC 
myonectin 
















Acaca ACC1 TGACAGACTGATCGCAGAGAAAG TGGAGAGCCCCACACACA 
Acacb ACC2 GGGCTCCCTGGATGACAAC GCTCTTCCGGGAGGAGTTCT 
Acadl LCAD TCTTTTCCTCGGAGCATGACA GACCTCTCTACTCACTTCTCCAG 
















































































































Lipc hepatic lipase CCCTGGCATACCAGCACTAC CTCCGAGAAAACTTCGCAGATT 









Table 1 – continued 














Nr1h4 FXR GCTTGATGTGCTACAAAAGCTG CGTGGTGATGGTTGAATGTCC 












Slc27a1 FATP1 CTGGGACTTCCGTGGACCT TCTTGCAGACGATACGCAGAA 
Slc27a5 FATP5 GTTCTCCCGTCCAAGACCATT GCTCCGTACAGAGTGTAGCAAG 














Table 1. Primers used for quantitative real-time PCR analyses 
 
Recovery after endurance exercise 
Mice used in this experiment were fed a standard chow diet. Mice were acclimated to the 
treadmill as previously described, but with the addition of a fourth acclimation day in which mice 
ran on the treadmill at 14 m/min for 5 min at a 10 incline (67). The endurance exercise run was 
performed on the fifth day when the mice were 11 weeks of age. Mice were fasted for 2 h in the 
morning before exercise. The run was conducted as previously described (68): 60 min at a speed 
of 14 m/min at a 10 incline. A shock grid at the back of the treadmill encouraged mice to continue 
running by administering a mild shock each time they stepped off the belt. If any mice met the pre-
determined criteria for exhaustion before the end of the run, they were removed from the treadmill 
and their data were omitted from analysis (67). The experimenter was blinded with respect to 
genotype during the treadmill run. Blood glucose and lactate values were measured at the indicated 
time points using glucose and lactate meters (Nova Biomedical). One cohort of mice received a 
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glucose gavage within 5 min of the end of the run (0.5 mg glucose/g body weight dissolved in 
saline). All mice were allowed to recover in their cages with free access to water but no food. After 
2 h of recovery following the end of the run, mice were euthanized. Blood and tissues were 
collected as described above. 
 
Tissue glycogen measurement 
Tissue glycogen was measured using a protocol adapted from the NIH-funded Mouse 
Metabolic Phenotyping Centers (https://mmpc.org/shared/protocols.aspx). Frozen whole liver and 
gastrocnemius muscle were pulverized in liquid nitrogen. Approximately 25 mg liver tissue or 50 
mg muscle were homogenized in 400 μL 0.9 N perchloric acid. Samples were clarified by 
centrifuging at 10,000 x g for 10 min at 4C and transferring the supernatant to a new tube. 50 μL 
supernatant were transferred to each of two reaction tubes, along with 25 μL 1M potassium 
bicarbonate and 125 μL 0.4 M sodium acetate buffer (pH 4.8) with or without 5 mg/mL 
amyloglucosidase (Sigma). Reactions were incubated for 2 h at 40C on a heat block. After 2 h, 
reactions were neutralized with NaOH then vortexed and centrifuged for 3 min at 10,000 x g at 
room temperature. Twenty μL of supernatant from each reaction was used to measure glucose 
using an Amplex Red glucose assay kit (Invitrogen) according to the manufacturer’s protocol. 
Amyloglucosidase hydrolyzes glycogen into free glucose monomers. For each tissue sample, the 
amount of glucose in the condition without amyloglucosidase (measuring free glucose) was 
subtracted from the amount of glucose in the condition with amyloglucosidase (measuring free 
glucose + glucose from glycogen) to yield the amount of glucose from glycogen only. This value 
was then normalized to tissue weight. 
 
 89 
Statistical analysis  
Comparisons between two groups of data were performed using two-tailed Student’s t-tests 
with Welch’s correction and 95% confidence intervals. For experiments with two independent 
variables, a 2-way ANOVA was conducted and the Bonferroni method was used for multiple 
comparisons. Graphpad Prism 7 software was used to conduct analyses. Values were considered 




Myonectin-deficient mouse model 
We used a whole-body knockout (KO) mouse model to assess the metabolic function of 
myonectin in vivo. To create a myonectin-null allele, exons 2 through 7 of the myonectin gene 
were replaced with a neomycin cassette (Fig. 1A). Using one set of primers that targeted the WT 
myonectin gene and another set that targeted the neomycin cassette, we could distinguish between 
WT, heterozygous, and homozygous null mice (Fig. 1B). To verify that myonectin was not 
expressed in the KO mice, we measured myonectin mRNA levels in the skeletal muscle—the 
tissue with the highest expression in WT mice (28)—by quantitative PCR. Using two independent 
primer sets, we confirmed the absence of myonectin transcript (Fig. 1C). In the absence of a 
reliable antibody that can recognize endogenous myonectin without cross-reactivity, we did not 
quantify myonectin protein level in WT and KO mice. Myonectin KO mice were viable, fertile, 





Figure 1. Myonectin-deficient mouse model. (A) Schematic of the gene targeting strategy used to 
generate myonectin-knockout (KO) mice. The majority of the myonectin gene (exons 2-7) was replaced 
with a neomycin resistance gene and lacZ reporter cassette. SA, splice acceptor; pA, polyadenylation signal. 
(B) PCR genotyping showing successful production of wildtype (+/+), heterozygous (Het; +/-), and 
homozygous KO (-/-) mice. (C) The absence of myonectin transcript in the mouse gastrocnemius muscle 
was confirmed by quantitative PCR using two independent primer pairs. Primer set #1 targets exon 2 and 
3, yielding a PCR product size of 143 bp. Primer set #2 targets exon 4 and 6, yielding a PCR product size 
of 381 bp. WT n=6 and KO n=6 female mice.  
 
Myonectin is not required for the physiological response to exercise 
Under basal conditions, myonectin is primarily produced in  skeletal muscle and its 
expression can be further induced by exercise (28, 29). We therefore first tested whether it is 
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required for the physiological response to exercise. During both maximal sprint and endurance 
exercise on a treadmill, loss of myonectin had no impact on total running distance and the post-
exercise serum levels of glucose, lactate, non-esterified free fatty acids, triglyceride, and ketone 
(β-hydroxybutyrate) levels in female WT and KO mice (Table 2). However, we did observe 
significantly higher pre-exercise serum ketones (β-hydroxybutyrate) in KO female mice relative 
to WT littermate controls. For male mice, with the exception of post-sprint exercise serum 
triglyceride levels that were significantly lower in the KO animals, no significant genotypic 
differences were noted in exercise parameters (Table 2). In the post-exercise recovery phase (with 
or without glucose gavage post-exercise), myonectin deficiency did not significantly affect the 
ability of KO animals to replenish their skeletal muscle or liver glycogen stores (Table 3). These 
results indicate that myonectin is not required for physiologic response and adaptation to an acute 
bout of exercise. 
  
Myonectin knockout mice fed a control low-fat diet show no overt metabolic phenotypes 
Given its potential role as a postprandial metabolic regulator (28, 36), we tested whether 
myonectin is necessary for metabolic homeostasis under basal conditions. Male and female WT 
and KO mice were fed a control low-fat diet (LFD) for 12 weeks, beginning at 6 weeks of age. 
Neither sex displayed genotypic differences in body weight over time or in body composition (Fig. 
2A-B). Organ weights (heart, kidney, spleen, liver, and adipose tissue) were also not different 
between genotypes of either sex (Table 4). Indirect calorimetry revealed no differences in ad-
libitum food intake, metabolic rate, or energy expenditure between WT and KO mice of either sex 
(Tables 5 and 6). However, ad-libitum fed female KO mice had a higher respiratory exchange 
ratio (RER) in the dark cycle and lower physical activity in the light cycle.   
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 Female mice Male mice 
 WT KO P-value WT KO P-value 
Endurance exercise capacity          
N 14 15  9 14   
Time to exhaustion (min) 116.1 ± 5.253 125.0 ± 4.317 0.2052 99.1 ± 7.172 101.5 ± 3.694 0.7714 
Running distance (m) 1770 ± 117.5 1968 ± 101.6 0.2135 1406 ± 141.2 1447 ± 75.8 0.8031 
Pre-exercise glucose (mg/dL) 161.9 ± 4.655 157.9 ± 3.933 0.5253 190.2 ± 6.357 183.3 ± 3.758 0.3640 
Post-exercise glucose (mg/dL) 148.5 ± 11.27 128.9 ± 6.84 0.1508 175.1 ± 17.39 161.4 ± 8.85 0.4953 
Pre-exercise lactate (mM) 2.000 ± 0.0989 1.873 ± 0.1197 0.4219 1.433 ± 0.1424 1.550 ± 0.1763 0.6120 
Post-exercise lactate (mM) 5.232 ± 0.3179 5.013 ± 0.3570 0.6508 5.300 ± 0.6388 4.779 ± 0.4960 0.5278 
Pre-exercise TG (mg/dL) 56.75 ± 5.872 50.17 ± 4.273 0.3740 53.01 ± 7.726 57.32 ± 6.143 0.6675 
Post-exercise TG (mg/dL) 52.00 ± 2.629 53.31 ± 2.485 0.7202 37.13 ± 2.472 43.26 ± 2.363 0.0905 
Pre-exercise NEFA (mM) 1.225 ± 0.0940 1.035 ± 0.0652 0.1113 1.196 ± 0.0543 1.172 ± 0.1284 0.8662 
Post-exercise NEFA (mM) 2.387 ± 0.1764 2.756 ± 0.1466 0.1196 1.633 ± 0.1979 2.020 ± 0.2182 0.2049 
Pre-exercise β-hydroxybutyrate (μM) 122.4 ± 8.09 163.8 ± 17.07 * 0.0405 139.2 ± 10.93 133.0 ± 15.28 0.7445 
Post-exercise β-hydroxybutyrate (μM) 545.7 ± 47.10 623.3 ± 52.92 0.2830 377.0 ± 58.62 370.2 ± 44.52 0.9278 
          
Sprint exercise capacity          
N 15 15  9 12   
Time to exhaustion (min) 14.52 ± 0.4734 14.71 ± 0.5862 0.7999 12.90 ± 0.6590 12.97 ± 0.4013 0.9373 
Running distance (m) 244.4 ± 13.20 250.6 ± 17.11 0.7764 200.8 ± 17.31 201.2 ± 10.79 0.9851 
Pre-exercise glucose (mg/dL) 169.6 ± 5.266 176.1 ± 4.392 0.3491 180.8 ± 4.481 186.1 ± 5.140 0.4461 
Post-exercise glucose (mg/dL) 180.8 ± 3.558 176.3 ± 5.092 0.4788 221.9 ± 8.093 209.8 ± 5.042 0.2219 
Pre-exercise lactate (mM) 2.270 ± 0.2750 2.027 ± 0.1584 0.4512 1.711 ± 0.1184 1.917 ± 0.1753 0.3440 
Post-exercise lactate (mM) 11.02 ± 0.4419 10.29 ± 0.5822 0.3293 8.872 ± 1.116 9.700 ± 0.803 0.5559 
Pre-exercise TG (mg/dL) 48.40 ± 4.332 49.07 ± 4.985 0.9203 59.03 ± 4.007 54.92 ± 3.592 0.4559 
Post-exercise TG (mg/dL) 46.93 ± 2.458 48.55 ± 2.033 0.6159 56.55 ± 3.604 45.31 ± 2.351 * 0.0202 
Pre-exercise NEFA (mM) 1.083 ± 0.1190 0.856 ± 0.1453 0.2368 1.199 ± 0.0983 1.307 ± 0.1314 0.5187 
Post-exercise NEFA (mM) 1.012 ± 0.0526 0.919 ± 0.1231 0.4964 0.982 ± 0.1055 0.814 ± 0.0894 0.2403 
Pre-exercise β-hydroxybutyrate (μM) 199.6 ± 13.41 244.9 ± 15.74 * 0.0371 161.9 ± 21.62 203.9 ± 33.47 0.3055 
Post-exercise β-hydroxybutyrate (μM) 224.0 ± 17.87 239.6 ± 14.98 0.5103 204.8 ± 24.29 224.4 ± 20.16 0.5423 
 
Table 2. Time to exhaustion, total distance run, and blood parameters during an endurance exercise capacity 
test or a sprint exercise capacity test in chow-fed male and female WT and myonectin-KO mice. Mice were 
12 weeks of age for the endurance test and 14.5 weeks of age for the sprint test. Values that are statistically 





  Female mice Male mice 
  WT KO P-value WT KO P-value 
No glucose gavage post exercise          
N 6 5   5 6   
Body weight (g) 18.23 ± 0.3836 18.10 ± 0.8701 0.8934 25.50 ± 0.7668 24.38 ± 0.7631 0.3293 
Liver weight (g) 0.7950 ± 0.0193 0.7340 ± 0.0370 0.1928 1.076 ± 0.0367 1.040 ± 0.0357 0.4999 
Pre-exercise glucose (mg/dL) 181.5 ± 5.30 187.0 ± 10.70 0.6614 211.8 ± 6.63 201.0 ± 8.67 0.3487 
0 min post-exercise glucose (mg/dL) 184.5 ± 6.35 191.6 ± 13.31 0.6478 207.0 ± 13.02 211.3 ± 11.13 0.8064 
30 min post-exercise glucose (mg/dL) 158.2 ± 7.85 150.4 ± 11.60 0.5959 159.0 ± 6.46 158.0 ± 6.81 0.9175 
60 min post-exercise glucose (mg/dL) 144.7 ± 13.11 154.8 ± 6.84 0.5139 140.8 ± 10.96 163.3 ± 5.90 0.1183 
120 min post-exercise glucose (mg/dL) 127.8 ± 5.88 135.2 ± 5.08 0.3682 145.4 ± 12.84 154.2 ± 4.74 0.5496 
Pre-exercise lactate (mM) 1.750 ± 0.1057 1.560 ± 0.0980 0.2200 2.400 ± 0.4572 2.033 ± 0.1333 0.4783 
0 min post-exercise lactate (mM) 3.950 ± 0.2814 4.300 ± 0.7987 0.6965 4.460 ± 0.1778 4.400 ± 0.3907 0.8928 
Muscle glycogen (nmol glucose from 
glycogen/mg tissue) 9.75 ± 0.5824 10.53 ± 1.3198 0.6115 11.16 ± 1.085 12.37 ± 1.981 0.6097 
Liver glycogen (nmol glucose from 
glycogen/mg tissue) 30.81 ± 7.6927 12.10 ± 0.8849 0.0591 67.37 ± 19.70 78.24 ± 11.16 0.6470 
           
With glucose gavage post exercise          
N 5 6   5 5   
Body weight (g) 19.94 ± 0.3444 20.33 ± 0.8887 0.6932 24.12 ± 0.5417 24.86 ± 0.6823 0.4216 
Liver weight (g) 0.8300 ± 0.0319 0.8417 ± 0.0464 0.8409 1.006 ± 0.0279 1.008 ± 0.0323 0.9638 
Pre-exercise glucose (mg/dL) 162.2 ± 7.51 160.7 ± 4.82 0.8684 198.2 ± 7.37 192.2 ± 5.21 0.5270 
0 min post-exercise glucose (mg/dL) 150.8 ± 17.89 159.5 ± 8.31 0.6754 197.4 ± 12.48 192.0 ± 10.22 0.7467 
30 min post-exercise glucose (mg/dL) 137.6 ± 9.48 153.2 ± 4.52 0.1906 179.0 ± 2.19 172.6 ± 8.35 0.4948 
60 min post-exercise glucose (mg/dL) 127.7 ± 6.74 129.0 ± 2.00 0.8649 156.0 ± 13.00 154.7 ± 0.67 0.9350 
120 min post-exercise glucose (mg/dL) 103.8 ± 12.01 105.5 ± 7.98 0.9094 139.4 ± 7.90 137.8 ± 4.42 0.8652 
Pre-exercise lactate (mM) 1.580 ± 0.1068 1.517 ± 0.0601 0.6225 1.540 ± 0.0872 1.740 ± 0.1568 0.3060 
0 min post-exercise lactate (mM) 6.520 ± 1.3782 4.433 ± 0.7697 0.2316 2.800 ± 0.1140 4.600 ± 1.1406 0.1901 
Muscle glycogen (nmol glucose from 
glycogen/mg tissue) 9.63 ± 0.5762 10.56 ± 0.2763 0.1976 12.15 ± 0.835 12.91 ± 0.836 0.5347 
Liver glycogen (nmol glucose from 
glycogen/mg tissue) 27.91 ± 4.6121 44.47 ± 9.4856 0.1596 42.61 ± 17.04 47.36 ± 11.02 0.8216 
 
Table 3. Chow-fed Male and female WT and myonectin-KO mice (at 11 weeks of age) were subjected to 
an endurance run on the treadmill, and blood glucose and lactate values were measured at the indicated 
timepoints. Half of the mice received a glucose gavage immediately after completing the run. All mice were 
allowed to recover for 2 h before euthanization.  
 
Similar to the female KO mice, ad-libitum fed male KO mice also had significantly lower physical 
activity in the light cycle and over a 24-hr period. Myonectin is robustly induced upon re-feeding 
following a fast (36). We therefore challenged the WT and KO mice with a 24-h fast followed by 
24-h free access to food while they were in the metabolic cages. No genotypic differences in either 
sex were observed during the fast (Tables 5 and 6).  However, in the refeeding phase, female KO 
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Figure 2. No overt metabolic phenotypes were observed in myonectin-KO mice fed a control low-fat 
diet. (A) Body weights of female (WT, n=6; KO, n=8) and male (WT, n=6; KO, n=8) mice over time. Mice 
were weaned at 3.5 weeks of age onto a standard chow diet. At 6 weeks of age, the diet was switched to a 
control low-fat diet (Research Diets). (B) Body composition analysis of female  (WT, n=6; KO, n=8) and 
male  (WT, n=6; KO, n=8) mice at 29 weeks of age. (C-D) Blood glucose levels during glucose tolerance 
tests (GTT) in female (WT, n=12; KO, n=13) and male (WT, n=12; KO, n=17) mice at 18 weeks of age. 
(E) Serum insulin levels in male mice at 0 min before glucose injection (WT, n=5; KO, n=5) and at 15 min 
after glucose injection (WT, n=6, KO, n=9); for some samples, insulin levels were below the threshold of 
detection. (F-G) Blood glucose levels during insulin tolerance tests (ITT) in female (WT, n=12; KO, n=13) 
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and male (WT, n=5; KO, n=7) mice at 24 weeks of age. Insulin was injected at a dose of 1 unit/kg body 
weight for both males and females. (H-I) Serum TG (H) and NEFA (I) levels during lipid tolerance tests 
(LTT) in male mice (WT, n=12; KO, n=15-16) at 23 weeks of age. 
 
 Female Mice Male Mice 
  WT KO P-value WT KO P-value 
Low fat diet          
N 6 5   12 16   
Body weight (g) 26.82 ± 1.096 25.70 ± 0.752 0.4240 35.87 ± 1.095 35.64 ± 1.194 0.8898 
Blood glucose (mg/dL) 155.5 ± 4.951 170.2 ± 9.687 0.2251 190.3 ± 5.656 186.3 ± 4.079 0.5703 
Liver weight (g) 1.273 ± 0.0943 1.178 ± 0.0658 0.4298 1.648 ± 0.0988 1.608 ± 0.1383 0.8186 
eWAT weight (g) 0.3517 ± 0.0393 0.3460 ± 0.0414 0.9232 0.8500 ± 0.0581 0.8200 ± 0.0569 0.7154 
iWAT weight (g) 0.2917 ± 0.0329 0.2440 ± 0.0303 0.3141 0.5917 ± 0.0535 0.5753 ± 0.0428 0.8139 
Kidney weight (g) 0.1117 ± 0.0040 0.1120 ± 0.0049 0.9593 0.1567 ± 0.0095 0.1514 ± 0.0070 0.6687 
Heart weight (g) 0.1517 ± 0.0079 0.1580 ± 0.0097 0.6263 0.2267 ± 0.0196 0.2100 ± 0.0089 0.4638 
Spleen weight (g) 0.0983 ± 0.0087 0.1300 ± 0.0147 0.1223 0.0833 ± 0.0068 0.0856 ± 0.0085 0.8349 
           
High fat diet          
N 7 8   12 16   
Body weight (g) 53.06 ± 0.818 55.29 ± 1.725 0.2700 50.98 ± 0.890 51.91 ± 1.065 0.5092 
Blood glucose (mg/dL) 198.4 ± 10.00 201.0 ± 9.58 0.8556 196.5 ± 10.62 194.0 ± 6.95 0.8458 
Liver weight (g) 1.786 ± 0.1177 1.771 ± 0.1085 0.9294 2.837 ± 0.1359 2.493 ± 0.1302 0.0793 
eWAT weight (g) 2.266 ± 0.1038 2.646 ± 0.1096 * 0.0256 0.806 ± 0.0564 1.009 ± 0.0702 * 0.0329 
iWAT weight (g) 1.596 ± 0.0695 1.819 ± 0.0784 0.0530 1.289 ± 0.0485 1.445 ± 0.0470 * 0.0296 
Kidney weight (g) 0.1429 ± 0.0064 0.1400 ± 0.0044 0.7207 0.2108 ± 0.0060 0.2033 ± 0.0058 0.3771 
Heart weight (g) 0.1479 ± 0.0051 0.1500 ± 0.0073 0.8142 0.1808 ± 0.0069 0.1907 ± 0.0090 0.3951 
Spleen weight (g) 0.1443 ± 0.0207 0.1338 ± 0.0146 0.6854 0.1200 ± 0.0049 0.1163 ± 0.0069 0.6633 
 
Table 4. Body weight, blood glucose, and organ weights from WT and myonectin-KO mice. All mice were 
euthanized after 2-4 h food removal in the morning. At the time of sacrifice, LFD-fed males and females 
were 35 weeks old, and HFD males and females were 39 weeks old. For LFD-fed males, N= 6 WT and 8 
KO for kidney and heart weights. Values that are statistically significant (* P < 0.05) are bolded and 
underlined.  
 
mice had lower RER in the light cycle, and male KO mice had significantly reduced physical 
activity in the dark cycle and over a 24-hr period (Tables 5 and 6). Because myonectin is also 
upregulated after an acute bout of exercise (28), we provided the WT and KO mice with a voluntary 
running wheel in the metabolic cages in a separate experiment. No major genotypic differences in 





 Female Mice Male Mice 
With access to running wheel  WT KO 
P-
value WT KO 
P-
value 
N 5 5   5 5   
body weight (g) 24.92 ± 0.85 22.93 ± 0.68 0.1064 34.44 ± 1.10 31.97 ± 1.16 0.1612 
Food intake (kcal) 16.57 ± 2.316 13.60 ± 1.027 0.2889 15.53 ± 1.032 14.21 ± 0.6769 0.3194 
VO2 (mL/kg lean mass/h) 5540 ± 290.24 5967 ± 215.82 0.2747 5010 ± 218.42 4865 ± 158.65 0.6086 
VCO2 (mL/kg lean mass/h) 5380 ± 182.51 5511 ± 150.72 0.5962 4639 ± 252.99 4445 ± 99.65 0.5062 
RER (VCO2/VO2) 0.9237 ± 0.0362 0.9270 ± 0.0331 0.9478 0.9246 ± 0.0157 0.9153 ± 0.0181 0.7072 
EE(kcal/kg lean mass/h) 27.76 ± 1.1344 29.55 ± 0.9034 0.2540 24.83 ± 1.1369 24.04 ± 0.7031 0.5740 
Total activity (beam breaks) 98718 ± 8863 97087 ± 17367 0.9361 45503 ± 4999 42172 ± 9876 0.7737 
Ambulatory activity (counts) 42468 ± 7579 49323 ± 10918 0.6216 16620 ± 2691 16296 ± 5834 0.9615 
Wheel activity (counts) 11553 ± 1989 10975 ± 1499 0.8229 3196 ± 465 2095 ± 893 0.3157 
Cumulative wheel activity (counts) 73647 ± 16929 62831 ± 5709 0.5719 15172 ± 1112 14373 ± 2802 0.8012 
 
Table 7. Indirect calorimetry, physical activity, and food intake of myonectin-KO and WT mice (age 30 
weeks) with access to a voluntary running wheel. Mice were given 4 days to acclimate to the metabolic 
cages and become accustomed to using the running wheel. Data were collected on day 5. 
 
To assess whether myonectin deficiency alters carbohydrate metabolism, glucose tolerance 
tests (GTT) were performed. The rate of glucose uptake in peripheral tissues in response to glucose 
injection was not different between genotypes of either sex (Fig. 2C,D). The magnitude of insulin 
secretion in response to a rise in blood glucose during GTT did not differ between genotypes in 
males (Fig. 2E). We also performed insulin tolerance tests (ITT) to assess insulin action in 
peripheral tissue. The rate of glucose disposal in response to a bolus of insulin did not differ 
between genotypes of either sex (Fig. 2F,G). We previously showed that recombinant myonectin 
infusion promotes lipid uptake in mice (28). To test whether myonectin deficiency affects the 
ability of mice to handle an acute lipid load, we performed lipid tolerance tests. Overnight-fasted 
mice were orally gavaged with a bolus of emulsified intralipid, and serum lipid levels were 
measured over time to assess the rate of lipid uptake and clearance by peripheral tissues. No 
genotypic differences were observed in the rate of clearance of serum TG or NEFA (Fig. 2H,I). 
Aside from physical activity in the ad-libitum fed state or during refeeding, our data indicate that 
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myonectin is dispensable for whole-body carbohydrate and lipid metabolism under basal 
conditions. 
 
Minimal impact of myonectin deficiency on carbohydrate metabolism in the context of 
obesity  
We next determined whether myonectin is required for a proper response to metabolic 
stress. A separate cohort of male and female WT and KO mice was challenged with a high-fat diet 
(HFD), beginning at 5 weeks of age, to induce obesity and insulin resistance. We performed the 
same sets of metabolic tests as in the control LFD-fed cohorts to determine whether myonectin 
deficiency exacerbates or improves the pathophysiological phenotypes associated with diet-
induced obesity and insulin resistance. Body weight and body composition did not differ between 
genotypes of either sex (Fig. 3A,B). Despite no difference in overall fat mass, the gonadal fat pad 
was larger in myonectin-KO female mice relative to WT littermates (Table 4). Indirect calorimetry 
analyses indicated no differences in metabolic rate, physical activity, or energy expenditure 
between genotypes of either sex under ad-libitum fed conditions, or during a 24-h fast and 24-h 
re-feed (Tables 8-9). However, we noted that ad-libitum fed female KO mice had significantly 
reduced food intake in the light cycle (Table 8). In the refeeding phase following a fast, female 
KO mice had reduced food intake and lower RER in the dark cycle; the reduction in food intake 
was also observed over the 24-hr refeed period. In contrast to female mice, the only difference 
seen in KO male mice was reduced RER in the light cycle in the ad-libitum fed state (Table 9). 
Myonectin-deficient female mice also showed a modest impairment in the rate of glucose uptake 
in peripheral tissues in response to glucose or insulin injection (Fig. 3C,F). Myonectin-deficient 




Figure 3. There are no overt carbohydrate metabolism phenotypes in the myonectin-KO mice fed a 
high-fat diet. (A) Body weights of female (WT, n=8; KO, n=8) and male (WT, n=12-13; KO, n=16) mice 
over time. Mice were weaned at 3.5 weeks of age onto a standard chow diet. At 5 weeks of age, the diet 
was switched to a high-fat diet (Research Diets). (B) Body composition analysis of female (WT, n=7; KO, 
n=8) and male (WT, n=12, KO, n=16) mice at 28 weeks of age. (C) Blood glucose levels during 
intraperitoneal glucose tolerance tests (ip-GTT) in 18-week-old female mice (WT, n=8; KO, n=8). (D) 
Blood glucose levels during oral-GTT in 19-week-old male mice (WT, n=12; KO, n=12). (E) Serum insulin 
levels in male mice at 0 min before glucose gavage (WT, n=11; KO, n=9) and at 15 min after glucose 
gavage (WT, n=12; KO, n=11); for some samples, insulin levels were below the threshold of detection. (F-
G) Blood glucose levels during ITT in female (WT, n=7; KO, n=8) and male mice (WT, n=11; KO, n=15) 
at 23 weeks of age. Insulin was injected at a dose of 1.2 units/kg body weight for female mice and 1.5 






tests (Fig. 3D,G).  The magnitude of insulin secretion in response to glucose injection during the 
glucose tolerance test did not differ between genotypes in males (Fig. 3E). Together, these results 
indicate that myonectin deficiency has minimal impact on whole body carbohydrate metabolism 
in the pathophysiological context of diet-induced obesity. 
 
Impact of myonectin deletion on hematologic parameters 
Myonectin (also referred to as erythroferrone) plays important roles in linking stress 
erythropoiesis and hepatic iron mobilization in response to blood loss or anemia by suppressing 
hepcidin expression in liver (37, 38). Here, under basal non-stressed conditions, myonectin 
deficiency did not alter any blood parameters, including hemoglobin level, hematocrit, and 
population counts of lymphoid and myeloid cell types in male mice (Table 10), consistent with 
previous findings (38). Interestingly, under basal conditions when mice were fed a control low-fat 
diet, female mice lacking myonectin had significantly elevated total white blood cell counts as 
well as lymphocyte counts (Table 10). Although diet-induced obesity can adversely affect multiple 
cell types in the immune system (69), metabolic stress from a high-fat diet did not alter any of the 
blood parameters in myonectin-deficient mice of either sex relative to control WT littermates 
(Table 10). Liver hepcidin expression was also indistinguishable between WT and KO mice (Fig. 
4). Thus, myonectin is not required for iron homeostasis under conditions where stress 
erythropoiesis is not induced. 
 
Myonectin deletion impairs lipid handling in diet-induced obese male mice 
Although HFD-fed female WT and myonectin-KO mice had similar rates of lipid clearance 
following an oral lipid gavage (Fig. 5), male KO mice exhibited significant impairment  
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 Female Mice Male Mice 
  WT KO P-value WT KO P-value 
Low fat diet          
Sample size (n) 6 6   6 9   
RBC (10^6/μL) 11.89 ± 0.2685 11.97 ± 0.2279 0.8214 12.80 ± 0.3004 12.35 ± 0.1321 0.2129 
HGB (g/dL) 17.17 ± 0.3442 17.28 ± 0.3563 0.8186 18.37 ± 0.3756 17.87 ± 0.2309 0.2871 
HCT (%) 56.93 ± 1.4317 56.97 ± 1.1575 0.9859 62.42 ± 1.9624 60.06 ± 0.8699 0.3078 
MCV (fL) 47.88 ± 0.2868 47.58 ± 0.2442 0.4447 48.70 ± 0.4517 48.59 ± 0.3385 0.8478 
MCH (pg) 14.45 ± 0.0563 14.43 ± 0.0615 0.8455 14.35 ± 0.1057 14.48 ± 0.0878 0.3724 
MCHC (g/dL) 30.17 ± 0.2216 30.35 ± 0.1996 0.5526 29.48 ± 0.4126 29.76 ± 0.2021 0.5712 
RET (10^3/μL) 811.8 ± 91.48 637.6 ± 25.27 0.1182 644.5 ± 43.98 701.1 ± 26.10 0.2984 
PLT (10^3/μL) 1037 ± 48.3 691 ± 248.3 0.2583 1069 ± 144.9 1093 ± 109.8 0.8997 
WBC (10^3/μL) 6.718 ± 0.5719 9.045 ± 0.5986 * 0.0185 6.637 ± 0.6392 7.682 ± 0.4734 0.2177 
NEUT (10^3/μL) 0.9000 ± 0.1218 0.6733 ± 0.0561 0.1346 0.5640 ± 0.0588 0.9922 ± 0.2907 0.1841 
LYMPH (10^3/μL) 5.533 ± 0.5610 8.068 ± 0.5548 ** 0.0093 5.590 ± 0.6740 6.319 ± 0.4194 0.3884 
MONO (10^3/μL) 0.1250 ± 0.0186 0.0933 ± 0.0167 0.2335 0.0450 ± 0.0050 0.0956 ± 0.0267 0.0976 
EO (10^3/μL) 0.1517 ± 0.0199 0.2050 ± 0.0257 0.1334 0.0817 ± 0.0101 0.2633 ± 0.1085 0.1333 
BASO (10^3/μL) 0.0083 ± 0.0031 0.0050 ± 0.0034 0.4850 0.0033 ± 0.0033 0.0122 ± 0.0022 0.0528 
           
High fat diet          
Sample size (n) 8 8   12 16   
RBC (10^6/μL) 12.02 ± 0.1721 12.21 ± 0.1471 0.4158 11.85 ± 0.2219 11.76 ± 0.1389 0.7460 
HGB (g/dL) 17.38 ± 0.2051 17.65 ± 0.2188 0.3747 17.07 ± 0.2577 17.03 ± 0.1895 0.9129 
HCT (%) 56.30 ± 0.7725 57.25 ± 0.7043 0.3790 56.26 ± 0.9363 56.26 ± 0.9798 0.9976 
MCV (fL) 46.86 ± 0.1936 46.89 ± 0.2787 0.9424 47.51 ± 0.2797 47.81 ± 0.4274 0.5651 
MCH (pg) 14.44 ± 0.0680 14.46 ± 0.0885 0.8262 14.42 ± 0.1036 14.48 ± 0.0823 0.6301 
MCHC (g/dL) 30.88 ± 0.1634 30.86 ± 0.3111 0.9723 30.35 ± 0.1681 30.32 ± 0.2532 0.9189 
RET (10^3/μL) 738.7 ± 39.02 762.1 ± 64.40 0.7615 678.1 ± 27.93 651.8 ± 22.40 0.4697 
PLT (10^3/μL) 973 ± 145.9 794 ± 129.5 0.3743 1063 ± 120.9 979 ± 95.0 0.5902 
WBC (10^3/μL) 8.653 ± 0.6896 9.700 ± 0.7905 0.3353 10.66 ± 1.0864 9.72 ± 0.5907 0.4594 
NEUT (10^3/μL) 0.8988 ± 0.1308 0.8500 ± 0.1179 0.7860 1.175 ± 0.1496 1.135 ± 0.1726 0.8623 
LYMPH (10^3/μL) 7.391 ± 0.5727 8.479 ± 0.6326 0.2234 9.093 ± 0.9694 8.201 ± 0.4738 0.4205 
MONO (10^3/μL) 0.0725 ± 0.0146 0.0638 ± 0.0110 0.6403 0.1183 ± 0.0148 0.1475 ± 0.0297 0.3884 
EO (10^3/μL) 0.2813 ± 0.0702 0.3013 ± 0.0919 0.8653 0.2575 ± 0.0796 0.2194 ± 0.0387 0.6722 
BASO (10^3/μL) 0.0088 ± 0.0030 0.0063 ± 0.0018 0.4856 0.0117 ± 0.0021 0.0169 ± 0.0025 0.1239 
 
 
Table 10. Complete blood count of WT and myonectin-KO mice. At the time of sample collection, LFD-
fed mice were 20 weeks of age, HFD-fed females were 22 weeks of age, and HFD-fed males were 26 weeks 
of age. Platelet counts were omitted from 1 WT and 2 KO LFD-fed females and 2 KO LFD-fed males due 
to the presence of platelet clumps in the sample. Values that are statistically significant are bolded and 
underlined. Abbreviation: RBC: red blood cell count, HGB: hemoglobin, HCT: hematocrit, MCV: mean 
corpuscular (erythrocyte) volume, MCH: mean corpuscular hemoglobin, MCHC: mean corpuscular 
hemoglobin concentration, RET: reticulocyte count, PLT: platelet count, WBC: white blood cell count, 
NEUT: neutrophil count, LYMPH: lymphocyte count, MONO: monocyte count, EO: eosinophil count, 





Figure 4. Myonectin WT and KO male mice fed a high-fat diet do not differ in liver hepcidin 
expression. Hepcidin mRNA expression in livers isolated from high-fat fed male mice sacrificed 




Figure 5. Myonectin WT and KO female mice fed a HFD do not differ in lipid tolerance. 
Serum triglyceride (TG; A) and non-esterified free fatty acid (NEFA; B) levels in mice during 
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in uptake of triglyceride and free fatty acids from the circulation compared to WT littermates (Fig. 
6). The impaired lipid clearance phenotype following lipid loading was confirmed in two 
additional independent cohorts of HFD-fed mice. Mice develop insulin resistance after exposure  
to a high-fat diet for a short period (1-4 weeks), whereas more pronounced differences in body 
weight gain occur after longer exposure to high-fat feeding (70). Because lipid tolerance was 
different between WT and KO male mice fed an HFD, we sought to determine whether insulin 
resistance due to HFD is sufficient to impair lipid disposal in response to oral lipid gavage. In 
contrast to chronic high-fat feeding, relatively short exposure to an HFD for 4 weeks did not alter 
lipid tolerance in myonectin-deficient mice compared to WT littermates (Fig. 7). This result 
suggests that excess adiposity from chronic high-fat feeding is necessary to alter lipid handling 




Figure 6. Impaired lipid tolerance in myonectin-KO male mice fed a high-fat diet. (A) Serum 
triglyceride (TG) and (B) non-esterified free fatty acids (NEFA) during lipid tolerance test (LTT) 





Figure 7. Insulin resistance alone is insufficient to induce impaired lipid clearance phenotype in 
myonectin-KO male mice fed a high-fat diet for only 4 weeks. Serum triglyceride (TG; A) and non-
esterified free fatty acids (NEFA; B) levels in male mice during lipid tolerance tests (LTT) at 9 weeks of 
age (WT, n=13; KO, n=9). 
 
Impact of myonectin deficiency on metabolic response to high-fat feeding later in life  
Diet-induced obese mice in our studies were exposed to HFD beginning at 5 weeks of age, 
which corresponds to adolescence. To determine whether myonectin is required for metabolic 
flexibility in adult animals, we exposed another cohort of mice to HFD after they reached 21 weeks 
of age. After switching from standard chow to HFD for 12 weeks, mice were assessed by several 
tolerance tests. Body weight and glucose and insulin tolerance did not differ between genotypes 
of either sex (Fig. 8A-G). No differences in lipid tolerance were noted between WT and KO female 
mice (Fig. 8H,I). Male myonectin-KO mice, however, exhibited reduced capacity to clear serum 
TG from the circulation following an oral lipid gavage (Fig. 8J,K). The magnitude of difference 
between genotypes in lipid tolerance was smaller in this older cohort of myonectin-deficient male 
mice as compared to younger cohorts (Figure 6). These results indicate that the severity of the lipid 
tolerance phenotype is contingent upon the age at which mice are exposed to the metabolic stress 
of high-fat feeding.  
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4 weeks of high-fat feeding
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Figure 8. Body weight analysis, and glucose, insulin, and lipid tolerance in WT and myonectin-KO 
mice exposed to a high-fat diet later in life. Mice were weaned onto a standard chow diet and switched 
to a high-fat diet at 21 weeks of age. (A) Body weight measurements over time of female (WT, n=14; KO, 
n=15) and male (WT, n=8; KO, n=14) mice. (B,D) Blood glucose levels during glucose tolerance tests 
(GTT) in female (WT, n=14; KO, n=15; B) and male (WT, n=8; KO, n=13; D) mice at 36 weeks of age. 
(C) Serum insulin levels during GTT in female mice at time 0 before glucose injection (WT, n= 10; KO, 
n=12) and at 15 min after glucose injection (WT, n=14; KO, n=15); for some samples, insulin levels were 
below the threshold of detection. (E) Serum insulin levels during GTT in male mice at time 0 before glucose 
injection (WT, n=8 ; KO, n=14) and at 15 min after glucose injection (WT, n=7; KO, n=14); for some 
samples, insulin levels were below the threshold of detection. (F) Blood glucose levels during insulin 
tolerance tests (ITT) in female mice at 43 weeks of age (WT, n=13; KO, n=15). (G) Blood glucose levels 
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during ITT in male mice at 41 weeks of age (WT, n=7; KO, n=13). Insulin was injected at a dose of 1.2 
units/kg body weight for female mice and 1.5 units/kg body weight for male mice. (H-I) serum TG (H) and 
NEFA (I) levels during lipid tolerance tests (LTT) in female mice at 34 weeks of age (WT, n=12-14; KO, 
n=15). (J-K) serum TG (J) and NEFA (K) levels during LTT in male mice at 34 weeks of age (WT, n=8; 
KO, n=13-14).  * P < 0.05 
 
Elevated postprandial VLDL-triglyceride levels in myonectin-deficient male mice 
Although myonectin deficiency impairs the capacity to acutely handle orally delivered 
emulsified intralipid, it is unclear whether myonectin is required for the proper handling of dietary 
lipids in a postprandial state following physiologically normal ad-libitum feeding. To test this, 
HFD-fed male mice were fasted overnight and then given free access to food for 2 h. Blood 
samples were taken before and after re-feeding, and serum lipid levels were measured. While 
fasting serum TG levels were similar between WT and KO mice, postprandial serum TG levels 
were significantly higher in myonectin-KO mice upon re-feeding following a fast (Fig. 9A). 
Fasting and postprandial serum NEFA and cholesterol levels were not different between genotypes 
(Fig. 9B,C). Food intake did not differ between WT and KO mice (Table 9), thus differences in 
calorie intake cannot explain differences in postprandial serum TG levels. Fractionation of pooled 
postprandial serum revealed that myonectin-KO male mice had significantly elevated and larger 
very-low-density lipoprotein (VLDL)-triglyceride particle levels compared to WT males (Fig. 
9D). Lipoprotein cholesterol profiles showed that the size, but not the amount, of HDL-cholesterol 
was larger in the myonectin-KO animals (Fig. 9E). These data indicate that myonectin is required 







Figure 9. Higher postprandial VLDL-triglyceride levels in myonectin-KO male mice fed a high-fat 
diet. Serum triglyceride (TG; A), non-esterified free fatty acids (NEFA; B), and cholesterol (C) levels in 
male mice after an overnight 14-h fast (“fasted”) or after an overnight fast followed by ad-libitum re-feeding 
for 2 h (“refed”). Mice (36 weeks of age) were euthanized after re-feeding for tissue collection. 2 WT mice 
did not eat during the re-feed period as assessed by 1) no increase in serum TG levels over fasting levels, 
and 2) an empty stomach. Therefore, re-fed data from these mice were not included in the analysis. Fasted: 
WT, n=12; KO, n=17. Re-fed: WT, n=10; KO, n=17. (D-E) Re-fed serum samples from 10 mice of each 
genotype were pooled and subjected to FPLC fractionation to separate lipoprotein species. Triglyceride (D) 
and cholesterol (E) levels were measured in each fraction. * P < 0.05 
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Loss of myonectin does not affect intestinal lipid absorption and secretion 
Several mechanisms could affect lipid clearance from the circulation. For example, 
elevated serum TG levels in myonectin-KO mice after oral lipid gavage or ad-libitum feeding 
could be due to enhanced intestinal lipid absorption and/or greater secretion of TG-rich 
chylomicrons by the enterocytes. To test this, overnight-fasted mice were injected with poloxamer 
407, a detergent that inhibits lipoprotein lipase (LPL) activity, preventing lipid uptake in peripheral 
tissue. After 1 h, mice were orally gavaged with intralipid. Accumulation of serum TG over time 
reflects intestinal lipid absorption and subsequent secretion of TG-rich chylomicrons. No 
differences in the kinetics of serum TG rise were noted between HFD-fed WT and KO mice (Fig. 
10A). Alternatively, impaired lipid uptake into peripheral tissues could result in the elevated TG 
levels seen in KO animals. LPL plays a major role in the cellular uptake of lipids derived from 
circulating lipoprotein particles; the enzyme is located on the surface of endothelial cells in most 
tissues and hydrolyzes TG to liberate free fatty acids, which can then be taken up by peripheral 
tissues (71). We therefore measured whole-body LPL activity in post-heparin sera collected from 
mice in the postprandial state. As we previously observed, a 2-h ad-libitum feeding following an 
overnight fast was sufficient to induce a difference in serum TG between genotypes; the heparin-
displaceable total LPL activity, however, was not different between WT and myonectin-KO mice 
(Fig. 10B,C). 
 
Myonectin deletion alters adipose fat storage and lipid accumulation in liver  
We next sought to determine whether myonectin deficiency alters lipid storage in 
peripheral tissues. Although HFD-fed WT and KO mice had similar body weights and body 
composition (Fig. 3A,B), the distribution of fat among tissues was altered. We noted that the KO  
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Figure 10. WT and myonectin-KO male mice fed a high-fat diet do not differ in intestinal lipid 
absorption or postprandial heparin-releasable serum lipase activity. (A) Serum TG levels over time 
during intestinal lipid absorption/secretion assay in male mice at 21 weeks of age (WT, n=12; KO, n=17). 
(B) Serum TG levels measured in serum samples collected after 2 h of re-feeding but before heparin 
injection in male mice (WT, n=12; KO, n=17). (C) Lipase activity in post-heparin serum from male mice 
at 34 weeks of age (WT, n=11; KO, n=17). ** P < 0.01 
 
mice (39-week-old) had significantly increased fat mass (both visceral and subcutaneous fat 
depots) and a modest reduction in liver weight (Fig. 11A-C and Table 4). Liver histology revealed 
a marked reduction in steatosis in KO mice relative to WT littermates (Fig. 11D). Quantification 




Figure 11. Myonectin deficiency alters lipid distribution in male mice fed a high-fat diet. WT and 
myonectin-KO mice were euthanized at 39 weeks of age after a 2–4-h fast in the morning. Unless otherwise 
specified, data in this figure are from analysis of WT (n=12) and KO (n=16) male mice. The wet weight of 
liver (A), visceral (gonadal) fat pad (B), and subcutaneous (inguinal) fat pad (C) are presented along with 
(D) representative images of H&E stained liver sections from WT and KO mice. (E-F) Quantification of 
TG (E) and cholesterol (F) levels in livers. (G) Western blot analysis of Perilipin 2. Two separate gels were 
run, each with WT (n=6) and KO (n=8) samples. PLIN2 levels were first normalized to HSC70 levels from 
the same gel and then normalized to the average WT value. Data were then combined from both gels for 
analysis. (H-I) Representative images of H&E stained epididymal white adipose tissue (eWAT) and 
inguinal white adipose tissue (iWAT) sections from WT and KO male mice. (J) Quantification of adipocyte 
size in eWAT sections (WT, n=5; KO, n=5). (K) Quantification of adipocyte size in iWAT sections (WT, 




11E,F). Consistent with the histologic data and hepatic TG content, the lipid droplet-associated 
protein perilipin 2 was also correspondingly reduced in myonectin-KO livers (Fig. 11G). 
Histologic analysis of visceral (epididymal) white adipose tissue (eWAT) and subcutaneous 
(inguinal) white adipose tissue (iWAT) indicated significantly larger adipocytes in myonectin-KO 
animals (Fig. 11H,I); this was further confirmed by cell size quantification (Fig. 11J,K). 
Differences in adipocyte cell size were more pronounced in the visceral fat depot (eWAT). These 
data suggest that myonectin plays a role in lipid partitioning between tissues and its deficiency 
promotes adipose tissue lipid storage and reduces lipid accumulation in liver. 
 
Myonectin deletion alters multiple liver metabolite levels  
Given the striking differences in lipid partitioning between adipose and liver of HFD-fed 
WT and KO animals, we measured circulating lipids from blood collected at the same time as 
tissue samples as shown in Fig. 11. Serum TG, NEFA, and β-hydroxybutyrate levels were similar 
between HFD-fed WT and KO male mice; serum cholesterol levels, however, were lower in 
myonectin-KO animals (Fig. 12A-D). To explore the genotypic difference in hepatic fat 
accumulation, we also performed unbiased metabolomics analysis to assess global changes in liver 
metabolites. Of the 642 metabolites quantified, only a small subset (32 in total) of metabolites 
significantly differed between WT and KO mice (Fig. 12E). Our data indicate that HFD-fed 
myonectin-KO male mice had elevated secondary bile acids, as well as increased levels of 
metabolites involved in one-carbon metabolism. Interestingly, the hepatic level of imidazole 
propionate, a molecule reported to induce insulin resistance (72), was also significantly elevated 
in myonectin-KO male mice; however, this did not impair insulin sensitivity in male mice as 
measured by glucose and insulin tolerance tests (Fig. 3D,G). In addition to metabolite profiling,  
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Figure 12.  Steady-state serum and liver metabolite levels in WT and myonectin-KO male mice fed a 
high-fat diet. Sera and livers were harvested from mice (39 weeks old) 2-4 h after food removal (A-E). 
Quantification of serum triglyceride (TG; A), non-esterified free fatty acids (NEFA; B), cholesterol (C), 
and ketones (-hydroxybutyrate; D) (WT, n=12; KO, n=16). (E) All liver metabolites that were significantly 
different (p<0.05) between WT (n=10) and myonectin-KO (n=10) male mice. * P < 0.05 
 
we performed extensive quantitative PCR to assess the expression of genes involved in lipid 
synthesis and catabolism in liver and adipose tissue. Of the major genes involved in lipid synthesis 
and oxidation and lipoprotein and iron metabolism, there were no significant differences in the 
expression levels between genotypes in the liver or two major fat depots (Fig. 13). However, for 
genes involved in bile acid metabolism, the expression of Cyp7a, the rate limiting  
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Figure 13. Expression of lipid metabolism genes in liver and visceral and subcutaneous fat depots of 
myonectin-KO and WT male mice fed a high-fat diet. (A-C) Expression of lipid metabolism genes in 
liver (A), epididymal white adipose tissue (eWAT; B), and inguinal white adipose tissue (iWAT; C) as 
measured by quantitative real-time PCR (WT, n=12; KO, n=15-16). (D-F) Expression of genes involved in 
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lipoprotein metabolism (D), bile acids and cholesterol metabolism (E), and heme and iron metabolism (F) 
in liver as measured by quantitative real-time PCR (WT, n=12; KO, n=16). Relative gene expression was 
first normalized to 36b4, then normalized to the average WT value. All data are from mice sacrificed at 39 
weeks of age following a 2–4-h fast in the morning. * P < 0.05 
 
enzyme in bile acid synthesis, was significantly upregulated in the liver of myonectin-KO male 
mice (Fig. 13E). 
 
Myonectin deficiency does not alter hepatic VLDL-TG secretion or fat oxidation 
Since steady-state levels of metabolites (after 2 h of food removal) and gene expression 
could not fully explain the differential lipid accumulation in adipose and liver, we tested specific 
pathways of lipid flux in vivo. Reduced hepatic steatosis in HFD-fed KO mice could be due to 
increased hepatic VLDL-TG secretion. To test this, mice were first fasted for 4 h, beginning at 2 
h into the light cycle, to ensure the absence of food-derived circulating chylomicrons secreted by 
enterocytes; in this physiological state, most of the circulating TG is likely derived from VLDL-
TG particles secreted from liver. Mice were next injected with poloxamer 407 to inhibit lipid 
uptake in peripheral tissue. Thus, the accumulation of serum TG over time reflects hepatic VLDL-
TG secretion. This experiment revealed no differences between WT and KO mice, indicating that 
hepatic VLDL-TG secretion cannot account for the reduced hepatic TG accumulation in 
myonectin-deficient male mice (Fig. 14A). Alternatively, enhanced hepatic fat oxidation can result 
in lower hepatic TG content. While not a direct measure of fat oxidation in liver, serum ketones 
are good proxies because ketogenesis in the liver is biochemically linked to fat oxidation (73); 
hence, circulating ketone levels correspond to the extent of hepatic fat oxidation. Circulating 
ketones (β-hydroxybutyrate) did not differ between WT and KO mice in either the fasted or fed 
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Figure 14. Hepatic VLDL secretion and fat oxidation in myonectin-KO and WT male mice fed a high-
fat diet. (A) Serum TG levels over time during hepatic VLDL secretion assay in male mice at 20 weeks of 
age (WT, n=13; KO, n=17). (B) Serum levels of -hydroxybutyrate in male mice at 36 weeks of age. Serum 
was collected after an overnight fast (“fasted”), and also collected upon overnight fast followed by refeeding 
(“refed”). Fasted: n=12 WT, 17 KO; refed: n=10 WT, 17 KO. Two WT mice did not eat during the re-fed 
period; therefore, refed serum data from these mice were not included in the analysis. 
 
Myonectin deficiency does not alter adipose tissue lipolysis 
Given that myonectin-KO mice had greater adiposity, decreased adipose tissue lipolysis 
could account for this phenotype. Although recombinant myonectin treatment does not affect ex 
vivo lipolysis in white adipose tissue explants (28), the impact of its deficiency on adipose lipolysis 
in vivo is unknown. To test this, mice were injected with a 3-adrenergic receptor agonist 
(CL316,243) to stimulate lipolysis following a 5-h fast. CL-stimulated lipolysis was assessed by 
measuring serum glucose, glycerol, and NEFA before and 15 min post-injection; no differences 
were observed between WT and KO mice (Fig. 15). Our data thus indicate that both basal (no 
changes in steady-state serum NEFA levels; Fig. 12B) and stimulated lipolysis were not altered in 
mice lacking myonectin.  
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Figure 15. Myonectin-KO and WT male mice fed a high-fat diet do not differ in their capacity for 
stimulated white adipose tissue lipolysis. (A) Blood glucose, (B) serum glycerol, and (C) serum NEFA 
levels in male mice at 24 weeks of age during an experiment assessing β3-adrenergic agonist (CL316,243)-
stimulated lipolysis (WT, n=12; KO, n=17). 
 
Myonectin-deficient male mice have higher postprandial LPL activity in the subcutaneous 
fat depot 
Increased lipid uptake into adipocytes could result in greater adiposity. The capacity for 
peripheral tissues to take up circulating lipid is largely dependent on LPL whose activity is 
regulated in a tissue-specific and metabolic state-dependent manner (71). In WAT, LPL expression 
is downregulated during fasting to divert lipid away from adipose to other oxidative tissues. In 
contrast, LPL activity is activated in WAT postprandially to promote lipid uptake and storage. We 
therefore measured LPL activity in subcutaneous (iWAT) and visceral (eWAT) fat depots obtained 
from HFD-fed mice euthanized after 2 h of food removal or in a postprandial state (overnight fast 
followed by 2 h ad-libitum feeding). LPL activity was significantly increased in iWAT from KO 
mice relative to WT controls, but only in the postprandial state (Fig. 16A,B). Increased LPL 
enzymatic activity was not due to increased expression of LPL mRNA or protein in the iWAT 
from KO animals (Fig. 16C-E). Angiopoietin-like proteins and apolipoproteins are known to 
regulate LPL activity (74). We therefore assessed the expression of known LPL inhibitors 
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Figure 16.  Postprandial lipoprotein lipase (LPL) activity in the subcutaneous (inguinal) fat depot is 
increased in myonectin-KO male mice fed a high-fat diet. (A) LPL activity in epididymal white adipose 
tissue (eWAT: WT, n=12; KO, n=16) and inguinal white adipose tissue (iWAT: WT, n=12; KO, n=15) 
from mice euthanized at 39 weeks of age following a 2–4-h fast in the morning. (B) LPL activity in eWAT 
and iWAT from mice (WT, n=10; KO, n=17) euthanized at 36 weeks of age after 2-h re-feeding following 
an overnight fast. (C) LPL mRNA expression in the same eWAT (WT, n=10; KO, n=16) and iWAT (WT, 
n=10; KO, n=15) samples as (B). (D-E) Western blot analysis of LPL in the same iWAT samples as in (B). 
Two separate gels were run, one with 6 WT and 8 KO samples, and the other with 4 WT and 8 KO samples. 
LPL levels were first normalized to HSC70 levels from the same gel, then normalized to the average WT 
value. Data were then combined from both gels for analysis (WT, n=10; KO, n=16) (E). Images from one 
gel are shown (D). *** P < 0.001 
 
(Angptl3, Angptl4, Angptl8, and ApoC3) and activators (ApoC2, ApoA4, and ApoA5) in the same 
fat tissue samples as well as in liver. We also examined the level of Fxr mRNA, the transcriptional 
regulator of angiopoietin-like proteins and apolipoproteins, as well as Gpihbp1 and Vldlr that are 
important for translocation of LPL to the cell surface. At the mRNA level, no significant genotypic 
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differences were observed for these transcripts in WAT and liver (Fig. 17A-C). We also measured 
protein levels of ANGPTL3 and ANGPTL4, two of the major LPL inhibitors, in fasting serum as 
well as the postprandial serum samples; their protein levels were also not significantly different 
between genotypes (Fig. 17D-E).  
 
Figure 17. Serum levels and expression of  genes involved in regulating lipoprotein lipase (LPL) 
activity or transcytosis in different fat depots and liver of myonectin-KO and WT male mice fed a 
high-fat diet. (A-C) Expression of LPL regulators, as measured by quantitative real-time PCR, in inguinal 
white adipose tissue (iWAT; A), epididymal white adipose tissue (eWAT; B), and liver (C) from mice 
sacrificed at 36 weeks of age after 2-h re-feeding following an overnight fast (WT, n=10; KO, n=15-17). 
Relative gene expression was first normalized to 36b4, then normalized to the average WT value. (D-E) 
Serum levels of ANGPTl3 (D) and ANGPTl4 (E) in myonectin-KO and WT male mice after an overnight 
fast (“fasted”) or following 2 h of re-feeding (“Refed”). Fasted: n=12 WT, 17 KO; refed: n=10 WT, 17 KO. 
Two WT mice did not eat during the re-fed period; therefore, refed serum data from these mice were not 
included in the analysis. 
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DISCUSSION 
We used a genetic loss-of-function mouse model to determine whether myonectin is 
required physiologically to maintain metabolic homeostasis. Under basal conditions where mice 
were fed a control low-fat diet (LFD) comparable to standard chow, myonectin was largely 
dispensable for regulating whole-body carbohydrate and fat metabolism, consistent with a recent 
report (62). However, there is one notable phenotype in male mice fed a control LFD: myonectin 
deficiency significantly reduced physical activity in the ad-libitum fed state, as well as in the refed 
(post-prandial) state following a 24 hour fast. In the fasted state where mice typically have 
heightened foraging behavior, physical activity level was not significantly different between 
genotypes; thus, there appears to be a physiological state-dependent change in ambulatory and 
total physical activity in the KO animals. We speculate that myonectin may modulate, directly or 
indirectly, a central pathway controlling physical activity in male mice between two opposing (fed 
and fasted) metabolic states. Of note, the reduced physical activity seen in myonectin-KO male 
mice is not the result of a functional deficit in the skeletal muscle since the capacity for an 
exhaustive sprint or endurance run was not significantly different between genotypes, nor were the 
pre- and post-exercise blood glucose, lactate, NEFA, or ketone levels. The ability of skeletal 
muscle and liver to replenish their glycogen stores following exercise (with or without glucose 
gavage post exercise) was also not significantly different, indicating that myonectin is not required 
for the metabolic response or adaptation to a single bout of exercise. It appears that myonectin is 
also dispensable for physiologic adaptation to chronic voluntary exercise. When indirect 
calorimetry analyses were conducted in WT and KO mice with access to a running wheel, we 
observed no significant differences in metabolic rate, food intake, or the amount of voluntary 
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exercise (wheel running) between genotypes of either sex. Similarly, a recent report indicates that 
myonectin is not required for normal heart function under normal, non-stressed conditions (29).  
In the pathophysiological context of obesity and insulin resistance induced by a high-fat 
diet (HFD), we observed two significant and notable phenotypes related to lipid metabolism in the 
myonectin-deficient animals. First, myonectin-KO mice displayed an impaired ability to handle 
an acute oral lipid load. Second, lipids appear to be partitioned differentially between adipose and 
liver; specifically, myonectin-KO male mice had strikingly reduced triglyceride accumulation in 
liver and, in parallel, a significant increase in adiposity due to greater lipid storage in hypertrophied 
adipocytes. These two lipid phenotypes in KO animals are sex-dependent. Apart of developing 
mild insulin resistance and a bigger gonadal fat pad, myonectin-KO female mice fed an HFD were 
largely indistinguishable from WT littermates with respect to whole-body lipid metabolism. It is 
known that female mice on a C57BL/6 genetic background are much less susceptible to diet-
induced obesity (75, 76). Many studies (77), including our previous studies (54-56) and the present 
study, reinforce the importance of sex as a biological variable that can influence the impact and 
phenotypic outcomes of a given genotype. Intriguingly, although our current study and previous 
findings (62) do not support a major role for myonectin in regulating glucose metabolism, recent 
reports suggest that circulating myonectin in human blood is correlated with insulin resistance, 
impaired glucose metabolism, and type 2 diabetes (60, 61). Whether myonectin plays a causal role 
in human carbohydrate metabolism and insulin sensitivity, distinct from rodents, remains to be 
determined.  
We previously showed that myonectin infusion lowers serum lipid levels in mice and, when 
given to cultured hepatocytes and adipocytes, also promotes lipid uptake into cells (28). 
Additionally, ingestion of lipid via oral gavage can upregulate myonectin expression (28). Based 
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on these previous findings, we hypothesized that myonectin deficiency would result in impaired 
lipid clearance following an oral lipid load. Indeed, myonectin-KO male mice exhibited a 
significantly greater rise in both serum TG and NEFA levels following an oral lipid challenge 
relative to WT littermates, a functional deficit we observed in multiple independent cohorts of 
HFD-fed male KO mice. Several mechanisms could account for the observed phenotype: 1) 
impaired lipid clearance and uptake by peripheral tissues as hypothesized, and/or 2) increased 
intestinal lipid absorption and chylomicron secretion. We ruled out the latter as the cause of the 
lipid intolerance seen in myonectin-deficient animals. To determine lipid uptake by peripheral 
tissues, we focused on LPL activity since this enzyme is a major determinant of lipid clearance in 
extrahepatic tissues (71). The biggest difference in serum lipid levels between genotypes was seen 
at 2 h after oral lipid gavage or 2 h post-feed following a fast; we therefore quantified the total 
heparin-displaceable LPL activity in the serum 2 h post-feeding. Although there were no 
significant genotypic differences in total lipase activity, we could not rule out potential differences 
in LPL-dependent lipid uptake between WT and KO mice. Of note, both WT and KO mice 
converged on the same baseline lipid levels 4 h after oral lipid gavage. Thus, the observed 
significant differences at earlier time points likely reflect differences in the kinetics of lipid uptake 
rather than the overall capacity for lipid disposal in peripheral tissues. For example, relative to WT 
littermates, the overall LPL activity may be lower in myonectin-KO mice shortly after oral lipid 
gavage, reflecting slower activation of the enzyme in response to altered nutritional state, which 
would result in a much greater rise in serum triglyceride at 0-2 h post-gavage that we observed. At 
later time points total LPL activity in KO mice may reach the same maximum level attained in 
WT mice, reflecting the marked decline in serum triglyceride observed in KO mice at 2-4 h post-
gavage, leading to the same baseline lipid levels between genotypes 4 h after oral lipid challenge. 
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Hence, it is possible that when we measured total LPL activity at 2 h post-feeding, LPL activity in 
WT mice was in the process of decreasing back to baseline and the activity in the KO animals was 
increasing to its maximal level. Future studies will help to determine the total heparin-displaceable 
LPL activity at different time points after oral lipid challenge. 
The second major phenotype observed in myonectin-KO male mice is a significant 
difference in lipid distribution between liver and adipose tissue. We observed significantly greater 
adipocyte hypertrophy, due to greater fat storage in lipid droplets, in both the visceral and 
subcutaneous fat depots of HFD-fed KO mice. Parallel to increased adiposity, we observed a 
striking reduction in fat accumulation in the liver of myonectin-deficient animals. Several 
mechanisms could underlie this phenotype, including liver-specific processes, adipose-specific 
processes, or a combination of both. Reduced hepatic steatosis could be a consequence of either 
increased fat oxidation, increased VLDL secretion, decreased lipid uptake from circulation, and/or 
decreased de novo lipogenesis. Serum ketones (β-hydroxybutyrate), a good proxy for liver fat 
oxidation (73), were not significantly different between WT and KO mice in either fed or fasting 
states, thus ruling out hepatic fat oxidation as the cause for reduced steatosis. We also ruled out 
enhanced hepatic VLDL-triglyceride secretion as a contributing factor to reduced fatty liver. 
Although lipid uptake and fatty acid synthesis have not been directly measured, our liver 
metabolite profiling, in addition to extensive PCR quantification of genes involved in hepatic lipid 
metabolism, does not suggest any differences in these two processes.  
Interestingly, despite a striking reduction in ectopic lipid accumulation in liver, myonectin-
KO male mice did not exhibit better hepatic glucose metabolism profiles relative to WT 
littermates; fasting blood glucose levels (dominated by hepatic gluconeogenesis) and insulin 
tolerance tests did not reveal any significant differences between genotypes. While fatty liver—
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resulting from excessive ectopic fat deposition in the obese state— is frequently associated with 
impaired hepatic insulin action (as reflected in greater hepatic glucose output) (4), these two 
phenomena appear to be uncoupled in myonectin-KO animals. Intriguingly, one of the liver 
metabolites that was significantly upregulated in myonectin-KO male mice is imidazole 
propionate. This molecule, thought to be produced from histidine by gut microbiota, was recently 
reported to be elevated in obese humans with type 2 diabetes and when given to mice can induce 
insulin resistance (72). While it seems that diabetic humans have a relatively wide range of 
imidazole propionate concentrations relative to non-diabetic controls, the level of upregulation (2-
3 fold) we observed in the myonectin-KO mice is not sufficient to disrupt normal insulin signaling 
as indicated by a lack of significant differences in fasting blood glucose, as well as glucose and 
insulin tolerance.    
An alternative explanation for the reduced fat accumulation seen in myonectin-KO liver 
could be secondary to changes in fat storage in adipose tissue, leading to reduced ectopic lipid 
deposition in other organs and tissues. Enlarged adipocytes seen in our myonectin-KO mice could 
result from decreased lipolysis, increased lipid uptake and storage, decreased fat oxidation, and/or 
increased de novo lipogenesis. We ruled out reduced adipose lipolysis as a cause of increased 
adiposity, as neither basal nor β3-adrenergic agonist stimulated lipolysis was significantly different 
between WT and KO mice. LPL activity was measured in adipose tissue as a proxy for the capacity 
for lipid uptake. Intriguingly, LPL activity was significantly greater in the subcutaneous (inguinal) 
fat depot of KO mice relative to WT littermates in the postprandial state. Increased fat uptake into 
adipocytes via LPL may, in part, account for the increase in adiposity and adipocyte cell size. 
However, this appears to be fat depot-specific; we did not observe a significant increase in LPL 
activity in the visceral (gonadal) fat of KO animals. Although fat oxidation and synthesis in adipose 
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tissue were not directly measured in this study, none of the lipid synthesis or catabolism genes we 
considered were significantly different in their expression levels between WT and KO mice. What 
accounts for the increased LPL activity seen in the iWAT of myonectin-KO mice is presently 
unclear, since none of the known regulators (angiopoetin-like proteins and apolipoproteins) of LPL 
activity and transcytosis were different in their expression or serum protein levels between WT 
and KO animals. 
In summary, we provide here a detailed analysis of the metabolic consequences of 
myonectin deletion in a genetic mouse model. Whereas myonectin is largely dispensable for 
whole-body glucose metabolism, it plays an important role in regulating local and systemic lipid 
metabolism. Loss of myonectin causes lipid intolerance in response to oral lipid loading and it 
alters lipid distribution between adipose and liver. Thus, in addition to regulating stress 
erythropoiesis in the context of blood loss (38), myonectin/erythroferrone is also a secreted 
metabolic regulator of fat metabolism in the physiological context of diet-induced obesity.  Future 
studies will help pinpoint the mechanisms by which myonectin controls fat metabolism in a tissue-









1. Wasserman, D. H., Kang, L., Ayala, J. E., Fueger, P. T., and Lee-Young, R. S. (2011) The 
physiological regulation of glucose flux into muscle in vivo. J Exp Biol 214, 254-262 
2. Roach, P. J., Depaoli-Roach, A. A., Hurley, T. D., and Tagliabracci, V. S. (2012) Glycogen and 
its metabolism: some new developments and old themes. Biochem J 441, 763-787 
3. Petersen, K. F., Dufour, S., Savage, D. B., Bilz, S., Solomon, G., Yonemitsu, S., Cline, G. W., 
Befroy, D., Zemany, L., Kahn, B. B., Papademetris, X., Rothman, D. L., and Shulman, G. I. 
(2007) The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic 
syndrome. Proc Natl Acad Sci U S A 104, 12587-12594 
4. Samuel, V. T., and Shulman, G. I. (2012) Mechanisms for insulin resistance: common threads 
and missing links. Cell 148, 852-871 
5. Pedersen, B. K. (2013) Muscle as a secretory organ. Compr Physiol 3, 1337-1362 
6. Pedersen, B. K., and Febbraio, M. A. (2012) Muscles, exercise and obesity: skeletal muscle as a 
secretory organ. Nat Rev Endocrinol 8, 457-465 
7. Henningsen, J., Rigbolt, K. T., Blagoev, B., Pedersen, B. K., and Kratchmarova, I. (2010) 
Dynamics of the skeletal muscle secretome during myoblast differentiation. Mol Cell Proteomics 
9, 2482-2496 
8. Chan, X. C., McDermott, J. C., and Siu, K. W. (2007) Identification of secreted proteins during 
skeletal muscle development. J Proteome Res 6, 698-710 
9. Hartwig, S., Raschke, S., Knebel, B., Scheler, M., Irmler, M., Passlack, W., Muller, S., Hanisch, 
F. G., Franz, T., Li, X., Dicken, H. D., Eckardt, K., Beckers, J., de Angelis, M. H., Weigert, C., 
Haring, H. U., Al-Hasani, H., Ouwens, D. M., Eckel, J., Kotzka, J., and Lehr, S. (2014) 
Secretome profiling of primary human skeletal muscle cells. Biochim Biophys Acta 1844, 1011-
1017 
10. McPherron, A. C., and Lee, S. J. (2002) Suppression of body fat accumulation in myostatin-
deficient mice. J Clin Invest 109, 595-601 
11. Shan, T., Liang, X., Bi, P., and Kuang, S. (2013) Myostatin knockout drives browning of white 
adipose tissue through activating the AMPK-PGC1alpha-Fndc5 pathway in muscle. FASEB J 27, 
1981-1989 
12. Guo, T., Bond, N. D., Jou, W., Gavrilova, O., Portas, J., and McPherron, A. C. (2012) Myostatin 
inhibition prevents diabetes and hyperphagia in a mouse model of lipodystrophy. Diabetes 61, 
2414-2423 
13. Pedersen, B. K. (2009) Edward F. Adolph distinguished lecture: muscle as an endocrine organ: 
IL-6 and other myokines. J Appl Physiol 107, 1006-1014 
14. Hojman, P., Pedersen, M., Nielsen, A. R., Krogh-Madsen, R., Yfanti, C., Akerstrom, T., Nielsen, 
S., and Pedersen, B. K. (2009) Fibroblast growth factor-21 is induced in human skeletal muscles 
by hyperinsulinemia. Diabetes 58, 2797-2801 
15. Izumiya, Y., Bina, H. A., Ouchi, N., Akasaki, Y., Kharitonenkov, A., and Walsh, K. (2008) 
FGF21 is an Akt-regulated myokine. FEBS Lett 582, 3805-3810 
16. Zeng, L., Akasaki, Y., Sato, K., Ouchi, N., Izumiya, Y., and Walsh, K. (2010) Insulin-like 6 is 
induced by muscle injury and functions as a regenerative factor. J Biol Chem 285, 36060-36069 
17. Ouchi, N., Oshima, Y., Ohashi, K., Higuchi, A., Ikegami, C., Izumiya, Y., and Walsh, K. (2008) 
Follistatin-like 1, a secreted muscle protein, promotes endothelial cell function and 
revascularization in ischemic tissue through a nitric-oxide synthase-dependent mechanism. J Biol 
Chem 283, 32802-32811 
18. Broholm, C., Laye, M. J., Brandt, C., Vadalasetty, R., Pilegaard, H., Pedersen, B. K., and 
Scheele, C. (2011) LIF is a contraction-induced myokine stimulating human myocyte 
proliferation. J Appl Physiol 111, 251-259 
 129 
19. Haugen, F., Norheim, F., Lian, H., Wensaas, A. J., Dueland, S., Berg, O., Funderud, A., 
Skalhegg, B. S., Raastad, T., and Drevon, C. A. (2010) IL-7 is expressed and secreted by human 
skeletal muscle cells. Am J Physiol Cell Physiol 298, C807-816 
20. Quinn, L. S., Anderson, B. G., Strait-Bodey, L., Stroud, A. M., and Argiles, J. M. (2009) 
Oversecretion of interleukin-15 from skeletal muscle reduces adiposity. Am J Physiol Endocrinol 
Metab 296, E191-202 
21. Nishizawa, H., Matsuda, M., Yamada, Y., Kawai, K., Suzuki, E., Makishima, M., Kitamura, T., 
and Shimomura, I. (2004) Musclin, a novel skeletal muscle-derived secretory factor. J Biol Chem 
279, 19391-19395 
22. Subbotina, E., Sierra, A., Zhu, Z., Gao, Z., Koganti, S. R., Reyes, S., Stepniak, E., Walsh, S. A., 
Acevedo, M. R., Perez-Terzic, C. M., Hodgson-Zingman, D. M., and Zingman, L. V. (2015) 
Musclin is an activity-stimulated myokine that enhances physical endurance. Proc Natl Acad Sci 
U S A 112, 16042-16047 
23. Bostrom, P., Wu, J., Jedrychowski, M. P., Korde, A., Ye, L., Lo, J. C., Rasbach, K. A., Bostrom, 
E. A., Choi, J. H., Long, J. Z., Kajimura, S., Zingaretti, M. C., Vind, B. F., Tu, H., Cinti, S., 
Hojlund, K., Gygi, S. P., and Spiegelman, B. M. (2012) A PGC1-alpha-dependent myokine that 
drives brown-fat-like development of white fat and thermogenesis. Nature 481, 463-468 
24. Welc, S. S., and Clanton, T. L. (2013) The regulation of interleukin-6 implicates skeletal muscle 
as an integrative stress sensor and endocrine organ. Exp Physiol 98, 359-371 
25. Staiger, H., Bohm, A., Scheler, M., Berti, L., Machann, J., Schick, F., Machicao, F., Fritsche, A., 
Stefan, N., Weigert, C., Krook, A., Haring, H. U., and de Angelis, M. H. (2013) Common genetic 
variation in the human FNDC5 locus, encoding the novel muscle-derived 'browning' factor irisin, 
determines insulin sensitivity. PLoS One 8, e61903 
26. Egan, B., and Zierath, J. R. (2013) Exercise metabolism and the molecular regulation of skeletal 
muscle adaptation. Cell Metab 17, 162-184 
27. Trayhurn, P., Drevon, C. A., and Eckel, J. (2010) Secreted proteins from adipose tissue and 
skeletal muscle - adipokines, myokines and adipose/muscle cross-talk. Arch Physiol Biochem 
117, 47-56 
28. Seldin, M. M., Peterson, J. M., Byerly, M. S., Wei, Z., and Wong, G. W. (2012) Myonectin 
(CTRP15), a novel myokine that links skeletal muscle to systemic lipid homeostasis. J Biol Chem 
287, 11968-11980   
29. Otaka, N., Shibata, R., Ohashi, K., Uemura, Y., Kambara, T., Enomoto, T., Ogawa, H., Ito, M., 
Kawanishi, H., Maruyama, S., Joki, Y., Fujikawa, Y., Narita, S., Unno, K., Kawamoto, Y., 
Murate, T., Murohara, T., and Ouchi, N. (2018) Myonectin Is an Exercise-Induced Myokine That 
Protects the Heart From Ischemia-Reperfusion Injury. Circ Res 123, 1326-1338 
30. Wong, G. W., Krawczyk, S. A., Kitidis-Mitrokostas, C., Ge, G., Spooner, E., Hug, C., Gimeno, 
R., and Lodish, H. F. (2009) Identification and characterization of CTRP9, a novel secreted 
glycoprotein, from adipose tissue that reduces serum glucose in mice and forms heterotrimers 
with adiponectin. FASEB J 23, 241-258   
31. Wong, G. W., Krawczyk, S. A., Kitidis-Mitrokostas, C., Revett, T., Gimeno, R., and Lodish, H. 
F. (2008) Molecular, biochemical and functional characterizations of C1q/TNF family members: 
adipose-tissue-selective expression patterns, regulation by PPAR-gamma agonist, cysteine-
mediated oligomerizations, combinatorial associations and metabolic functions. Biochem J 416, 
161-177 
32. Wong, G. W., Wang, J., Hug, C., Tsao, T. S., and Lodish, H. F. (2004) A family of 
Acrp30/adiponectin structural and functional paralogs. Proc Natl Acad Sci U S A 101, 10302-
10307  
33. Wei, Z., Peterson, J. M., Lei, X., Cebotaru, L., Wolfgang, M. J., Baldeviano, G. C., and Wong, G. 
W. (2012) C1q/TNF-related protein-12 (CTRP12), a novel adipokine that improves insulin 
sensitivity and glycemic control in mouse models of obesity and diabetes. J Biol Chem 287, 
10301-10315   
 130 
34. Wei, Z., Peterson, J. M., and Wong, G. W. (2011) Metabolic regulation by C1q/TNF-related 
protein-13 (CTRP13): activation of AMP-activated protein kinase and suppression of fatty acid-
induced JNK signaling. J Biol Chem 286, 15652-15665   
35. Wei, Z., Seldin, M. M., Natarajan, N., Djemal, D. C., Peterson, J. M., and Wong, G. W. (2013) 
C1q/Tumor Necrosis Factor-related Protein 11 (CTRP11), a Novel Adipose Stroma-derived 
Regulator of Adipogenesis. J Biol Chem 288, 10214-10229   
36. Seldin, M. M., Lei, X., Tan, S. Y., Stanson, K. P., Wei, Z., and Wong, G. W. (2013) Skeletal 
muscle-derived myonectin activates the mTOR pathway to suppress autophagy in liver. J Biol 
Chem 289, 36073-36082 
37. Kautz, L., Jung, G., Nemeth, E., and Ganz, T. (2014) Erythroferrone contributes to recovery from 
anemia of inflammation. Blood 124, 2569-2574 
38. Kautz, L., Jung, G., Valore, E. V., Rivella, S., Nemeth, E., and Ganz, T. (2014) Identification of 
erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 46, 678-684 
39. Peterson, J. M., Aja, S., Wei, Z., and Wong, G. W. (2012) C1q/TNF-related protein-1 (CTRP1) 
enhances fatty acid oxidation via AMPK activation and ACC inhibition. J Biol Chem 287, 1576-
1587   
40. Peterson, J. M., Seldin, M. M., Wei, Z., Aja, S., and Wong, G. W. (2013) CTRP3 attenuates diet-
induced hepatic steatosis by regulating triglyceride metabolism. Am J Physiol Gastrointest Liver 
Physiol 305, G214-224.   
41. Peterson, J. M., Wei, Z., Seldin, M. M., Byerly, M. S., Aja, S., and Wong, G. W. (2013) CTRP9 
transgenic mice are protected from diet-induced obesity and metabolic dysfunction. Am J Physiol 
Regul Integr Comp Physiol 305, R522-533  
42. Peterson, J. M., Wei, Z., and Wong, G. W. (2010) C1q/TNF-related Protein-3 (CTRP3), a Novel 
Adipokine That Regulates Hepatic Glucose Output. J Biol Chem 285, 39691-39701   
43. Byerly, M. S., Swanson, R., Wei, Z., Seldin, M. M., McCulloh, P. S., and Wong, G. W. (2013) A 
Central Role for C1q/TNF-Related Protein 13 (CTRP13) in Modulating Food Intake and Body 
Weight. PLoS One 8, e62862   
44. Enomoto, T., Ohashi, K., Shibata, R., Higuchi, A., Maruyama, S., Izumiya, Y., Walsh, K., 
Murohara, T., and Ouchi, N. (2011) Adipolin/C1qdc2/CTRP12 functions as an adipokine that 
improves glucose metabolism. J Biol Chem 286, 34552-34558 
45. Su, H., Yuan, Y., Wang, X. M., Lau, W. B., Wang, Y., Wang, X., Gao, E., Koch, W. J., and Ma, 
X. L. (2013) Inhibition of CTRP9, a novel and cardiac-abundantly expressed cell survival 
molecule, by TNFalpha-initiated oxidative signaling contributes to exacerbated cardiac injury in 
diabetic mice. Basic Res Cardiol 108, 315-326 
46. Uemura, Y., Shibata, R., Ohashi, K., Enomoto, T., Kambara, T., Yamamoto, T., Ogura, Y., 
Yuasa, D., Joki, Y., Matsuo, K., Miyabe, M., Kataoka, Y., Murohara, T., and Ouchi, N. (2013) 
Adipose-derived factor CTRP9 attenuates vascular smooth muscle cell proliferation and 
neointimal formation. FASEB J 27, 25-33 
47. Kambara, T., Ohashi, K., Shibata, R., Ogura, Y., Maruyama, S., Enomoto, T., Uemura, Y., 
Shimizu, Y., Yuasa, D., Matsuo, K., Miyabe, M., Kataoka, Y., Murohara, T., and Ouchi, N. 
(2012) CTRP9 protein protects against myocardial injury following ischemia-reperfusion through 
AMP-activated protein kinase (AMPK)-dependent mechanism. J Biol Chem 287, 18965-18973 
48. Sun, Y., Yi, W., Yuan, Y., Lau, W. B., Yi, D., Wang, X., Wang, Y., Su, H., Gao, E., Koch, W. J., 
and Ma, X. L. (2013) C1q/Tumor Necrosis Factor-Related Protein-9, a Novel Adipocyte-Derived 
Cytokine, Attenuates Adverse Remodeling in the Ischemic Mouse Heart via Protein Kinase A 
Activation. Circulation 128, S113-120 
49. Appari, M., Breitbart, A., Brandes, F., Szaroszyk, M., Froese, N., Korf-Klingebiel, M., 
Mohammadi, M. M., Grund, A., Scharf, G. M., Wang, H., Zwadlo, C., Fraccarollo, D., 
Schrameck, U., Nemer, M., Wong, G. W., Katus, H. A., Wollert, K. C., Muller, O. J., Bauersachs, 
J., and Heineke, J. (2017) C1q-TNF-Related Protein-9 Promotes Cardiac Hypertrophy and 
Failure. Circ Res 120, 66-77 
 131 
50. Yan, W., Guo, Y., Tao, L., Lau, W. B., Gan, L., Yan, Z., Guo, R., Gao, E., Wong, G. W., Koch, 
W. L., Wang, Y., and Ma, X. L. (2017) C1q/Tumor Necrosis Factor-Related Protein-9 Regulates 
the Fate of Implanted Mesenchymal Stem Cells and Mobilizes Their Protective Effects Against 
Ischemic Heart Injury via Multiple Novel Signaling Pathways. Circulation 136, 2162-2177 
51. Kambara, T., Shibata, R., Ohashi, K., Matsuo, K., Hiramatsu-Ito, M., Enomoto, T., Yuasa, D., 
Ito, M., Hayakawa, S., Ogawa, H., Aprahamian, T., Walsh, K., Murohara, T., and Ouchi, N. 
(2015) C1q/Tumor Necrosis Factor-Related Protein 9 Protects against Acute Myocardial Injury 
through an Adiponectin Receptor I-AMPK-Dependent Mechanism. Mol Cell Biol 35, 2173-2185 
52. Yuasa, D., Ohashi, K., Shibata, R., Mizutani, N., Kataoka, Y., Kambara, T., Uemura, Y., Matsuo, 
K., Kanemura, N., Hayakawa, S., Hiramatsu-Ito, M., Ito, M., Ogawa, H., Murate, T., Murohara, 
T., and Ouchi, N. (2016) C1q/TNF-related protein-1 functions to protect against acute ischemic 
injury in the heart. FASEB J 30, 1065-1075 
53. Lei, X., Seldin, M. M., Little, H. C., Choy, N., Klonisch, T., and Wong, G. W. (2017) C1q/TNF-
related protein 6 (CTRP6) links obesity to adipose tissue inflammation and insulin resistance. J 
Biol Chem 292, 14836-14850 
54. Petersen, P. S., Lei, X., Wolf, R. M., Rodriguez, S., Tan, S. Y., Little, H. C., Schweitzer, M. A., 
Magnuson, T. H., Steele, K. E., and Wong, G. W. (2017) CTRP7 deletion attenuates obesity-
linked glucose intolerance, adipose tissue inflammation, and hepatic stress. Am J Physiol 
Endocrinol Metab 312, E309-E325 
55. Rodriguez, S., Lei, X., Petersen, P. S., Tan, S. Y., Little, H. C., and Wong, G. W. (2016) Loss of 
CTRP1 disrupts glucose and lipid homeostasis. Am J Physiol Endocrinol Metab 311, E678-E697 
56. Tan, S. Y., Little, H. C., Lei, X., Li, S., Rodriguez, S., and Wong, G. W. (2016) Partial deficiency 
of CTRP12 alters hepatic lipid metabolism. Physiol Genomics 48, 936-949 
57. Wei, Z., Lei, X., Petersen, P. S., Aja, S., and Wong, G. W. (2014) Targeted deletion of C1q/TNF-
related protein 9 increases food intake, decreases insulin sensitivity, and promotes hepatic 
steatosis in mice. Am J Physiol Endocrinol Metab 306, E779-790 
58. Wolf, R. M., Lei, X., Yang, Z. C., Nyandjo, M., Tan, S. Y., and Wong, G. W. (2016) CTRP3 
deficiency reduces liver size and alters IL-6 and TGFbeta levels in obese mice. Am J Physiol 
Endocrinol Metab 310, E332-345 
59. Lu, L., Zhang, R. Y., Wang, X. Q., Liu, Z. H., Shen, Y., Ding, F. H., Meng, H., Wang, L. J., Yan, 
X. X., Yang, K., Wang, H. B., Pu, L. J., Zhang, Q., Chen, Q. J., De Caterina, R., and Shen, W. F. 
(2016) C1q/TNF-related protein-1: an adipokine marking and promoting atherosclerosis. Eur 
Heart J 37, 1762-1771 
60. Li, K., Liao, X., Wang, K., Mi, Q., Zhang, T., Jia, Y., Xu, X., Luo, X., Zhang, C., Liu, H., Zhen, 
H., Li, L., and Yang, G. (2018) Myonectin Predicts the Development of Type 2 Diabetes. J Clin 
Endocrinol Metab 103, 139-147 
61. Toloza, F. J. K., Mantilla-Rivas, J. O., Perez-Matos, M. C., Ricardo-Silgado, M. L., Morales-
Alvarez, M. C., Pinzon-Cortes, J. A., Perez-Mayorga, M., Arevalo-Garcia, M. L., Tolosa-
Gonzalez, G., and Mendivil, C. O. (2018) Plasma Levels of Myonectin But Not Myostatin or 
Fibroblast-Derived Growth Factor 21 Are Associated with Insulin Resistance in Adult Humans 
without Diabetes Mellitus. Front Endocrinol (Lausanne) 9, 5 
62. Coffey, R., Sardo, U., Kautz, L., Gabayan, V., Nemeth, E., and Ganz, T. (2018) Erythroferrone is 
not required for the glucoregulatory and hematologic effects of chronic erythropoietin treatment 
in mice. Physiol Rep 6, e13890 
63. Tang, T., Li, L., Tang, J., Li, Y., Lin, W. Y., Martin, F., Grant, D., Solloway, M., Parker, L., Ye, 
W., Forrest, W., Ghilardi, N., Oravecz, T., Platt, K. A., Rice, D. S., Hansen, G. M., Abuin, A., 
Eberhart, D. E., Godowski, P., Holt, K. H., Peterson, A., Zambrowicz, B. P., and de Sauvage, F. 
J. (2010) A mouse knockout library for secreted and transmembrane proteins. Nat Biotechnol 28, 
749-755 
64. Qiao, L., Zou, C., van der Westhuyzen, D. R., and Shao, J. (2008) Adiponectin reduces plasma 
triglyceride by increasing VLDL triglyceride catabolism. Diabetes 57, 1824-1833 
 132 
65. Mizunoya, W., Haramizu, S., Shibakusa, T., Okabe, Y., and Fushiki, T. (2005) Dietary 
conjugated linoleic acid increases endurance capacity and fat oxidation in mice during exercise. 
Lipids 40, 265-271 
66. Schmittgen, T. D., and Livak, K. J. (2008) Analyzing real-time PCR data by the comparative 
C(T) method. Nat Protoc 3, 1101-1108 
67. Little, H. C., Tan, S. Y., Cali, F. M., Rodriguez, S., Lei, X., Wolfe, A., Hug, C., and Wong, G. W. 
(2018) Multiplex Quantification Identifies Novel Exercise-regulated Myokines/Cytokines in 
Plasma and in Glycolytic and Oxidative Skeletal Muscle. Mol Cell Proteomics 17, 1546-1563 
68. Leick, L., Wojtaszewski, J. F., Johansen, S. T., Kiilerich, K., Comes, G., Hellsten, Y., Hidalgo, J., 
and Pilegaard, H. (2008) PGC-1alpha is not mandatory for exercise- and training-induced 
adaptive gene responses in mouse skeletal muscle. Am J Physiol Endocrinol Metab 294, E463-
474 
69. Mathis, D., and Shoelson, S. E. (2011) Immunometabolism: an emerging frontier. Nat Rev 
Immunol 11, 81 
70. Winzell, M. S., and Ahren, B. (2004) The high-fat diet-fed mouse: a model for studying 
mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 53 Suppl 
3, S215-219 
71. Wang, H., and Eckel, R. H. (2009) Lipoprotein lipase: from gene to obesity. Am J Physiol 
Endocrinol Metab 297, E271-288 
72. Koh, A., Molinaro, A., Stahlman, M., Khan, M. T., Schmidt, C., Manneras-Holm, L., Wu, H., 
Carreras, A., Jeong, H., Olofsson, L. E., Bergh, P. O., Gerdes, V., Hartstra, A., de Brauw, M., 
Perkins, R., Nieuwdorp, M., Bergstrom, G., and Backhed, F. (2018) Microbially Produced 
Imidazole Propionate Impairs Insulin Signaling through mTORC1. Cell 175, 947-961 e917 
73. McGarry, J. D., and Foster, D. W. (1980) Regulation of hepatic fatty acid oxidation and ketone 
body production. Annu Rev Biochem 49, 395-420 
74. Zhang, R. (2016) The ANGPTL3-4-8 model, a molecular mechanism for triglyceride trafficking. 
Open Biol 6, 150272 
75. Yang, Y., Smith, D. L., Jr., Keating, K. D., Allison, D. B., and Nagy, T. R. (2014) Variations in 
body weight, food intake and body composition after long-term high-fat diet feeding in C57BL/6J 
mice. Obesity (Silver Spring) 22, 2147-2155 
76. Hong, J., Stubbins, R. E., Smith, R. R., Harvey, A. E., and Nunez, N. P. (2009) Differential 
susceptibility to obesity between male, female and ovariectomized female mice. Nutr J 8, 11 
77. Varlamov, O., Bethea, C. L., and Roberts, C. T., Jr. (2014) Sex-specific differences in lipid and 










Ph.D. expected            2019                Program: Biochemistry,                             Johns Hopkins University 
                          Cellular, and Molecular Biology                          School of Medicine 
            Mentor: G. William Wong, PhD 
 
B.S.            2013                Biological Sciences    University of California, Irvine 
 
 
Other Professional Experience: 
Undergraduate            2011-2013       Mentor: Zhibin Guan, PhD           University of California, Irvine 
researcher      
 
Summer intern           Summers         Mentors: Shannon Holloway, PhD;           Los Alamos National 
          2009-2012       Toshihiko Kawano, PhD            Laboratory 
 
 
Scholarships and Fellowships: 
Fellowship           2017-2019       National Institute of Diabetes and           Johns Hopkins University 
            Digestive and Kidney Diseases         School of Medicine 
(F31DK116537; F31 pre-doctoral fellowship; $88,088) 
 
Fellowship                2015-2017       American Heart Association                      Johns Hopkins University  
(15PRE25710315; Pre-doctoral fellowship; $50,000)           School of Medicine 
 
Scholarship           2013         UC Irvine Department of    University of California, Irvine 
            Biological Sciences 
(Jane Unzelman Scholarship; $3,000) 
 
Scholarship           2013         UC Irvine Department of    University of California, Irvine 
            Biological Sciences 
(UC Irvine Biological Sciences Leadership Scholars Program Scholarship; $10,000) 
 
Scholarship           2009-2013       University of California Regents   University of California, Irvine 




Rodriguez, S.; Little, H.C.; Shepard, B.D.; Wolfe, A.; Cheema, M.U.; Jandu, S.; Woodward, O.M.; 
Talbot Jr., C.C.; Berkowitz, D.E.; Pluznick, J.L.; Wong, G.W. (2019) Late-onset renal hypertrophy and 
dysfunction in mice lacking CTRP1. FASEB J. Under review. 
 
Little, H.C.; Rodriguez, S.; Lei, X.; Tan, S.Y.; Stewart, A.N.; Sahagun, A.; Sarver, D.C.; Wong, G.W. 
(2019) Myonectin deletion promotes adipose fat storage and reduces liver steatosis. FASEB J. [Epub 
ahead of print]  
 
 134 
Little, H.C.; Tan, S.Y.; Cali, F.M.; Rodriguez, S.; Lei, X.; Wolfe, A.; Hug, C.; Wong, G.W. (2018) 
Multiplex quantification identifies novel exercise-regulated myokines/cytokines in plasma and in 
glycolytic and oxidative skeletal muscle. Mol. Cell. Proteomics. 17, 1546 – 1563. (PMCID: 
PMC6072542) 
 
Lei, X.; Seldin, M.M.; Little, H.C.; Choy, N.; Klonisch, T.; Wong, G.W. (2017) C1q/TNF-related protein 
6 (CTRP6) links obesity to adipose tissue inflammation and insulin resistance. J. Biol. Chem. 292, 14836-
14850. (PMCID: PMC5592665) 
 
Petersen, P.S.; Lei, X.; Wolf, R.M.; Rodriguez, S.; Tan, S.Y.; Little, H.C.; Schweitzer, M.A., Magnuson, 
T.H.; Steele, K.E.; Wong, G.W.  (2017)  CTRP7 deletion attenuates obesity-linked glucose intolerance, 
adipose tissue inflammation, and hepatic stress.  Am. J. Physiol. Endocrinol. Metab. 312, E309-E325. 
(PMCID: PMC5406989) 
 
Tan, S.Y.; Little, H.C.; Lei, X.; Li, S.; Rodriguez, S.; Wong, G.W.  (2016)  Partial deficiency of CTRP12 
alters hepatic lipid metabolism.  Physiol. Genomics.  48, 936-949. (PMCID: PMC5206390) 
 
Rodriguez, S.; Lei, X.; Petersen, P.S.; Tan, S.Y.; Little, H.C.; Wong, G.W.  (2016)  Loss of CTRP1 
disrupts glucose and lipid homeostasis.  Am. J. Physiol. Endocrinol. Metab.  311, E678-E697. (PMCID: 
PMC5241556) 
 
Zeng, H.; Little, H. C.; Tiambeng, T.; Williams, G. A.; Guan, Z.  (2013)  Multifunctional Dendronized 




Little, H.C.; Tan, S.Y.; Lei, X.; Rodriguez, S.; Petersen, P.S.; Wong, G.W. (2018) Myonectin Deficiency 
Alters Lipid Metabolism in High Fat Fed Mice. Abstract for poster presentation, Keystone Symposia on 
Organ Crosstalk in Obesity and NAFLD. Keystone, CO, January 21, 2018. 
 
Little, H.C.; Tan, S.Y.; Lei, X.; Rodriguez, S.; Petersen, P.S.; Wong, G.W. (2017) Myonectin Deficiency 
Alters Lipid Metabolism in High Fat Fed Mice. Abstract for poster presentation, Navigating Lipid 
Research in Baltimore. Baltimore, MD, May 5, 2017.  
 
Little, H.C.; Tan, S.Y.; Lei, X.; Rodriguez, S.; Petersen, P.S.; Wong, G.W. (2016) Myonectin Deficiency 
Alters Lipid Metabolism in High Fat Fed Mice.  Abstract for poster presentation, Kern Lipid Conference.  
Vail, CO, August 8, 2016. 
 
 
Service and Leadership: 
Co-founder        2016-present Graduate Student Peer           Johns Hopkins University,  
     Mentoring Program          School of Medicine 
(Co-founded a peer mentoring program that facilitates organized peer support among graduate students 
by hosting monthly discussions and workshops focused on common hardships faced in graduate school) 
 
Lead mentor        2013-2017  Thread     Non-profit organization, 
 Baltimore, MD 
(Mentored an at-risk Baltimore City high school student for four years; oversaw three other mentors of 
the same student and delegated roles and tasks based on each mentor’s strengths) 
